exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 3/234  
W00090 GE 2 01 
APPROVAL FORM  
Protocol Version 9 – 17JU L2020 
 
  
Sponsor’s Representative : 
Clinical Study Physician : 
 
       
 Date:    
  Signature:   
 
 
Study Coordinating Investigators : 
 
      
 
        
  
Date:    
      Date:    
   
Signature  
      
Signature  
 
  
 
  
PII
PII
PII
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 4/234  
W00090 GE 2 01  
COUNTRY COORDINATING  INVESTIGATOR  
SIGNATURE FORM  
Protocol Version 9 – 17JUL2020 
 
 
Country : …………………………………….. 
 
Country Coordinating Investigator:   
 
"Name"  Date:    
 Signature:   
 
 
 
     
 
   
 
   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 5/234  
W00090 GE 2 01  
INVESTIGATOR SIGNATURE FORM  
Protocol Version 9 – X17JUL2020  
 
 
By my signature below, I Dr / Pr"  Name" , hereby confirm that I agree:  
• to conduct the trial described in the protocol W00090 GE 2 01, dated  17 July 2020 in 
compliance with GCP, with applicable regulatory requirements and with the protocol agreed 
upon by the Sponsor Pierre Fabre Medicament and given approval by the Ethics Committee / IRB;  
• to document the delegation of significant study- related tasks and to notify the Sponsor of 
changes in site personnel involved in the study; 
• to comply with the procedure for data recording and reporting; 
• to allow monitoring, auditing and inspection; 
• to retain the trial- related essential documents until the Sponsor informs that these documents 
are no longer needed. 
Furthermore, I hereby confirm that I will have and will use the available adequate resources, 
personnel and fa cilities for conduct this trial.  
I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre 
Medicament to obtain and supply details about the I nvestigator’s ownership interest in the Sponsor 
or the study treatment, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with 
regulatory requirements. 
Hence I agree:  
• to supply the Sponsor with any information regarding ownership interest and financial 
relationships with the Sponsor (including those of my spouse and dependent chil dren);  
• to promptly update this information if any relevant changes occur during the course of the 
study and for 1 year following completion of the study; 
• that the Sponsor may disclose this information about such ownership interests and financial 
relation ships to regulatory authorities. 
 Date:
      Signature:  
   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 6/234  
TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL  
 
 
1. INTRODUCTION AND STUDY RATIONALE  ............................................................ 47  
1.1. BACKGROUND INFORM ATION ON THE TARGET PATHOLOGY AND 
THERAPY ...................................................................................................................... 47  
1.2. INFORMATION ON THE TEST PRODUCT  ............................................................... 52  
1.2.1.  ENCORAFENIB  ............................................................................................................. 52  
1.2.2.  BINIMETINIB  ................................................................................................................ 59  
1.2.3.  CETUXIMAB  ................................................................................................................. 64  
1.3. STUDY RATIONALE  .................................................................................................... 67  
1.4. OVERALL RISK AND BENEFIT ASSESSMENT  ...................................................... 70  
2. STUDY OBJECTI VE AND ENDPOINTS  ...................................................................... 71  
2.1. PRIMARY OBJECTIVE  ................................................................................................ 71  
2.2. SECONDARY OBJECTIVES  ........................................................................................ 71  
2.3. EXPLORATORY OBJECTIVES  ................................................................................... 72  
2.4. PRIMARY ENDPOINTS  ............................................................................................... 72  
2.5. SECONDARY ENDPOINTS  ......................................................................................... 72  
2.6. EXPLORATORY ENDPOINT S: ................................................................................... 73  
3. ETHICAL CONSIDERATIO NS RELATING TO THE S TUDY ................................. 73  
4. STUDY DESIGN  ................................................................................................................ 74  
4.1. OVERALL DESCRIPTION ........................................................................................... 74  
4.2. DISCUSSION OF THE STUDY DESIGN  .................................................................... 77  
4.2.1.  Choice of the Study Population ....................................................................................... 77  
4.2.2.  Choice of the Study Design ............................................................................................. 77  
4.2.3.  Choice of the Dose and Administration Modalities ........................................................ 78  
4.2.4.  Choice of sample size  ...................................................................................................... 79  
5. STUDY POPULATION .................................................................................................... 80  
5.1. INCLUSION CRITERIA ................................................................................................ 80  
5.2. EXCLUSION CRITERIA ............................................................................................... 82  
5.3. LIFESTYLE GUIDELINES  ........................................................................................... 85  
5.3.1.  Contraception .................................................................................................................. 85  
5.3.2.  Photosensitivity  ............................................................................................................... 87  
5.4. NUMBER OF SUBJECTS  ............................................................................................. 87  
5.5. RECRUITMENT MODALITIES  ................................................................................... 87  
5.6. SUBJECTS IDENTIFICAT ION ..................................................................................... 88  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 7/234 5.7. SUBJECT DISCONTINUATION REASONS  ............................................................... 88  
5.7.1.  Treatment Discontinuation for Individual Subject .......................................................... 88  
5.7.2.  Study Discontinuation for individual Subject ................................................................. 90  
5.8. STUDY DISCONTINUATION ...................................................................................... 90  
5.9. REPLACEMENT OF SUBJECTS .................................................................................. 90  
5.10.  POST -STUDY EXCLUSION PERIOD  ......................................................................... 90  
5.11.  SUBJECT CARD  ............................................................................................................ 90  
6. STUDY TREATMENT(S)  ................................................................................................ 91  
6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL 
PRODUCT(S) AND ASSOCIATED PRODUCT(S)  ..................................................... 92  
6.1.1.  Encorafenib 75 mg hard capsule ..................................................................................... 92  
6.1.2.  Binimetinib 1 5 mg film- coated tablet  ............................................................................. 92  
6.1.3.  Cetuximab solution for infusion ...................................................................................... 93  
6.2. PACKAGING AND LABELL ING ................................................................................ 94  
6.2.1.  Packaging  ........................................................................................................................ 94  
6.2.1.1.  Encorafenib 75 mg capsule ......................................................................................... 94  
6.2.1.2.  Binimetinib 15 mg film coated tablet  .......................................................................... 95  
6.2.1.3.  Cetuximab ERBITUX® 5 mg/mL solution for infusion ............................................. 95  
6.2.2.  Labelling .......................................................................................................................... 96  
6.3. DISTRIBUTION TO CENTERS AND STORAGE  ....................................................... 98  
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO SUBJECTS  ............ 99  
6.5. TREATMENT ADMINISTRA TION  ............................................................................. 99  
6.5.1.  Duration of Treatment ..................................................................................................... 99  
6.5.2.  Route and Conditions of Administration of Encorafenib and Binimetinib ................... 101  
6.5.3.  Route and Condition of Administration of Cetuximab ................................................. 102  
6.5.4.  Dose Modification ......................................................................................................... 103  
6.5.4.1.  Dose Modification for Encorafenib and/or Binimetinib ........................................... 106  
6.5.4.2.  Dose Modifications for Cetuximab ........................................................................... 116  
6.6. REPLACEMENT PROCEDUR E ................................................................................. 117  
6.7. BLIND BREAKING PROCE SS ................................................................................... 117  
6.8. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT(S) AND ASSOCIATED PRODUCT(S)  .............. 117
 
6.9. RECALL OF INVESTIGATIONAL PRODUCT(S) AND RESCUE MEDICATION .............................................................................................................. 117
 
7. CONCOMITANT THERAPY AND THERAPEUTIC / DIAGNOSTIC PROCEDURES  ................................................................................................................ 118
 
7.1. PROHIBITED THERAPY AND THERAPEUTIC/DIAGNOSTIC PROCEDURES  . 119  
7.2. AUTHORIZED THERAPY, THERAPEUTIC AND DIAGNOSTIC PROCEDURES  ............................................................................................................. 120
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 8/234 7.2.1.  Skin Toxicity Treatments  .............................................................................................. 120  
7.2.2.  Hand -Foot Skin Reac tion Treatment ............................................................................. 120  
7.2.3.  Anti-Diarrheal  ............................................................................................................... 121  
7.2.4.  Antiemetics .................................................................................................................... 121  
7.2.5.  Permitted Concomitant Therapy requiring Caution and/or Action ............................... 121  
7.2.5.1.  CYP and UGT Substrates and Inhibitors .................................................................. 121  
7.2.5.2.  Transporter Substrate and Inhibitors ......................................................................... 122  
7.2.5.3.  Drugs with a Conditional or Possible Risk to Prolong the QT Interval and/or 
Induce Torsade de Pointes  ......................................................................................... 122  
8. ASSESSMENTS  ............................................................................................................... 123  
8.1. EFFICACY ASSESSMENTS ....................................................................................... 123  
8.2. PHARMACOKINETICS ASS ESSMENT  ................................................................... 125  
8.2.1.  Blood Samples Collection  ............................................................................................. 125  
8.2.1.1.  Collection Schedule ................................................................................................... 125  
8.2.1.2.  Technical Handling  ................................................................................................... 129  
8.2.2.  Samples Handling and shipping .................................................................................... 130  
8.2.3.  Analytical determination  ............................................................................................... 130  
8.2.4.  Sample Storage .............................................................................................................. 130  
8.3. SAFETY ASSESSMENT  ............................................................................................. 130  
8.3.1.  Adverse Events  .............................................................................................................. 130  
8.3.2.  Clinical Safety Laboratory As sessments ....................................................................... 131  
8.3.2.1.  Schedule .................................................................................................................... 132  
8.3.2.2.  Parameters  ................................................................................................................. 134  
8.3.3.  Physical Examination  .................................................................................................... 136  
8.3.4.  Vital Signs  ..................................................................................................................... 137  
8.3.4.1.  Schedule .................................................................................................................... 137  
8.3.4.2.  Technical Procedure and Parameters ......................................................................... 137  
8.3.5.  Electro cardiogram (ECG) and Echocardiogram/Multi-gated Acquisition Scans 
(ECHO/MUGA)  ............................................................................................................ 139  
8.3.5.1.  Schedule .................................................................................................................... 139  
8.3.5.2.  Technical Procedure and Parameters ......................................................................... 139  
8.3.6.  Ophthalmic Assessments ............................................................................................... 140  
8.3.7.  Dermatologic Evaluations ............................................................................................. 141  
8.3.8.  ECOG Performance Status  ............................................................................................ 142  
8.4. TISSUE AND BLOOD BIOMARKER ASSESSMENTS  ........................................... 142  
8.4.1.  Tumor Biomarker Assessments .................................................................................... 142  
8.4.2.  Blood Biomarker Assessments...................................................................................... 143  
8.4.2.1.  C-reactive protein  ...................................................................................................... 143  
8.4.2.2.  Tumor markers  .......................................................................................................... 143  
PII
exclusive property of Pierre Fabre W00090 GE 2 01  
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 9/234 8.4.2.3.  Circulating DNA (ct- DNA)  ....................................................................................... 144  
8.4.3.  Predictive Biomarkers of Activity ................................................................................. 144 
8.4.4.  Optional tumor biopsy ................................................................................................... 145  
8.4.5.  Retention of Samples for Future Analysis .................................................................... 146  
8.5. CONCOMITANT THERAPY AND THERAPEUTIC / DIAGNOSTIC 
PROCEDURE ASSESSMENT ..................................................................................... 147  
8.6. QUALITY OF LIFE ASSE SSMENT  ........................................................................... 147  
8.7. HEALTHCARE RESOURCE UTILIZATION  ............................................................ 148  
8.8. COMPLIANCE  ............................................................................................................. 149  
9. STUDY PROCEDURES  ................................................................................................. 150  
9.1. MAIN STUDY PERIOD (FROM F IRST SUBJECT SCREENE D TO 27 DEC 
2020).............................................................................................................................. 150 
9.1.1.  VISIT 1 – Screening visit (Day -28 to -1 prior to Cycle 1 Day 1)_ Main study period ............................................................................................................................. 150
 
9.1.2.  Cycle 1 - Day 1 _ Main studyperiod ............................................................................. 152  
9.1.3.  Cycle 1 - Day 8 _ Main study period ............................................................................ 153  
9.1.4.  Cycle 1 - Day 15 _ Main study period .......................................................................... 154  
9.1.5.  Cycle 1 - Day 22 _ Main study period .......................................................................... 154  
9.1.6.  Subsequent Cycles _ Main study period ....................................................................... 155  
9.1.7.  Subsequent Cycles Day 1 _ Main study period............................................................. 155  
9.1.8.  Subsequent Cycles - Day 8, Day 15 and Day 22 _ Main study period ......................... 156  
9.1.9.  End-of-Treatment Visit _ Main study period  ................................................................ 157  
9.1.10.  Safety Follow-up Visit and Survival Visits _ Main study period ................................. 158  
9.1.10.1.  Safety 30 Day -Follow-up Visit _ Main study period ................................................ 159  
9.1.10.2.  Survival Visit (every 3 months) _ Main study period  ............................................... 160  
9.2. STUDY EXTENSION PERI OD (FROM 28 DEC 2020) ............................................. 160  
9.2.1.  Subsequent Cycles_Study extension period .................................................................. 160  
9.2.2.  Subsequent Cycles Day 1 _ Study extension period ..................................................... 161  
9.2.3.  Subsequent Cycles - Day 15 _ Study extension period ................................................. 162  
9.2.4.  End-of-Treatment Visit _ Study extension period ........................................................ 162  
9.2.5.  Safety Follow-up Visit and Survival Visits _ Study extension period .......................... 163  
9.2.5.1.  Safety 30 Day -Follow-up Visit _ Study extension period......................................... 163  
9.2.5.2.  Survival Visit (every 3 months) _ Study extension period ....................................... 164  
10. ADVERSE EVENTS: DEFI NITION, NOT IFICATION AND REPORTING  .......... 166  
10.1.  ADVERSE EVENTS  .................................................................................................... 166  
10.1.1.  Definition  ...................................................................................................................... 166  
10.1.2.  Severity of Adverse Events ........................................................................................... 167  
10.2.  SERIOUS ADVERSE EVENTS  .................................................................................. 168  
10.2.1.  Definition  ...................................................................................................................... 168  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 10/234 10.2.2.  Reporting of Serious and non-serious AEs ................................................................... 169  
10.2.3.  Follow-up of SAEs ........................................................................................................ 170  
10.2.4.  SAEs occurring after the 30-day safety follow- up period ............................................. 170  
10.3.  REPORTING OF STUDY T REATMENT OVERDOSE TO  THE SPONSOR  .......... 170  
10.4.  REPORTING OF PREGNANCY TO THE SPONSOR  ............................................... 171  
10.5.  SPONSOR'S RESPONSIBI LITIES FOR SAFETY RE GULATORY REPORTING 
PURPOSES  ................................................................................................................... 171  
11. DATA COLLECTION AND STUDY MONITORING  ............................................... 172  
11.1.  DATA COLLECTION  .................................................................................................. 172  
11.1.1.  Case Report Forms  ........................................................................................................ 172  
11.1.2.  Source Documents......................................................................................................... 173  
11.2.  STUDY MONITORING  ............................................................................................... 173  
11.2.1.  Monitoring visits ........................................................................................................... 173  
11.2.1.1.  Site Preselection Visit ............................................................................................... 173  
11.2.1.2.  Initiation Visit ............................................................................................................ 174  
11.2.1.3.  Follow- up Visits  ........................................................................................................ 174  
11.2.1.4.  Closing Visit  .............................................................................................................. 175  
11.2.2.  Direct Access to Source Documents  ............................................................................. 175  
11.3.  PERIODIC S AFETY DATA REVIEW  ........................................................................ 175  
11.4.  STEERING COMMITTEE ........................................................................................... 176  
11.5.  IDSMC  .......................................................................................................................... 176  
12. DATA MANAGEMENT  ................................................................................................. 176  
12.1.  DATA COLLECTION  .................................................................................................. 177  
12.1.1.  Electronic Case Report Form (e- CRF)  .......................................................................... 177  
12.1.2.  Pharmacokinetics data  ................................................................................................... 177  
12.1.3.  Biomarkers  .................................................................................................................... 178  
12.1.4.  Imaging.......................................................................................................................... 178  
12.2.  DATA CLEANING  ...................................................................................................... 179  
12.3.  DATA CODING  ........................................................................................................... 179  
12.4.  DATABASE LOCK  ...................................................................................................... 179  
12.5.  DATA STORAGE  ........................................................................................................ 180  
13. STATISTICAL ANALYSIS  ........................................................................................... 180  
13.1.  GENERAL CONSIDERATIONS  ................................................................................ 180  
13.2.  OUTCOME MEASURES  ............................................................................................. 181  
13.2.1.  Primary outcome measure ............................................................................................. 181  
13.2.2.  Secondary outcome measures  ....................................................................................... 181  
13.3.  SAMPLE SIZE  .............................................................................................................. 182  
13.4.  PROTOCOL DEVIATIONS ......................................................................................... 183  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 11/234 13.5.  ANALYSIS SETS  ......................................................................................................... 183  
13.6.  HANDLING OF DROPOUTS  AND MISSING DATA  .............................................. 184  
13.7.  DEMOGRAPHIC AND OTHE R BASELINE CHARACTER ISTICS  ........................ 184  
13.8.  ANALYSIS OF OUTCOME MEASURES  .................................................................. 185  
13.8.1.  Analysis of Primary Outcome Measure ........................................................................ 185  
13.8.1.1.  Primary Analysis  ....................................................................................................... 185  
13.8.1.2.  Supportive Analysis .................................................................................................. 185  
13.8.1.3.  Exploratory Analysis ................................................................................................. 185  
13.8.2.  Analysis of Secondary Outcome Measures ................................................................... 186  
13.9.  SAFETY ANALYSIS  ................................................................................................... 187  
13.9.1.  Treatment exposure  ....................................................................................................... 187  
13.9.2.  Adverse Events  .............................................................................................................. 187  
13.9.3.  Clinical Safety Laboratory Evaluation .......................................................................... 188  
13.9.4.  Other Safety Data  .......................................................................................................... 189  
13.10.  QUALITY OF LIFE ANAL YSIS  ................................................................................. 189  
13.11.  EXPLORATORY ANALYSIS  ..................................................................................... 189  
13.12.  CONCOMITANT THERAPIE S AND THERAPEUTIC/ DIAGNOSTIC 
PROCEDURE  ............................................................................................................... 190  
13.13.  HEALTHCARE RESOURCE UTILIZATION  ............................................................ 190  
13.14.  PHARMACOKINETICS ANALYSIS  ......................................................................... 190  
13.15.  INTERIM ANALYSIS  ................................................................................................. 191  
14. GENERAL ETHICAL CONS IDERATIONS  ............................................................... 192  
14.1.  ETHICAL CONDITIONS  ............................................................................................ 192  
14.2.  INDEPENDENT ETHICS C OMMITTEE AND LEGAL REQUIREMENTS  ............ 192  
14.3.  SUBJECT’S INFORMATION LEAFLET AND INFORMED CONSENT FORM  .... 193  
14.4.  PERSONAL DATA PROTEC TION  ............................................................................ 194  
14.5.  INSURANCE POLICY................................................................................................. 194  
14.6.  FINANCIAL CONSIDERATIONS  .............................................................................. 194  
15. ADMINISTRATIVE PROCEDURES  ........................................................................... 195  
15.1.  PROTOCOL AMENDMENTS ..................................................................................... 195  
15.2.  SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE  .............................. 195  
15.3.  END OF STUDY  .......................................................................................................... 196  
15.3.1.  Definition of the end of study ....................................................................................... 196  
15.3.2.  Supply of product after Main study period ................................................................... 196  
15.4.  AUDIT  .......................................................................................................................... 196  
15.5.  INSPECTION ................................................................................................................ 197  
15.6.  CONFIDENTIALITY  ................................................................................................... 197  
15.7.  CLINICAL STUDY REPOR T ..................................................................................... 197  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 12/234 15.8.  STUDY RESULTS COMMUN ICATION  ................................................................... 197  
15.9.  STUDY RESULTS PUBLICATION ............................................................................ 198  
16. REFERENCES  ................................................................................................................. 199  
17. APPENDICES  .................................................................................................................. 206  
17.1.  RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF 
CETUXIMAB -INDUCED, ENCORAFENIB -INDUCED AND/OR 
BINIMETINIB -INDUCED SKIN TOXICITY  ............................................................ 206  
17.2.  RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF ENCORAFENIB -INDUCED HAND- FOOT SKIN REACT IONS (HFSR) ................ 209
 
17.3.  RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF BINIMETINIB -INDUCED DIARRHEA  ..................................................................... 211
 
17.4.  SNELLEN EQUIVALENCE (VISUAL ACUITY CONVERSION CHART)  ............ 214  
17.5.  LIST OF CONCOMITANT MEDICATIONS  ............................................................. 215  
17.6.  RESPONSE EVALUATION CRITERIA IN SOLID TUMORS RECIST VERSION 1.1 ................................................................................................................ 220
 
17.6.1.  Measurability of Tumor at baseline .............................................................................. 220  
17.6.2.  Specifications by methods of measurements ................................................................ 221  
17.6.3.  Tumor Response Evaluation ......................................................................................... 223  
17.6.4.  Evaluation of non- target lesion  ..................................................................................... 226  
17.6.5.  Time point response ...................................................................................................... 229  
17.7.  RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF BINIMETINIB AND CETUXIMAB - ASSOCIATED INTERSTITIAL LUNG 
DISEASE/PNEUMONITIS  .......................................................................................... 232
 
17.8.  PATIENT GLOBAL IMPRESSION OF CHANGE (PGI C) ........................................ 234  
   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 14/234  
 
SYNOPSIS 
 
Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
Title of the Study:  Phase II, open -label, single arm, multicenter study of encorafenib , binimetinib plus cetuximab in 
subjects with previously untreated BRAFV600E -mutant Metastatic Colorectal Cancer.  
Study Coordinating Investigator:   
 
Study Centre(s): Approximately 70 centers in Europe , North America and Japan  
Publication(s) / Rationale:  BRAF  mutations, which lead to constitutive activation of BRAF kinase and sustained 
RAS/RAF/MEK/ERK pathway signaling resulting in increased cell proliferation and survival occur in 
approximately 10% (range, 5 –22%) of the unselected colorectal cancer (CRC) popu lation ( Rozek LS et 
al, 2010 ; Shaukat A et al, 2010; Sorbye et al, 2015 ) with lower prevalence in mo re advanced subject 
populations . 
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in subjects with mCRC  
(metastatic ColoRectal Cancer)  with a median survival of approximately 12 to 14 months in the first line 
metastatic setting compared to 21 to 25 months for subjects with BRAF wild-type ( BRAF wt) tumors ( Van 
Cutsem E et al, 2011 ; Sorbye et al, 2015). 
Preclinical data  
The combination of binimetinib, encorafenib, and cetuximab was tested in a BRAFV600E  mutant human 
colorectal xenograft model. The average reduction in tumor volume across all animals was better in the 
group that received the triplet compared to the group that received encorafenib and cetuximab.  
Clinical data  
Consistent with nonclinical data in human colorectal cancer cell models ( Corcoran R B et al, 2010 ; Yang 
H et al 2012 ), BRAF+MEK+EGFR inhibitors result in greater  activity than a dual combination 
BRAF+EGFR of inhibitors  in subjects with BRAFV600E mCRC ( Van Cutsem E et al, 2015) . 
 
 
PII
PII
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 15/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
Publication(s) / Rationale:  There is a large ongoing multicenter randomized phase III study ([STUDY_ID_REMOVED]), the BEACON CRC 
study , evaluating binimetinib + encorafenib + cetuximab vs encorafenib + cetuximab compared with 
Investigator’s choice of irinotecan + cetuximab or FOLFIRI + cetuximab in subjects with BRAFV600E 
mutant mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. A total 
of 30 subjects were treated in the safety lead -in (SLI), all of whom received binimetinib (45 mg twice 
day ( BID)) + encorafenib (300 mg once daily ( QD)) + cetuximab (400 mg /m2 initial dose then 250 mg/m2  
once weekly ( QW) ). Among the 29 subjects with BRAFV600E muta nt tumors (one patient had a BRAF 
non-V600E muta nt tumor) the confirmed overall response rate ( cORR) was 48% (14/29 patients) and 
was 62% in patients with one previous line of therapy (10/16 patients) including 8 partial responses (PR ) 
and 2 complete responses (CR); and in those with two prior lines of therapy the c ORR was 31%, (4/13) 
including 3 PR and 1 CR. Preliminary estimate of median progression– free survival ( PFS) is 8.0 months 
(95% confidence interval ( CI), 5.6 –8.5 months), with 7 of 29 patients (24%) still in follow -up and 
progression-free at the cut off dat e. PFS was similar between patients who had 1 vs 2 previous regimens 
(median, 95% CI, 7.6 [4.0– 8.3] vs 8.1 [4.1 –10.8] months)  (Van Cutsem E et al, 2018).  
 
The confirmed ORR of 48% and median PFS of 8.0 months with the triplet combination of binimetinib 
+ encorafenib+cetuximab exceeds historical standard -of-care and exceeds the ORR of 22% in a phase II 
trial of the doublet of encorafenib + cetuximab  (Tabernero J et al, 2016).  
 
The encouraging preliminary efficacy results observed in the SLI part of the BEACON CRC study are 
consistent with the preclinical data and together justify the evaluation of this triple co mbination in the 
first-line setting of this population, which represents a high-unmet medical need.  
 
 
Main Study Period:  Nov 2018 – 27 
Dec 2020  Clinical Phase: II  
Estimated Study 
Extension Period  28 Dec 2020 – 
approximately 
Dec 2021  Study extension  
From 28 Dec 2020, access to study treatment will be provided through a Study 
extension to all subjects whom the investigator considers are continuing to benefit 
from study treatment (i.e. do not experience unacceptable toxicities and none of the 
treatment discontinuation criteria are met) until:  
• the last ongoing subject will discontinue study treatments (including 30-
day Safety Follow -Up visit) for any reason (unacce ptable toxicity, 
progression of disease, subject’s decision, withdrawal of consent , 
initiation of subsequent anticancer therapy or death),  
• or binimetinib/encorafenib are commercially available in the first line 
setting of BRAF V600E mutated mCRC,  
• or the binimetinib/encorafenib development program is stopped, 
whichever comes first. 
 
 
Objectives:  Primary:  
• To evaluate the antitumor activity of the combination of encorafenib, binimetinib and cetuximab 
by assessing the confirmed overall response rate (cORR) by local radiologist/investigator 
assessment in adult subjects with previously untreated BRAF V600E -mutant ( BRAFV600E) 
metastatic colorectal cancer (mCRC).  
 
 
 
 
Objectives:  Secondary:  
• To evaluate the cORR by central radiologist assessment.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 16/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
• To evaluate the ORR (for confirmed and unconfirmed responses) by local 
radiologist/investigator and central assessment.  
• To assess the effect of the combination of encorafenib , binimetinib and cetuximab on the 
duration of response (D OR). 
• To assess the effect of the combination of encorafenib , binimetinib and cetuximab on other  time-
related efficacy parameters: time to response (TTR), progression -free survival (PFS) and overall 
survival (OS) . 
• To characterize the safety and tolerability of the combination of encorafenib , binimetinib and 
cetuximab . 
• To assess the effect on quality of life (QoL) . 
• To explore health care resource utilization . 
• To describe the pharmacokinetics (PK) of encorafenib, binimetinib, a metabolite of binimetinib (AR00426032) and cetuximab. 
Exploratory:  
• To assess the relationship between changes in tumor markers (carcinoembryonic antigen [CEA] 
and carbohydrate antigen 19- 9 [CA19-9]) and radiographic response to treatment . 
• To assess BRAF
V600E status in blood circulating tumor DNA (ctDNA)  at baseline. 
• To assess the potential predictive significance of the mi crosatellite instability (MSI) status in 
subject s with BRAFV600E  mutant  mCRC.  
• To assess blood - and tissue -based predictive biomarkers of activity . 
 
Endpoints  Primary:  
• cORR as assessed by local radiologist/investigator review  as per Response Evaluation Criteria 
in Solid Tumors (RECIST 1.1) .  
Secondary:  
• cORR as assessed by central radiologist review as per RECIST 1.1. 
• ORR (for confirmed and unconfirmed responses) as per local  radiologist/investigator and central 
assessment.  
• DOR assessed based on local radiologist/investigator and central review.  
• TTR assessed based on local radiologist/investigator and central review.  
• PFS assessed based on local radiologist/investigator and central review.  
• OS. 
• Type and severity of adverse even ts (AEs) and serious adverse events (SAEs), changes in 
hematology and chemistry values, physical examinations, vital signs, electr ocardiogram ( ECGs ) 
and echocardiogram ( ECHO)/ multi-ga ted acquisition ( MUGA ) scans and ophthalmological 
examinations graded according to the National Cancer Institute Common Terminology Criteria 
for Adverse Events  v4.03 (NCI -CTCAE v4.03).  
• Change from baseline in the European Organization for Research and Treatment of Cancer 
(EORTC) Quality of Life Questionnaire for Cancer subjects (QLQ -C30), EuroQol -5D-5L (EQ -
5D-5L), and Patient Global Impression of Change (PGIC) . 
• Resource utilization focused on hospitalizations occurring during the study treatment phase . 
• Plasma concentration s of encorafenib, binimetinib  and the active metabolite of binimetinib 
(AR00426032) and serum concentration of cetuximab.  
Exploratory:  
• Changes from baseline in blood CEA and CA19-9 at the beginning of each cycle and at the end 
of treatment . 
• BRAF V600E mutation status in ct -DNA at baseline. 
• MSI status in formalin -fixed paraffin -embedded ( FFPE ) samples via established PCR assays in 
tumor sample versus germline control  at screening . 
• Genomic and proteomic analysis of tumor tissue at baseline and at end of treatment (optional 
tumor tissue sample at end of treatment).  
• Genomic and proteomic analysis of blood samples at baseline . 
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 17/234  
 
Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
Methodology:  This is a multinational, multicenter, open -label, single -arm phase II study to evaluate the combination of 
encorafenib, binimetinib and cetuximab in subjects with BRAFV600E mutant mCRC who have not  received 
any prior systemic therapy for metastatic disease.   
Subjects will be eligible for the study based on identification of a BRAFV600E mutation in the tumor tissue 
as determined by local laboratory result obtained at any time prior to Screening. Only polymerase chain reaction (PCR) and next generation sequencing (NGS) -based results will be acceptable. The BRAF  mutation 
status must be con firmed by central laboratory no later than 30 days after the first dose of study treatment. 
In cases where there is discordance between the local assay and central laboratory results, or if the central laboratory is not able to confirm presence of a BRAF
V600E mutation due to inadequate or poor sample 
condition or insufficient amount of tumor cells in sample within 30 days of initiating study therapy, subjects 
may only continue treatment if there is no clinical indication of deterioration or disease progress ion and the 
Investigator determines that the subject is deriving benefit. In such instances, subjects must be informed 
that the BRAF mutation status is unconfirmed and must sign a separate informed consent form (ICF) that 
includes this information and desc ribes alternative treatment options.  
 
Main study period design (treatment phase)  
The Main study period will include two stages according to a two -stage design.  
Stage 1: In the first stage, 40 subjects will be treated. In case of discordance in the results between the local 
assay and the central laboratory (potential false-positive local result), or lack of BRAFV600E confirmation, 
subject will be replaced for the primary analysis of the futility analysis. If there are 11 or fewer confirmed 
responses (CR or P R) in the 40 treated subjects with a centrally confirmed BRAFV600E mutation, the study 
will be stopped. Otherwise, additional subjects will enter stage 2 . Stage 2 may be initiated as soon as 40 
subjects with a centrally confirmed BRAFV600E mutation are tr eated and confirmed responses are observed 
in at least 12 subjects.  
Stage 2: 50 additional subjects will be treated, for a total of 90 subjects with a centrally confirmed 
BRAFV600E mutation. In case of discordance in the results between the local assay and  the central laboratory 
(potential false -positive local result), or lack of BRAFV600E confirmation, subject s enrolled in the stage two 
of the trial will be replaced for the primary analysis.  
If at any time during the study, either in stage 1 or in stage 2 , there is discordance between the local assay 
and the central laboratory in 3 subjects (≥ 3% of the total targeted 90 treated subjects)  or impossibility to 
confirm the BRAFV600E mutation in 6 subjects  (≥ 6% of the total targeted 90 treated subjects),  all subsequent 
subjects will be required to have BRAFV600E determined by the central laboratory prior to study treatment 
assignment.For the statistical design, please refer to the statistical section hereunder.  
 
Treatment will be administered in 28 -day cycles until disease progression, unacceptable toxicity, 
withdrawal of consent, initiation of subsequent anticancer therapy or death.   
  An independent Data Safety Monitoring Committee (iDSMC) will review the available safety information at regular intervals as defined in the iDSMC charter.  
 Main study period will end, as initially planned, 1 year after the start of study treatment of the last subject enrolled (as the last enrolled subject started study treatment on 27 Dec 2019, Main study period will end on 27 Dec 2020).  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 18/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
Methodology:  Study extension period design  
 
After the Main study period (period from first subject screened to 1 year after the start of study treatment 
of the last subject enrolled), access to study treatment will be provided from 28 Dec 2020 through a Study 
extension to all subjects whom the inves tigator considers are continuing to benefit from study treatment 
(i.e. do not experience unacceptable toxicities and none of the treatment discontinuation criteria are met) 
until:  
• the last ongoing subject will discontinue study treatments (including 30- day Safety Follow -Up 
visit) for any reason (unacceptable toxicity, progression of  disease, subject’s decision, withdrawal 
of consent, initiation of subsequent anticancer therapy or death),  
• or binimetinib/encorafenib are commercially available in the first l ine setting of BRAF V600E 
mutated mCRC,  
• or the binimetinib/encorafenib development program is stopped, whichever comes first.  
 
Number of subjects:  Target: 90 treated*subjects  
Stage 1: 40 treated subjects; Stage 2: 50 treated subjects.  
 
*In case of discordance in the results between the local assay and the central laboratory (potential false-
positive local result), or lack of BRAF
V600E confirmation, subject will be replaced. If at any time there is 
lack of confirmation of the BRAFV600E mutation in a total of 6 subjects (≥ 6% of the total targeted 90 treated 
subjects ) or discordance between the local assay and thec entral  laboratory in 3 subjects (≥ 3% of the total 
targeted 90 treated subjects ), all subsequent subjects will be required to ha ve BRAFV600E determined by the 
central laboratory prior to study treatment assignment.  
 
Diagnosis and Criteria for eligibility  
 
 Each subject fulfilling all the inclusion criteria and none of the exclusion criteria will be eligible.  
 
Inclusion Criteria  
 
1. Provide a signed and dated informed consent document.  
2. Male or female ≥ 18 years of age at time of informed consent.  
3. Histologically or cytologically confirmed CRC that is metastatic and unresectable at time of study entry (i e. not 
suitable for complete surgical resection at screening).  
4. Presence of BRAFV600E mutation in tumor tissue previously determined by a local assay at any time prior to 
screening.  
Notes:  
a. Only PCR and NGS -based local assays results will be acceptable.  
 
b. If at any time there is lack of confirmation of the BRAFV600E mutation in a total of 6 subjects (≥ 6% of the total 
targeted 90 treated subjects) or discordance between the local assay and the central laboratory in 3 subjects (≥ 3% of the total targeted 90 treated subjects), all subsequent subjects will be required t o have BRAF
V600E 
determined by the central laboratory prior to study treatment assignment.  
 
c. Central testing cannot be repeated to resolve discordances with a local result once the central laboratory 
delivers a definitive result (positive or negative).  
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 19/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
d. If the result from the central laboratory is indeterminate or the sample is deemed inadequate for testing, 
additional samples should be submitted (archival material only).  
 
e. If more than 1 discordant result from any local laboratory leads to subject enrollment , subsequent results from 
this local laboratory  will not be accepted for further subject enrollment.  
5. Eligible to receive cetuximab per locally approved label with regards to tumor RAS status.  
 e.g.  In agreement with EU label, evidence of wild type RAS (KRAS and NRAS) in EU countries.  
 6. Able to provide a sufficient amount of representative tumor specimen (primary or metastatic, archival or newly 
obtained) for  testing of BRAF and RAS mutation status.  
 Note  FFPE tumor tissue block or a minimum of 10 slides, optimally up to 15 slides  
 
7. Evidence of measurable disease, as per RECIST 1.1.  
Note  Lesions  in areas of prior radiotherapy or other loco -regional therapies are considered measurable only if 
progression has been documented in the region following therapy.  
 8. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.  
9. Adequate bone marrow f unction at screening and baseline:  
i. Absolute neutrophil count (ANC) ≥ 1.5 x 10
9/L. 
ii. Platelets ≥ 100 x 109/L. 
iii. Hemoglobin ≥ 9.0 g/dL.  
Note  Blood transfusions are allowed provided that the subject has not received more than 2 units of red blood cells in the 4  weeks prior to achieve the minimum required hemoglobin level.  
 10. Adequate renal function at screening and baseline:  
i.  Serum creatinine ≤ 1.5x upper limit of normal (ULN) or  
ii. Calculated creatinine clearance (CrCl) ≥ 50 mL/min by Cockroft -Gault formula  
11. Adequate electrolytes at screening and baseline, defined as serum potassium and magnesium levels within 
institutional normal limits.  
Note  replacement treatment to achieve adequ ate electrolytes will be allowed  
 
12. Adequate hepatic function at screening and baseline:  
i. Serum total bilirubin ≤ 1.5 x ULN and < 2 mg/dL. Note  Total bilirubin > 1.5 x ULN is allowed if 
direct (conjugated) bilirubin is ≤ 1.5 x ULN (and indirect (unconjugated) bilirubin is ≤ 4.25 x ULN – Only applicable for France).  
ii. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x ULN, or ≤ 5 x ULN in the presence of liver metastases.  
 
13. Adequate cardiac function at screening:  
i. Left ventricular ejec tion fraction (LVEF) ≥ 50% as determined by MUGA scan or ECHO.  
ii. Mean triplicate QT interval corrected for heart rate according to Fridericia’s formula (QTcF) value ≤ 480 msec.  
14. Subject able to take oral medications.  
15. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.  
16. Female subjects are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy.  
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 20/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
Notes 
(a) Precautions to avoid pregnancy must be conducted from screening  through 6 months after the last dose of 
cetuximab or through 30 days after the last dose of encorafenib or binimetinib, whichever is later if of childbearing 
potential.  
(b) Permitted methods of contraception as provided (in Section 5.3.1 ) should be communicated to the subjects and 
their understanding confirmed. For all females, the pregnancy test must be negative at screening and baseline.  
 17. Male subject must agree to take appropriate precautions to avoid fathering a child  
Notes  
(a) from screening through 6 months after the last dose of cetuximab or through 90 days afte r the last dose of 
encorafenib or binimetinib, whichever is later.  
(b) permitted methods of contraception as provided (in Section 5.3 ) should be commun icated to the subjects and their 
understanding confirmed.  
 18. Subjects under guardianship or partial guardianship will be eligible unless prohibited by local laws or by 
local/central ethic committees.  
Note  where allowed, all procedures prescribed by law must be followed.  
 
19. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation).  
 
 
Diagnosis and 
Criteria for 
eligibility  Exclusion Criteria  
 
1. Prior systemic therapy for metastatic disease.  
Note  previous adjuvant/neoadjuvant therapy is allowed provided that 1) the interval from the end of chemotherapy to relapse is >6 months OR 2) in the case of neoadjuvant therapy, complete surgical resection was achieved and the interval from the end of chemotherapy to r elapse is >12 months. Prior locoregional radiotherapy is allowed.  
 
2. Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti -EGFR treatment.  
3. Symptomatic brain metastasis.  
Note  subjects previously treated or untreated for these conditions who are asymptomatic in the absence of corticosteroid and anti -epileptic therapy are allowed. Brain metastases must be stable for ≥ 4 weeks with imaging (e.g. 
brain magnetic resonance imaging [MRI] or computed tomography [CT] demonstrating no current e vidence of 
progressive brain metastases at screening).  
 4. Leptomeningeal disease.  
5. History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors for RVO.  
Note  Risk factors for RVO are uncontrolled glaucoma or ocular hypertension, history of hyperviscosity syndrome or hypercoagulability syndrome.  
 6. Use of any herbal medications/supplements or any medications or foods that are moderate or strong inhibitors or 
inducers of CYP3A4/5 ≤ 1 week prior to the start of treatment.  
7. Note  However, subjects who either discontinue moderate or strong inhibitors or inducers of CYP3A4/5 or switch to another medication at least 7 days prior to starting study treatment are eligible.  Known history of acute or 
chronic pancreatitis within 6 months prior to the start of the treatment.  
8. History of chronic inflammatory bowel disease or Crohn’s disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first dose.  
9. Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:  
i. History of acute myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft (CABG), coronary angioplasty or stenting) ≤ 6 months prior to start of study treatment.  
ii. Symptomatic congestive heart failure (Grade 2 or higher), history or current evidence of clinically significant arrhythmia and/or conduction abnormality ≤ 6 months prior to start of  study treatment, except 
rate controlled atrial fibrillation and paroxysmal supraventricular tachycardia.    
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 21/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
10. Uncontrolled hypertension defined as persistent elevation of systolic blood pressure ≥ 150 mmHg or diastolic 
blood pressure ≥ 100 mmHg despite optimal  therapy.  
11. Impaired hepatic function, defined as Child -Pugh class B or C.  
12. Known history of Gilbert's syndrome or is known to have any of the following genotypes: UDP glucoronosyl 
transferase (UGT)1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28. No more applicable from Protocol 
V6.0/Amendment PA03  
13. Impaired gastrointestinal function or disease* which may significantly alter the absorption of encorafenib or 
binimetinib or recent changes in bowel function suggesting current or impending bowel obstruction.  
*e.g. ulcerat ive diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection.  
 
14. Previous or concurrent malignancy* within 5 years of study.  
*except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, 
carcinoma in- situ of the cervix or any other malignancy that has been adequately treated and has not recurred within 
3 years prior to study entry.  
 15. History of thromboembolic* or cerebrovascular events** ≤ 6 months prior to starting study treatment.  
*excluding venous thrombosis related to indwelling catheters and treated with low -grade anticoagulants  
**including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli.  
16. Concurren t neuromuscular disorder that is associated with the potential of elevated Creatine Kinase (CK).  
Note  e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy.  
 17. Residual CTCAE ≥ Grade 2 toxicity from any pri or anticancer therapy, with the exception of Grade  2 alopecia or 
Grade 2 neuropathy.  
18. Known history of human immunodeficiency virus (HIV) infection.  
Note  HIV testing will only be conducted in jurisdictions specifically requiring it.  
 19. Active hepatitis B or hepatitis C infection.  
20. Known contraindication to receive cetuximab at the planned doses. Refer to the most recent cetuximab summary 
of product characteristics (SPC) or local label as applicable.  
21. Subjects who have any medical condition  that would, in the Investigator’s judgment, prevent the subject’s 
participation in the clinical study due to safety concerns or compliance with study procedures.  
22. Any medical or psychiatric condition or laboratory abnormality that may increase the risk with study participatio n or study drug administration or that may interfere with the interpretation of study.  
23. Pregnancy, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test result, or breastfeeding.  
 
24. Is a family member of the Investigator or any associate,  colleague, or employee assisting in the conduct of the 
study (secretary, nurse, technician).  
25. Is in a position likely to represent a conflict of interest.  
26. Participation in a clinical study with administration of an investigational product within 4 weeks o r five times the 
half-life of the investigational product, whichever is longer, before the first dose of study treatment.  
Is mentally unable to understand the nature, objectives and possible consequences of the trial; or he/she refuses to 
its constraints.  
27. Is mentally unable to understand the nature, objectives and possible consequences of the trial; or he/she refuses to 
its constraints.
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 22/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
Test Product, dose and mode of administration:   Encorafenib: 300 mg PO (oral capsule 4X 75 mg) QD.  
Binimetinib: 45 mg PO (oral tablet 3X 15 mg) BID.  
Cetuximab: 400 mg/m
2 intravenous (IV) at Cycle 1 day 1 then 250 mg/m2 IV every week (QW) for the first 
28 weeks. Then, 500mg/m2 IV every two weeks (Q2W) from week 29 (Cycle 8 day 1).  
Since implementation o f the Urgent Safety Measure (USM) on 26 Mar 2020, to ensure the subjects’  safety 
in the clinical trial by decreasing the number of clinic visits in the context of COVID -19 pandemic , 
Cetuximab infusions can be given every two weeks at the dose of 500 mg/m2 administered as a 120 -min 
IV infusion  (i.e. on D1 and D15 of each cycle) regardless of  the cycle number , after  the investigator has  
evaluated the benefi t/risk ratio for the subjec t with regards to Covid -19 pandemic.   
If there is a dose modification prior to switching to the biweekly schedule, the total dose per cycle should 
be maintained (i.e. 200mg/m2 QW may be changed to a 400mg/m2 Q2W).Cycle duration: 28 days.  
Duration of Treatment:  The treatment will be administered during Main s tudy and Study extension periods
 until disease 
progression, unacceptable toxicity, subject’s decision, withdrawal of consent, initiation of subsequent 
anticancer therapy or death. After discontinuation of stu dy treatment, there will be a 30 -day safety follow -
up period. Subjects will then enter a survival follow -up period. If a subject discontinues the treatment for a 
reason other than progressive disease, tumor assessment must be performed (as per local and central review) until the start of new anti -cancer therapy, disease progression, death, lost to follow -up, subject decision or 
withdrawal consent  or until the End of the Study.  
Statistical Methods:  Sample Size Determination  
 
The sample size is based on a two -stage design with nominal alpha=2.5% and beta=20%. The null 
hypothesis that the true response rate is 30% (maximum unacceptable probability of response) will be tested against a one -sided alternative. In the first stage, 40 subjects will be treated. Subjects in whom the presence 
of  BRAF
V600E  is not confirmed by central laboratory will be replaced.  If there are 11 or fewer confirmed 
responses in the 40 treated subjects with a centrally confirmed BRAFV600E mutation, inactiv ity will be 
declared and the study will be stopped for futility.  
The time point for the futility analysis will be after all 40 treated subjects of stage 1 with centrally confirmed 
BRAFV600E mutation had the opportunity to complete four post baseline asses sments and after subjects with 
an initial objective response have had an opportunity to have a confirmation scan. However, it will be 
possible to proceed to Stage 2 as soon as 40 subjects with a centrally confirmed BRAFV600E mutation are 
treated and 12 confirmed responses are observed.  
Subjects data that will be analyzed during the futility analysis will be reviewed on an ongoing basis in order to determine as soon as possible (even before the inclusion of the 40th subject ) whether the criteria for 
continuing to stage 2 (12 confirmed responses ) are satisfied or not.  
 
As it may take several treatment cycles for subjects to achieve a confirmed response, a limited number of 
subjects (maximum  12) from stage 2 may be treated  while waiting for all subject s in the initial cohort of 40 
subjects in Stage 1 to be evaluable for a confirmed response providing no safety concern was raised by the iDSMC . These additional subjects will not count towards responses in Stage 1 but will be included as part 
of the Stage 2 cohort, should the study move forward into Stage 2.  
If at any time it becomes evident that the threshold of 12 responses is unlikely to be met, then additional subjects may not be recruited (eg: 6 or fewer responses among 35 subjects with sufficient foll
ow up 
[potential for at least 2 assessments]). If the study continues to the second stage, 50 additional subjects will be treated for a total of 90. Subjects in whom the presence of BRAF
V600E mutation is not confirmed by 
central laboratory will be replaced . The null hypothesis will be rejected if 37 or more confirmed responses 
are observed in 90 treated subjects  with a centrally confirmed BRAFV600E mutation. This design yields a 1 -
sided type I error rate of 1.6% and power of 80% when the true response rate  is 45%.  
The cut -off for stage 2 analysis will be after all 90 treated  subjects of stage 1 and 2 with centrally confirmed 
BRAFV600E mutation had the opportunity to complete four post -baseline tumor assessments , and after 
subjects with an initial objective  response have had an opportunity to have a confirmation scan.  
 
 
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 23/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
Statistical 
Methods:  
  
Data analysis  
 
The Full Analysis Set (FAS) is composed of all included subjects having received at least one dose of study 
treatment (partial or full).  
The Efficacy Set (ES) is composed of all FAS subjects with a centrally confirmed BRAFV600E mutation.The 
Per-Protocol Set (PPS) will consist of all subjects from the FAS without any major protocol deviations.  
The PK Set will consist of all subjects who receive at least 1 dose of encorafenib, binimetinib or cetuximab and who have at least 1 post -dose PK blood collection wit h associated bioanalytical results.  
 
Efficacy:  
The FAS and ES will be used for all efficacy analyses unless otherwise specified.  
For the main analysis of the primary endpoint, the 95% confidence interval (CI) will be provided on the ES. This analysis will  be  repeated on the FAS and PPS (supportive analysis).  
OS will be analyzed using the Kaplan-Meier method that will show median time with accompanying 95% CI and estimates for OS at several time points (including at least 2, 4, 6, 8, 10 and 12 months after start of treatment). Subjects without a death date by the data cut -off date will be censored for OS at their last contact 
date or the cutoff date, whatever is earlier. Analysis of PFS, DOR and TTR will be performed according to the Kaplan -Meier metho d. 95% CIs for the median values will be provided.  
Descriptive methods will be used to present all relevant data:  
- Continuous data will be summarized with: frequency, median, range, mean, standard deviation and 
standard error if relevant.  
- Categorical data will be presented in contingency tables with frequencies and percentages of each modality 
(including missing data modality).  
 
Safety:  
 FAS will be used for all safety analyses.  
Maximum grade or severity will be tabulated, for each Medical Dictionary F or Regulatory Activities 
(MedDRA) System Organ Class and Preferred Term, by cycle and by subject.  
All analyses will be performed in two different ways: regardless or not of the relationship to treatment as 
assessed by the investigator.  
 
QoL : 
 
Results of Q oL questionnaires (EORTC QLQ -C30, EQ -5D-5L, PGIC) will be summarized for each visit 
using descriptive statistics on the FAS. Additionally, changes from baseline in the domain scores at the 
time of each assessment will be summarized for EORTC QLQ -C30 and EQ -5D-5L. Further analysis will 
be detailed in the Statistical Analysis Plan.  
 
Pharmacokinetic analyses  
 
Plasma concentrations of encorafenib, binimetinib and the active metabolite of binimetinib (AR00426032) 
and serum concentration of cetuximab will be determined using validated assays. Descriptive statistics of 
concentrations will be reported.  
Ad-hoc PK parameters may be generated by compartmental approaches as appropriate.  
 
 
 
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
  
 
Clinical Study Protocol W00090 GE 2 01_Version 9_ 17 JUL20 24/234 Name of Sponsor:  Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)  
Name of Finished 
Product:  Encorafenib, Binimetinib, Cetuximab  
End of study definition:  The end of the study is defined as the time point when all treated subjects will have either progressed or 
discontinued study treatmen ts (including 30- day Safety Follow -Up visit) fo r any other reason  (unacceptable 
toxicity, subject’s decision, withdrawal of consent, initiation of subsequent anticancer therapy or death ). 
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
   
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  33/234 
   
a Except C1D1, if visit is missed . 
Theoretical cycles dates (7 days ± 3) are kept constant irrespectively of whether the visit is done and/or the product is administered or not.  
If subjec t doesn´t come for CnD1 visit, the CnD1 assessments will still need to be performed (and shall be recorded on the unscheduled v isit in the e -CRF).  
b Local urine pregnancy test for women of childbearing potential except serum pregnancy test at EOT.  
c Hematology - list of analytes: basophils, eosinophils, hematocrit, hemoglobin, lymphocytes, monocytes, neutrophils/absolute neutrophil count (ANC), platelets, red blood cells (RBC), white blood cells (WBC)  
d Clinical Chemistry – list of analytes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (total and direct),albumin, alk aline phosphatase, bicarbonate (HCO3), blood urea nitrogen (BUN)/  
urea, calcium, chloride, creatine kinase (CK), creatinine, glucose, lactate dehydrogenase (LDH), magnesium, potassium, sodium, total protein, troponin I or T, uric acid, amylase, lipase.   
Calcul ated creatinine clearance (Cockroft -Gault formula) will be measured at screening   
Bicarbonates  (HCO3) : not mandatory in Japan  
e Coagulation – list of analytes: prothrombin time (PT) or International Normalized Ratio (INR);activated partial thromboplastin time (aPTT)  
f Urinalysis – list of analytes: blood, glucose, ketones, leukocytes, hydrogen ion concentration (pH), protein  
g Procedure does not have to be repeated if performed within 72 hours prior to Cycle 1 Day 1 (i.e., first day of dosing).  
h -Electrocardiograms are to be performed in triplicate after 5 min utes rest predose on Cycle 1 Day 1 (conducted within approximately 5 to 10 minutes total time), followed by a single ECG at 2.0  (+/- 0.5) hours after 
administration of encorafenib and binimetinib and before the start of the cetuximab infusion.  
 -Single ECGs are to be performed on Cycle 2 Day 1 predose and at 2.0 (+ /- 0.5) hours after administration of encorafenib and binimetinib  and before the start of the cetuximab infu sion.  
-Single ECGs are to be performed predose at remaining time points. Electrocardiograms should be performed prior to PK and PD b lood collection at equivalent nominal timepoints.  
i Visual assessment (General inspection of the eyes, examination of motility and alignment, visual disturbance including diminished central vision, blurred vision or loss of visio n) to be performed on site by the 
investigator . 
Full ophthalmic examination  by ophthalmologist to be performed at EOT and, if clinically indicated during treatment , including best corrected visual acuity for distance testing , slit lamp examination, intraocular 
pressure and dilated fundoscopy with attention to retinal abnormalities , OCT and/or fluorescein angiography  as appropriate . 
A full ophthalmic examination at the 30 -day follow up is  only required if there was a clinically significant abnormality noted at EOT.   
j Dermatologic examinations are to be performed every 8 weeks from Cycle 1 Day 1 (i.e., on Day 1 of Cycles 3, 5, 7…).  
k ECHO/MUGA scans are to be performed on Cycle 2 Day 1 and Cycle 5 Day 1, then every 12 weeks and EOT  
l Tumor evaluations are to be perfo rmed every 6 weeks (±7 days) from first dose for the first 12 weeks, then every 8 weeks (±7  days) until disease progression. The time window allowed for the first tumor  
assessment (i.e. day 42 from first dose) is +7 days.  
m If a subject  discontinue study treatment for reasons other than disease progression, then tumor assessments must be performed (as per local and central review) every 6 weeks (first 12 weeks)  
 then every 8 weeks  until the start of new anti -cancer therapy, disease prog ression, death, lost to follow -up, subject ’s decision or consent withdrawn.  
n PK samples will be collected during Cycle 1 and Cycle 2 only. On Cycle 1 Day 1 postdose at 2 h (± 10 min) and 6 h (± 30 min).  PK samples will be collected on Cycle 2 Day 1 predose (just prior to dosing) and  
postdoseat 2 h (± 10 min). PK blood samples for encorafenib/binimetinib and potentially relevant metabolites will be processed to plasma. PK blood samples for cetuximab will be processed to serum.  
o Optional tumor sample will be requested only for subject s that discontinue study  drug treatment due to disease progression.  
p For subjects who discontinue study treatment due to disease progression , the survival follow up phase will start after the 30 -days safety follow up is complete  The subject will be contacted by phone for collection of 
information This may be conducted more frequently as needed . 
For subjects who discontinue study treatment due to reasons other than disease progression ,  tumor assessm ent  must be performed until start of new anti cancer therapy,disease progression, death, lost to follow -up, 
subject’s decision or consent withdrawn.  
q To be performed 30 -day after end of treatment (EOT) , when clinically appropriate, it is recommended subject s be monitored with physical examinations, dermatological examinations and chest CT scans for  
cutaneous and non -cutaneous secondary malignancies for up to 6 months after the last encorafenib dose or until initiation of another antineopla stic therapy.   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
   
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  34/234 
  r To be performed prior to study treatment administration. Only for vital signs: n ot to be performed at D8 and D22 starting week 29.  
Complete physical examination to be perfo rmed at screening. For all other visits, physical examination should be targete d as clinically indicated  
s The questionnaires should be completed by the subject s at the beginning of the study visit prior to receiving any study treatment, prior to any other study assessment or consulta tion with the Investigator,  
and prior to being informed of their current disease status.  
t Cetuximab wil l be administered as a weekly schedule for the first 28 weeks. Subjects on study will switch to a biweekly schedule starting on  week 29 (Cycle 8 day 1).  
Since implementation of the  Urgent Safety Measure on 26  Mar 2020, in order to ensure the subjects’ saf ety in the clinical trial by decreasing the number of clinic visits  in the context of COVID -19 pandemic , 
Cetuximab infusions can be given every two weeks at the dose of 500 mg/m2 administered as a 120 -min IV infusion (i.e. on D1 and D15 of each cycle) regardless of the cycle number, after the investigator ha s 
evaluated the benefit/risk ratio for the subjec t with regards to Covid -19 pandemic . 
 
If there was a dose modification prior  to switching to the biweekly schedule, the total dose per cycle should be main tained (i.e. 200mg/m2 QW, may be changed to a 400mg/m2 Q2W) .  
 
u Information related to the length of stay, hospital facilities used, reasons for hospitalization, and hospital discharge info rmation will be collected  
v From Week 29 (cycle 8), D8 and D22 visits will not be performed  (biweekly infusions of cetuximab: no cetuximab infusion on D8 and D22)  
Since implementation of the  Urgent Safety Measure on 26  Mar 2020, in order to ensure the subjects’ safety in the clinical trial by decreasing the numbe r of clinic visits  in the context of COVID -19 pandemic , 
Cetuximab infusions can be given every two weeks at the dose of 500 mg/m2 administered as a 120 -min IV infusion (i.e. on D1 and D15 of each cycle) regardless of the cycle number, after  the investigato r has  
evaluated the benefit/risk ratio for the subjec t with regards to Covid -19 pandemic . 
If the investigator implements this change, D8 and D22 visit s before C8D1  will be performed by phone calls to ensure subjec t’s safety and will have to be documented in source documents for subjects  not having yet 
reached C8D1 at the time of USM implementation . 
Abbreviations:  BSA = body surface area; CA19 -9 = cancer antigen 19 -9; CEA = carcinoembryonic antigen; CT = computed tomography; ECG = electrocardiogram; ECHO = echocardiogram; ECOG PS = Easter n Cooperative  
Oncology Group Performance Status; EORTC QLQ -C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; EQ -5D-5L = EuroQol -5D-5L; HIV= Human immuno deficiency virus; IV 
= intravenous(ly); MRI = magnetic resonance imaging; MSI = micros atellite instability; MUGA = multi- gated a  
cquisition; PD = progressive disease; PGIC = Patient's Global Impression of Change; PK  = pharmacokinetic(s).  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
   
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  37/234 
  a From 28 dec  2020 (start of Study extension period), all treated subjects who are still benefiting from study treatments, will continue , if they consent,  to receive study treatment in the Study 
extension period (protocol  amendment 6 – protocol V9).  
After treatment is discontinued (during Main study or Study extension period s), all subjects , if they consent,  will be followed for survival until.the End of t he Study (defined as the time point 
when all treated subjects will have either progressed or discontinued study treatments (including 30 -day Safety Follow- Up visit) f or any other reason (unacceptable toxicity, subject’s 
decision, withdrawal of consent, ini tiation of subsequent anticancer therapy or death).   
b Theoretical cycles dates (15 ± 3  days) are kept constant irrespectively of whether the visit is done and/or the product is administered or not.  
If subject  doesn´t come for CnD1 visit, the CnD1 assessments will still need to be performed (and shall be recorded on the unscheduled v isit in the e -CRF).  
c Local urine pregnancy test for women  of childbearing potential except serum pregnancy test at  EOT.  
d Hematology - list of analytes: basophils, eosinophils, hematocrit, hemoglobin, lymphocytes, monocytes, neutrophils/absolute neutrophil cou nt (ANC), platelets, red blood cells (RBC), white 
blood cells (WBC)  
e Clinical Chemistry – list of analytes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (total and direct), albumin, al kaline phosphatase,, calcium, chloride, 
creatinine, glucose, magnesium, potassium, sodium, total protein,      
f Urinalysis – list of analytes: blood, glucose, ketones, leukocytes, hydrogen ion concentration (pH), protein  
g Blood sample for tumor markers (CEA, CA19 -9)  should be collected only  if performed as per clinical routine practice  
h  ECGs scans must be performed  every 3 cycles at D1  and at EOT ; and more frequently  if clinically indicated during study .  
ECHO MUGA must be performed every 12 weeks at D1, and at EOT  or more frequently if clinically indicated during study  
i Visual as sessment ( general inspection of the eyes, examination of motility and alignment, visual disturbance including diminished central vision,  blurred vision or loss of vision) to be 
performed on site by the investigator.  
Full ophthalmic examination by ophthalmologist to be performed at EOT and, if clinically indicated during treatment, including best corrected visual acuity for dista nce testing, slit lamp 
examination, intraocular pressure and dilated fundoscopy with attention to retinal abnormalities, OCT and/or  fluorescein angiography as appropriate.  
A full ophthalmic examination at the 30 -day FU is only required if there was a clinically significant abnormality noted at EOT  
j Tumor evaluations to be performed  every 12 weeks (±7  days) until disease progression  
k If a subject  discontinue s study treatment for reasons other than disease progression, then tumor assessments should continue to be performed ( per loca l and central r eview)  every 12 weeks  
until the start of new anti- cancer therapy, disease progression, death, lost to follow -up, patient decision, consent withdrawn or study end  
l For subjects who discontinue study treatment due to disease progression, the survival follow up phase will start after the 30 -days safety follow up is complete. The subject will be contacted 
by phone for collection of information every 3 months.  
For subje cts who discontinue study treatment due to reasons other than disease progression,  tumor assessment  must be performed until  start of new anti cancer therapy,disease progression, 
death, lost to follow -up, subject’s decision, consent withdrawn or study end . 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
   
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  38/234 
  m To be performed  30 -days after end of treatment (EOT).  
When clinically appropriate,as per standard of care it is recommended that subjects   be monitored for physical examinations, dermatological examinations and chest CT scans for cutaneous 
and non -cutaneous secondary malignancies for up to 6 months after the last encorafenib dose or until initiation of another antineoplas tic therapy.  
n To be performed prior to study treatment administration.  
For Physical examination: examination should be should be targeted as clinically indicated - dermatologic examinations are to be performed every 8 weeks at D1  of the cycle  
o Optional tumor sample will be requested only for subjects  that discontinue study due to disease progression.  
Abbreviations:  BSA = body surface area; C A19-9 = cancer antigen 19 -9; CEA = carcinoembryonic antigen; CT = computed tomography; ECG = electrocardiogram; ECHO = echocardiogram; ECOG PS = 
Eastern Cooperative Oncology Group Performance Status; IV = intravenous(ly); MRI = magnetic resonance imaging;  MUGA = multi -gated acquisition; PD = progressive disease .  
 
 
 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  40/234 
   
LIST OF ABBREVIATIONS  
 
ADL activities of daily living  
AE adverse event  
AESI  adverse event of special interest  
ALT  alanine aminotransferase  
AMP  Association for Molecular Pathology  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
ASCO  American Society of Clinical Oncology  
ASCP  American Society for Clinical Pathology  
AST  aspartate aminotransferase  
ATC  anatomical therapeutic chemical  
AUC  area under the concentration -time curve  
BCRP  breast cancer resistance protein  
BID twice daily  
BP blood pressure  
bpm beat per minute  
BRAF  B-RAF proto -oncogene, serine/threonine kinase  
BRAFV600E B-RAF proto -oncogene, serine/threonine kinase V600E -mutant  
BRAFwt  B-RAF proto -oncogene, serine/threonine kinase wild -type 
BSA  body surface area  
BUN  blood urea nitrogen  
CA competent authority  
CA19 -9 carbohydrate antigen 19 -9 
CABG  coronary artery bypass graft  
CAP  College of American Pathologists  
CEA  carcinoembryonic antigen  
CI confidence interval  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  41/234 
  CK creatine kinase  
Cmax maximum concentration  
CR complete response  
CRA  clinical research associate  
CRC  colorectal cancer  
CrCl  creatinine clearance  
CRO  contract research organization  
CRP  C-reactive protein  
CSR  clinical study report  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CT DNA  blood circulating tumor DNA  
CTFG  Clinical Trials Facilitation Group Guidelines  
CYP  cytochrome P450  
D Day 
DBP  diastolic blood pressure  
DLT  dose-limiting toxicity  
DMC  data monitoring committee  
DNA  desoxyribonucleic acid 
DOR  duration of response  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
ECOG PS  Eastern Cooperative Oncology Group performance status  
e-CRF  electronic case report form  
EDTA  ethylenediaminetetraacetic acid  
EGFR  epidermal growth factor receptor  
EGFRI  EGFR inhibitor  
EMEA  European Medicines A gency  
EORTC  European Organization for Research and Treatment of Cancer  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  42/234 
  EOT  end of treatment  
EQ-5D-5L EuroQol -5D-5L  
ERK  extracellular signal -regulated kinase  
ESMO  European Society of Medical Oncology  
EU European Union  
FA folinic acid  
FAS full analysis set  
FDA  United States Food and Drug Administration  
FDG -PET fluorodeoxyglucose positron emission tomography  
FFPE  formalin -fixed paraffin -embedded  
FOLFIRI  5-fluorouracil/folinic acid/irinotecan  
FOLFOX  5-fluorouracil/folinic acid/oxaliplatin  
FOLFOXIRI  5-fluorouracil/folinic acid/oxaliplatin/irinotecan  
FSH follicle -stimulating hormone  
5-FU 5-fluorouracil  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
H1 histamine receptor  
HC03  Bicarbonate  
hCG  human chorionic gonadotropin  
HDPE  high-density polyethylene  
hERG  human ether -a-go-go-related gene  
HFSR  hand -foot skin reaction  
Hg Mercury  
HIV human immunodeficiency virus  
HR hazard ratio or heart rate  
ICF informed consent form  
ICH International Council for  Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
iDSMC  independent Data Safety Monitoring Committee  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  43/234 
  INR international normalized ratio  
IEC independent ethics committees  
ILD interstitial lung disease  
IRB institutional review board  
IRPF  Institut de Recherche Pierre Fabre  
IRT Interactive Response Technology  
IUD intrauterine device  
IUS intrauterine hormone -releasing system  
IV intravenous(ly)  
KA Keratoacanthoma  
KM Kaplan -Meier  
KRA S V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  
LC/MS -MS liquid chromatography -tandem mass spectrometry  
LDH  lactase dehydrogenase  
LFT liver function tests  
LH luteinizing hormone  
LLN  lower limit of the normal reference range  
LOQ  limit of quantitation  
LVEF  left ventricular ejection fraction  
mCRC  metastatic colorectal cancer  
MAPK  mitogen -activated protein kinase  
MedDRA  Medical Dictionary for Regulatory Activities  
MEK  mitogen activated protein kinase kinase  
MRI  magnetic resonance imaging  
MSI microsatellite instability  
MTD  maximum tolerated dose  
MUGA  multi -gated acquisition  
NaF PET  sodium fluoride positron emission tomography  
NCCN  National Comprehensive Cancer Network  
NCI  National Cancer Institute  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  44/234 
  NGS  next generation sequencing   
NRAS  neuroblastoma ras viral oncogene  
NSAID  nsaids (non -steroidal anti -inflammatory drugs)  
NTI narrow therapeutic index  
OAT  organic anionic transporter  
OATP  organic anion -transporting peptide  
OCT  optical coherence tomography  
OCT organic cationic transporter  
ORR  objective response rate / overall response rate  
cORR  confirmed objective response rate  
OS overall survival  
PABA  para-aminobenzoic acid  
PCR  polymerase chain reaction  
pERK  phosphorylated extracellular signal -regulated kinase  
PD progressive disease + pharmacodynamic  
PFS progression -free survival  
PGIC  Patient’s Global Impression of Change  
P-gp P-glycoprotein  
pH hydrogen ion concentration  
PK pharmacokinetic(s)  
PMDA  Pharmaceuticals and Medical Devices Agency  
PO oral(ly) per os  
PP Polypropylene  
PPS per-protocol set  
PR partial response  
PRO  patient  reported outcome  
PT preferred term or prothrombin time  
QD once daily  
QLQ -C30 quality of Life Questionnaire for Cancer Subjects  
QoL quality of life  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  45/234 
  QTc corrected QT interval  
QTcF  QT interval corrected for heart rate using Fridericia’s formula  
QW once weekly  
Q2W  every two weeks  
RAF  raf rapidly accelerated fibrosarcoma I 3K  
RAS  oncogene rat sarcoma  
RBC  red blood cells  
RECIST  Response Evaluation Criteria In Solid Tumors  
RNA  ribonucleic acid  
RNA Seq  RNA sequencing  
RPED  retinal pigment epithelial detachment  
RP2D  recommended Phase 2 dose  
RR response rate  
RTQPCR  real time quantitative polymerase chain reaction  
RVO  retinal vein occlusion  
SAE  serious adverse event  
SAP statistical analysis plan  
SBP systolic blood pressure  
SC steering committee  
SCC  squamous cell carcinoma  
SD stable disease  
SLI safety lead in  
SOC  system organ class  
SPC summary of product characteristics  
SPF sun protection factor  
SSA sessile serrated adenoma  
t1/2 terminal half -life 
TEAE  treatment emergent adverse event  
Tmax  time of maximum concentration  
TdP torsade de pointes  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  46/234 
  TSA  traditional serrated adenoma  
TTR  time to response  
UGT  UDP -glucuronosyl transferase  
ULN  upper limit of normal  
US United States  
USM  Urgent Safety Measure  
V Version  
VEGFi  vascular endothelial growth factor inhibitor  
Wt wild-type 
WBC  white blood cells  
WHO  World Healh Organization  
 
    
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  47/234 
   
1. INTRODUCTION AND STU DY RATIONALE  
1.1. BACKGROUND INFORMATION ON THE TARGET PATHOLOGY 
AND THERAPY 
Metastatic colorectal cancer (mCRC) continues to be a serious, life -threatening condition. 
According to GLOBOCAN data,  1.36 million new cases affecting 17.2 individuals per 100000 
population (746000 men and 614000 women) are diagnosed in the world each year, and 693000 
people (373000 men and 320000 women) di e from colorectal cancer (CRC), accounting for a yearly 
mortality rate of 8.4 per 100000. In the United States, t he American Cancer Society’s estimate for 
the number of colorectal cancer cases for 2017 are 95,520 new cases. In the World Health 
Organisation (WHO) European Region, CRC is the first tumor by incidence, with 471000 new cases 
each year and a mean mortality rate of 28.2 per 100000 population.  
Approximately 25% of subjects present with metastases and 50% eventually develop metastatic 
disease ( Van Cutsem et al, 2014).  
Standard therapy in subjects with unresectable mCRC includes combination regimens with cytotoxic and targeted agents. In the last decade, substantial advances in the treatment of mCRC 
have resulted in an improvement in overall survival (OS) from 10 to 12 months to more than 20 
months. This improvement is thanks to the addition of irinotecan, oxaliplatin, bevacizumab, cetuximab, and panitumumab to the standard treatment with 5- fluorouracil ( 5 FU)/folinic acid (FA).  
 
BRAF
V600E MUTANT COLORECTAL CANCER 
BRAF mutations, which lead to constitutive activation of BRAF kinase and sustained 
RAS/RAF/MEK/ERK pathway signaling resulting in increased cell proliferation and survival , 
occur in approximatel y 10% (range, 5–22%) of the unselected CRC population ( Rozek LS et al, 
2010; Shaukat A et al, 2010).  
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  48/234 
   
According to the European Society of Medical Oncology ( ESMO ) Consensus Guidelines for the 
management of subjects with mCRC ( Van Cutsem E et al, 2016),  BRAF mutation status should be 
assessed alongside RAS  mutation status for prognostic assessment (and/or potential selection for 
clinical trials) [level I, B].   
In the  United States ( US), the National Comprehensive Cancer Network panel (NCCN) strongly 
recommends genotyping of tumor tissue (either primary tumor or metastasis) in all subjects with 
mCRC, for RAS  (KRAS exon 2 and non- exon 2; NRAS) and BRAF upon diagnosis of stage IV 
disease ( Benson AB et al, 2017) Testing for the BRAF V600E mutation ( BRAFV600E) can be performed 
on formalin- fixed paraffin -embedded (FFPE) tissues and is usually performed by polymerase chain 
reaction (PCR) amplification and direct Deoxyribonucleic Acid ( DNA) sequence analysis.  
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in subjects with 
mCRC and is associated (in the first line setting  for metastatic disease) with a median survival of 
approximately 12 to 14 months compared to 21 to 25 months for subjects with BRAF wild-type 
(BRAFwt) tumors ( Van Cutsem E et al, 2011). Failure to achieve good survival outcomes through 
standard doublet chemotherapy agents in subjects  with BRAF V600E mutant mCRC  has ignited efforts 
to combine multiple target therapies ( Kopetz S el al, 2017;  Corcoran RB et al, 2016).  
 
First line treatment options for BRAFV600E mutant mCRC patients  
Currently, there are no agents specifically indicated for subjects with BRAFV600E mutant mCRC. 
However, since BRAF  and KRAS  mutations are almost always mutually exclusive, subjects with 
BRAFV600E mCRC have typically been treated with standard -of-care regim ens for RAS wt mCRC. 
Subjects with RASwt mCRC typically receive infusional 5 -FU/FA/oxaliplatin (FOLFOX) or (5 -
FU/FA/irinotecan (FOLFIRI) with or without bevacizumab (anti VEGF antibody) or cetuximab 
(anti EGFR antibody) as initial therapy. A retrospective s tudy reported no differences in PFS 
irrespective of whether oxaliplatin - or irinotecan- based chemotherapy was administered in the first -
line setting in patients with BRAF mutant CRC (6.4 versus 5.4 months; P=0.99). ( Morri s V et al, 
2014). There is insufficient evidence to conclude that BRAF is a predictive biomarker for irinotecan 
or oxaliplatin, as patients benefit regardless of their mutational status.  
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  49/234 
   
Some authors have proposed more intensive treatment based on the combination of 5-fluoruracil, 
leucovorin, oxaliplatin, irinotecan and bevacizumab (FOLFOXIRI -Beva) based on a retrospective 
analysis of a prospective phase II trial evaluating this combination, ( Loupakis F et al, 2014) which 
included 15 BRAF mutant CRC patients. Results were initially encouraging compared with 
historical controls with median PFS and OS of 11.8 and 24.1 months and a 72% response rate (RR).  
In the follow up phase III trial which randomized a tot al of 28 patients with BRAF mutant mCRC, 
FOLFOXIRI -Bev had improved results compared with FOLFIRI Bev with respect to OS ( median 
19.0 versus 10.7 months ; HR, 0.84; 95% CI, 0.24 –1.2), PFS ( median 7.5 versus 5.5 months; HR, 
0.57; 95% CI, 0.27– 1.23), and ORR (55% versus 42%; Odd Ratio, 1.82; 95% CI, 0.38–8.78). 
 
Use of EGFRi with standard chemotherapy in the first line setting for BRAFV600E mutant 
mCRC patients  
Limited data from unplanned retrospective subset analyses of subjects with mCRC treated in the 
first-line setting suggest that, although a BRAFV600E mutation confers a poor prognosis regardless 
of treatment, subjects with disease characterized by this mutation may receive some benefit from the addition of cetuximab to front -line therapy ( Van Cutsem E et al, 2011; Bokemeyer C et al, 
2012). On the other hand, results from the randomized phase III Medical Research Council (MRC) COIN trial sugges t that cetuximab may have no effect or even a detrimental one in subjects with 
BRAF- mutated tumors treated with CapeOx ( Douillard JY et al, 2013;  Maughan TS et al, 2011).  
While data suggest BRAF mutation status has clear prognostic value in mCRC, its predictive value 
for response and benefit from EG FR-directed treatments, such as cetuximab, remain controversial. 
Retrospective analyses of recent trials have suggested that BRAF mutations are not predictive of 
outcome with EGFR -directed therapies ( Tol J and Punt CJ, 2010) in certain settings whereas other 
analyses have suggested that cetuximab and panitumumab are most active in subjects with BRAFwt 
mCRC ( Di Nicolantonio  F et al, 2008; De Roock W et al, 2010). In a recent meta- analysis of 7 
randomiz ed controlled trials in which subjects received panitumumab or cetuximab in different 
lines of therapy, and with a range of background chemotherapy, no significant interaction was noted 
between the benefits of anti -EGFR therapy (measured as OS and PFS) and  the presence of BRAF 
mutations.  These results suggest that anti -EGFR therapy may have benefit for subjects with 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  50/234 
  BRAFV600E CRC. Consistent with this recent publication, a joint committee of the American Society 
for Clinical Pathology (ASCP), the College of  American Pathologists (CAP), the Association for 
Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO), issued draft 
guidelines for the evaluation of molecular markers for CRC which stated that there is insufficient 
evidence to r ecommend BRAFV600 E mutation status as a predictive molecular marker for response 
to EGFR directed therapies  (see Table  1). 
 
Table 1: First line Phase II and III clinical trials with EGFR and VEGFi and BRAF 
mutational status for metastatic colorectal cancer subjects  
Reference No of 
patients  Treatment  BRAFm 
(%) OS 
(months)  PFS 
(months  RR 
NORDIC ( Tveit 
KM et al, 2012) 457 FLOX+C  
FLOX  20 NA NA 19.4%  
21% 
NSS 
CRYSTAL/OPUS  
(Bokemeyer C et 
al, 2012)  1535  FOLFIRI/FOLFOX+C  
FOLFIRI/FOLFOX  8.2 14.1 
9.9 
HR, 0.62  
P=0.076  7.1 
3.7 
HR, 0.67  
P=0.23  21.3%  
13.2%  
OR,1.6  
P=0.46  
COIN ( Smith CG 
et al, 2013) 2445  FP + Oxaliplatin + C  
FP + Oxaliplatin  9 7.2 
10 
HR 1.18  
P=0.46  NA  
NA 
HR1.25 
P=0.54  NA 
PRIME ( Douillard 
JY et al, 2013) 
 1183  FOLFOX + P  
FOLFOX  10 10.5 
9.2 
HR0.9  
P=0.76  6.1 
5.4 
HR0.58 
P=0.12  NA 
FIRE 3 (Stintzing 
S et al, 2014)  342 FOLFIRI  + C 
FOLFIRI + Bev  13.7 12.3 
13.7 
HR0.87 
P=0.65  4.9 
6 
HR0.87 
P=0.64  52.2%  
40% 
OR 1.64  
P=0.29  
TRIBE ( Cremolini 
C et al, 2015)   508 FOLFIRI + Bev  
FOLFOXIRI+Bev  5.5 10.7 
19.0 
HR:0.5 4 5.5 
7.5 
HR=0.5 7 42% 
56% 
OR:1.82  
(0.38 -8.78)  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  51/234 
   
Treatment options after first line for BRAFV600E mutant mCRC patients  
In a retrospective analysis of subjects with chemo -refractory mCRC treated with chemotherapy and 
an anti -epidermal growth factor receptor (EGFR) agent, the median progression- free survival (PFS) 
and OS in subjects with BRAF mutant tumors were 2 months and 6.5 months , respectively, 
compared with a median PFS of 6.5 months and a  median OS of 13,5 months   in subjects with 
BRAFwt tumors. In a study evaluating 5- FU/FA/irinotecan (FOLFIRI) plus panitumumab in a pure 
second -line setting, subje cts with BRAFV600 E mutant mCRC had a median PFS of 2.5 months and a 
median  OS of 4.7 months, compared with a median PFS and a  median OS of 6.9 and 18.7 months, 
respectively, in subjects with BRAFwt tumors. Finally, in 71 subjects with BRAFV600E mutant mCRC 
treated at the MD Anderson Cancer Center between 2003 and 2012, the median PFS with second-
line therapy was 10 weeks in the overall group (n=58) and 12 weeks in subjects who were treated 
with an irinotecan -based regimen (n=39), 28 of whom had received panitumumab or cetuximab 
concomitantly with irinotecan. The median PFS in subjects receiving second- or third -line therapy 
corresponded to the timing of the first restaging scan ( Morris V et al, 2014 ). 
Benefits of combination therapies have been demonstrated in clinical studies of patients with mCRC, including: dual inhibition of BRAF + EGFR such as panitumumab + dabrafenib ( Corcoran 
RB et al, 2016)  and cetuximab + encorafenib  (Tabernero J et al, 2016) , the ORR reported in these 
studies were 10% and 22%, respectively; or triplet combinations consisting of BRAF + EGFR 
inhibition plus MEK inhibition or chemotherapy such as cetuximab +vemurafenib+ irinotecan  
(Kopetz S el al, 2017) or panitumumab + dabrafenib + trametinib ( Corcoran RB et al, 2016) , the 
ORR reported in these studies were 16% and 21% respectively . In particular, the phase II study of 
cetuximab + encorafenib demonstrated a median PFS of 4.2 months, and the median overall survival 
exceeded 1 year, whi ch is substantially improved over the historical standard of care for this 
population.   
 
Inhibition of BRAF, MEK, and EGFR in BRAF
V600E Colorectal Cancer Cells  
Cancer cells with BRAF  mutations are highly dependent on MEK/ERK signaling. As demonstrated 
in melanoma cells, MEK -dependent activation of MAP Kinase ( MAPK) signaling occurs following 
BRAF inhibition and near -complete inhibition of phospho- ERK is required for tumor responses. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  52/234 
  The combination of a BRAF inhibitor and a MEK inhibitor has been shown to be more active than 
either agent alone, presumably due to delaying or preventing resistance  (Thakur MD and Stuart 
DD, 2014). Nonclinical studies in CRC cells has shown that BRAF inhibition causes a rapid 
feedback activation of EGFR that supports continued proliferation of BRAFV600E CRC tumor cells 
(Corcoran RB et al, 2012; Prahallad A et al, 2012). Activation of  EGFR can be effectively 
prevented by the combination of vemurafenib with anti -EGFR agents such as the small -molecule 
kinase inhibitor, erlotinib, or the monoclonal antibody, cetuximab.  
These reports suggest that activation of EGFR may partially explain t he limited therapeutic effect 
of BRAF inhibitor monotherapy in subjects with BRAFV600E mutant mCRC and that this can be 
overcome with concomitant EGFR inhibition. The dependence of BRAF -mutant CRC cells on 
MAPK signaling provides a compelling rationale for inhibiting MEK in addition to BRAF and 
EGFR to achieve more robust inhibition of the pathway. 
1.2. INFORMATION ON THE TEST PRODUCT  
1.2.1.  ENCORAFENIB  
Chemical and pharmaceutical characteristics  
Encorafenib (LGX818 or W0090), is a novel oral small- molecule kinase inhibitor with potent and 
selective inhibitory activity against mutant BRAF kinase, a member of the RAF/MEK/ERK MAPK 
pathway, which plays a prominent role in controlling several key cellular functions including 
growth, proliferation and survival. 
For further details, please refer to the current  Encorafenib Investigator’s Brochure  (Enco IB ). 
Non-clinic al data 
In 1- to 4-week toxicology studies in rats and cynomolgus monkeys, encorafenib was well tolerated 
at systemic exposures which result in tumor regression in mouse xenograft studies. Findings 
included hyperplasia and hyperkeratosis in the skin (plant ar surface of feet) and non -glandular 
stomach in the rat. An absence of the later stages of spermatid maturation in male rats was also observed. Significant mortality/morbidity was observed mostly in female rats at the highest dose of 
400 mg/kg/day, a dose well above the maximum tolerated dose (MTD) in rats.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  53/234 
  In the 13 -week toxicology study in monkeys, the only drug- related finding was blister -like lesions 
identified over the macular region of the retina, observed in 2 monkeys treated at a dose of 60 
mg/kg/day. Exposure (maximum area under the concentration–time curve (AUC) 0-24 achieved in 
the study at any time point) in the 2 affected monkeys was 5 to 8- fold and 4 to 6- fold greater than  
that achieved at the 300 and 450 mg once daily (QD) dose levels, respectively, in humans at steady 
state in Clinical Study CLGX818X2101. One of the animals with this finding showed evidence of 
recovery after the drug withdrawal. Histopathology examination of the affected eyes suggested that 
the findings were similar to the retinopathy associated with MEK inhibitors.  
Preclinical safety pharmacology data do not indicate a clinical risk for QT interval corrected for 
heart rate (QTc) prolongation, or adverse effects on the CNS or respiratory system. In Good 
Laboratory Practice (GLP) 4 - and 13- week oral (gavage) toxicity studies in monkeys and a GLP 
monkey telemetry study, encorafenib had no adverse effect on electrocardiographic (ECG) morphology, rhythm or PR, QRS, QT and QTc duration. Using cloned hERG potassium channels 
expressed in mammalian cells, the IC
50 for hERG inhibition by encorafenib was determined to be 
73.4 μM indicating that there is unlikely to be an effect of encorafenib on repolarization and QT 
interval .  
The GLP Ames and chromosomal aberration assays as well as a rat micronucleus study indicated that encorafenib is not genotoxic.  
Encorafenib was rapidly absorbed in mouse, rat and dog studies. Median Tmax was 2 hours when 
dosed as a suspension and 0.5 hours when dosed as a solution. For further details, please refer to the current  Encorafenib Investigator’s Brochure ( Enco IB ). 
Clinical safety  
As of the data  cutoff date of 11 May 2017, 1431 patients with advanced cancer have received at 
least one dose of encorafenib, either as a single agent  or in combination with other agents  in 10 
clinical studies . 
For further details, please refer to the current  Encorafenib Investigator’s Brochure ( Enco IB ). 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  54/234 
   
Single -agent encorafenib  
Single- agent encorafenib was evaluated in a first -in-human, Phase I dose -escalation/dose-expansion 
study (Clinical Study CLGX818X2101) in adult patients with BRAFV600E mutant locally advanced 
or metastatic melanoma (dose- escalation and dose -expansion phases) or mCRC (dose -expansion 
phase only). A total of 107 subjects were treated at doses ranging from 50 mg to 700 mg QD. 
In the dose -expansion ph ase of Study CLGX818X2101, the first 34 patients received encorafenib 
450 mg QD (i.e., MTD). Nine of these subjects experienced a dose -limiting toxicity (DLT) during 
Cycle 1   
 
 
 le
ading to a dose reduction to 300 mg QD in 6 subjects and discontinuation 
of encor
afenib for the remaining 3 subjects. Among the patients who did not have a DLT, the 
encorafenib dose was reduced to 300 mg QD in 8 subjects, and 1 subject discontinued due to an AE. Based on these findings, 300 mg QD was identified as the recommended Phase 2 dose (RP2D)  
as single agent .  
Eighteen s
ubjects with mCRC received encorafenib in the dose -expansion phase of the study. 
Twelve subjects received encorafenib 450 mg QD and 6 patients received 300 mg QD. Doselimiting - toxicities were reported in 3 subjects treated at the 450 mg QD dose and in none of 
the subjects treated at the 300 mg QD dose. The most common (occurring in ≥ 20% of subjects) AEs, regardless of causality, observed at the MTD of 450 mg QD and the RP2D of 300 mg QD in 
the mCRC subjects in the dose-expansion phase are shown in Table 2 .  
 
  
PII
CCI
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  56/234 
   
Encorafenib in combination with an anti EGFR  
Study CLGX818X2103 
Clinical Study CLGX818X2103 is an ongoing phase Ib/II study evaluating the combination of 
encorafenib and cetuximab and the triple combination of encorafenib, cetuximab and alpelisib (a 
PI3Kα inhibitor) in subjects with BRAF -muta nt mCRC who ex perienced disease progression after 
≥ 1 prior standard-of- care regimen or who were intolerant to irinotecan -based regimens. Phase Ib 
has been completed and enrollment to phase II is complete. The aim of the phase Ib portion of the 
study was to determine the MTD and/or RP2D of the dual combination of encorafenib plus cetuximab and the triple combination.The phase II portion is an ongoing randomized study (N=102) 
designed to assess the relative clinical efficacy of the dual and triple combinations and to furt her 
characterize the safety of the two regimens.  
Study CLGX818X2103 Phase Ib 
A total of 26 subjects with locally determined BRAF mutation status (confirmed using Foundation 
Medicine) were treated with the dual combination and 28 patients were treated with triple 
combination. The MTD was not formally reached for either regimen, however, based on general 
tolerability, the RP2D for the triple combination was determined to be encorafenib 200 mg QD, 
alpelisib 300 mg QD in combination with standard dose of cetuxi mab (initial dose 400 mg/m
2 
followed by 250 mg/m2 weekly). The dual combination was studied up to doses of 450 mg QD of 
encorafenib in combination with cetuximab without reaching MTD and with generally acceptable 
toxicity. In order to determine the contribution of alpelisib to the efficacy of the triple combination, 
an equal dose of encorafenib (200 mg QD) in both arms of the phase 2 portion was selected. 
In the 26 subjects treated in the dual combination arm, the median age was 63 years (range 43-80 
years) . At baseline, Eastern Cooperative Oncology Group (ECOG) performance status (PS) was 0 
in 8 (30.8%) subjects, 1 in 16 (61.5%) subjects, and 2 in 2 (7.7%) subjects.  
They had received a median of 2 prior therapies (range 1 -5) and 11 ( 42%) patients had received ≥3 
prior regimens. Four dose levels of encorafenib QD:100 mg QD (n=2), 200 mg QD (n=7), 400 QD 
(n=9), and 450 QD (n=8), and cetuximab (400 mg/m2 initial and 250 mg/m2 weekly) were evaluated 
in the dual combination treatment arm. Complete response (CR) was observed in 1 subject and  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  57/234 
  partial responses (PR) were observed in 5 subjects for an overall response rate (ORR) of 23.1%. All 
except one of the responses (a PR) was confirmed. The median duration of response was 34.7 weeks 
(range 4.1 -73.3 weeks). Of the 14 patients with stable disease (SD) as best radiological response, 
tumor regression was observed in 7 (27%). The median PFS was 3.7 months (95% CI, 2.8–10.6 months) and the activity of the dual combination appeared durable with 8 (30.7%) patients w ith 
duration of exposure for greater than 1 year with the longest duration being > 88 weeks.  
CLGX818X2103 phase II  
A total of 50 subjects were randomized to the dual combination arm in phase II. The median age 
was 60 years (range 29- 76) and ECOG PS was 0/ 1/2 in 45%/56%/2% of patients. The median 
number of prior treatment regimens was 2 (range 1- 6) and 40% had 2 prior regimens and 18% had 
≥3 prior regimens. The ORR was 22% (95% CI: 12- 36). The median PFS in the subjects treated 
with encorafenib plus cetuxim ab was 4.2 months (95% CI, 3.4-5.4). The observed ORR and PFS 
compare favorably to historical controls, which were normally below 10% ORR and generally 2 
months for PFS. The median OS of subjects in the dual combination arm was 12.4 months (95% 
CI, 7.6, not estimable) which compared favorably to historical controls  (Tabernero J et al, 2016 ). 
The dual combination was generally well tolerated, as most adverse events observed were Grade 1 
or 2 with few Grade 3 or 4 events. Notably, although rash is observed in the majority of patients 
treated with cetuximab, in the dual combination arm, it was observed in only 7 (14%) patients, all 
of whom experienced Grade 1/2 rash. Summary of adverse events in the dual combination arm are 
summarized in  Table 3 . 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  58/234 
   
Table 3: Adverse Events (Regardless of Study Drug Relationship) Reported in ≥ 20% of 
Dual -Combination Therapy (encorafenib plus cetuximab) (N=50), by Preferred Term — 
CLGX818X2103, Phase 2 
 Encorafenib 200mg /  
Cetuximab  
(N=50)  
Preferred Term  All Grades  
n (%)  Grade 3/4  
n (%)  
Any Adverse Event  50 (100)  31 (62.0)  
Nausea 23 (46.0)  0 
Fatigue  25 (50.0)  2  (4.0)  
Vomiting  16 (32.0)  0 
Abdominal pain  21 (42.0)  4  (8.0)  
Diarrhoea  14 (28.0)  2  (4.0)  
Decreased appetite 17 (34.0)  1  (2.0)  
Arthralgia  17 (34.0)  0 
Headache  16 (32.0)  0 
Pyrexia  13 (26.0)  0 
Dry skin  9 (18.0)  0 
Hyperglycaemia  5 (10.0)  1  (2.0)  
Rash  7 (14.0)  0 
Lipase increased  15 (30.0)  11 (22.0)  
Back pain  12 (24.0)  1  (2.0)  
Dermatitis acneiform  9 (18.0)  0 
Stomatitis  5 (10.0)  0 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  59/234 
   
1.2.2.  BINIMETINIB  
Chemical and pharmaceutical characteristics  
Binimetinib (MEK162 or W0074) is an orally bioavailable, selective and potent mitogen -activated 
protein kinase kinase (MEK) 1 and MEK 2 inhibitor that is active in inhibiting phosphorylated 
extracellular signal -regulated kinase (pERK) and growth of BRAF- mutant cancer cells in the low 
nanomolar range.  
Non-clinical data  
Acute, sub-chronic, chronic and reproductive toxicity, genotoxicity and phototoxicity studies were 
completed in rats and monkeys to support chronic administration of binimetinib to adult subj ects. 
There was no evidence of a genotoxic potential in vitro or in vivo. The adverse effects of MEK inhibitors in humans are similar to those observed in rats and monkeys, with the exception of ocular 
findings. These adverse effects include gastrointestinal intolerance and diarrhea, rash (skin findings 
in rats only), retinal events (only seen in humans) and retinal vein occlusion (rarely seen in humans). 
In vitro and in vivo phototoxicity studies conducted in mice indicate that binimetinib has a low risk 
of weak phototoxic potential at therapeutic doses. Furthermore, there has been no evidence of 
phototoxicity or photosensitivity in humans treated with binimetinib for cancer or for rheumatoid 
arthritis.  
Given the embryo- lethal effects seen in rats and rabbits and the teratogenic effects seen in rabbits, 
binimetinib should not be used in pregnant women. Women of child- bearing potential must be 
advised to use highly effective contraception methods  as described in CTFG 2014 (see Section 
5.3.1 in the protocol). 
For further details, please refer to the current  Binimetinib Investigator’s Brochure ( Bini IB ). 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  60/234 
   
Clinical Safety  
As of 20 January 2018, a total of 2816 healthy subjects and patients have received at least 1 dose of 
binimetinib, either as a single agent or in combination with other targete d agents, standard 
chemotherapy agents or immunomodulating agents. These patients constitute the binimetinib safety population, which includes 229 healthy subjects, 17 subjects with hepatic dysfunction, 6 subjects 
with renal dysfunction, 164 patients with rheumatoid arthritis and 2400 patients with advanced 
cancer .
 
For further details, please refer to the current  Binimetinib Investigator’s Brochure ( Bini IB ).  
Single -agent binimetinib  
Based on two phase I studies (one conducted in subjects with advanced solid tumors, advanced or metastatic biliary cancer and  KRAS - or BRAF -mutant metastatic CRC (Clinical Study ARRAY -
162-111) and the other conducted in Japanese s ubjects with advanced solid tumors (Clinical Study 
CMEK162X1101), the recommended single-agent dose of binimetinib is 45 mg twice daily (BID). 
This dose was further confirmed in phase II studies :  (1) conducted in BRAF
V600 E or NRAS -mutant 
melanoma subjects  (Clinical Study CMEK162X2201) ; (2) in advanced solid tumors (Clinical Study 
CMEK162AUS11) ; and  (3) in Chinese subjects with advanced Neuroblastoma RAS Vital 
Oncogene KRAS /BRAF/NRAS -mutant non- small cell lung cancer (Clinical Study CINC280X2205) 
and in pha se III studies: (1) in subjects with NRAS -mutant melanoma (Clinical Study 
CMEK162A2301) and (2) in low grade serous carcinomas of the ovary, fallopian tube or primary peritoneum (Clinical Study ARRAY-162-311). 
Available clinical data indicate a predictable safety profile consistent with that reported for other 
allosteric MEK1/2 inhibitors. Frequently reported treatment -emergent AEs in patients receiving 
binimetinib include rash, dermatitis acneiform, nausea, vomiting, diarrhea, peripheral edema, 
fatigue, an d creatine kinase (CK) elevation. Other clinically relevant toxicities are retinal events, 
increased blood pressure, decreased ejection fraction, and noninfectious pneumonitis/interstitial 
lung disease, all of which should be monitored closely with appropriate diagnostic evaluations.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  61/234 
   
These observed AEs are generally reversible and manageable by appropriate supportive medical 
care and/or dose modifications. Table 4  describes the safety profile of binimetinib as single agent 
in subjects with NRAS – mutant melanoma (Clinical study CMEK162A2301)  [Dummer R et al, 
2017 (NEMO) ].  
Table 4: Adverse events regardless of causality in at least 5% (grade 1 or 2) or at least 1% 
(grade 3 or 4) of patients (Clinical study CMEK162A2301) 
 All patients (N=269) binimetinib 45mg BID  
 Grade 1 -2 
N (%)  Grade 3  
N (%)  Grade 4  
N (%)  
Diarrhoea  104 (39)  4 (1)  0 
Oedema peripheral  96 (36)  1 (<1)  0 
Dermatitis acneiform  88(33)  7 (3)  0 
Rash  87 (32)  11 (4)  0 
Nausea 75 (28)  4 (1)  0 
 Blood creatine phosphokinase increased  61 (23)  33 (12)  19 (7)  
Fatigue  54 (20)  6 (2)  0 
Vomiting  51 (19)  6 (2)  0 
Asthenia  40 (15)  8 (3)  0 
Retinal detachement  39 (14)  0 0 
Constipation  35 (13)  2 (1)  0 
Pruritus  30 (11)  2 (1)  0 
Aspartate aminotransferase increased  29 (11)   6 (2)  0 
Decreased appetite 29 (11)  2 (1)  0 
Pyrexia  28 (10)  0 0 
Skin fissures  28 (10)  0 0 
Dyspnoea  26 (10)  3 (1)  0 
Ejection fraction decreased  20 (7)  10 (4)  0 
Hypertension  17 (6)  20 (7)  0 
Alanine aminotransferase increased  15 (6)  7 (3)  0 
Anaemia 14 (5)  4 (1)  1 (<1)  
Preferred terms are presented by descending order of frequency of grade 1 –2 adverse events. A patient with multiple 
occurrences of an adverse event under a preferred term is counted only once for that preferred term. A patient with 
multiple adverse events is counted only once in the total row. As per the study protocol, deaths were not graded and 
therefore were not included in this table; please refer to the ( Bini IB ) for more  detail.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  62/234 
   
Binimetinib in Combination with Anti -EGFR Agents  
The combination of binimetinib and panitumumab was evaluated in patients with mCRC in the 
Phase 1b/2 Clinical Study CMEK162X2116. Ten patients were treated in the Phase 1b portion of 
the study with binimetinib (45 mg BID) and the labeled dose of panitumumab (6 mg/kg IV 
biweekly) which was declared the MTD/RP2D. An additional 40 patients were enrolled in the Phase 2 portion of the study. In the Phase 2 portion, AEs, regardless of causality, reported in ≥  15% of 
patients included all grade (%)/Grade 3 -4 (%): diarrhea (70.0/12.5), vomiting (55.0/2.5), rash 
(50.0/12.5), nausea (47.5/5.0), fatigue (35.0/5.0), abdominal pain (32.5/2.5), dermatitis acneiform 
(32.5/5.0), blood creatine kinase (CK) increased (27.5/7.5), dry skin (25.0/5.0), anemia (20.0/10.0), 
asthenia (20.0/2.5), constipation (20.0/0), hypokalemia (20.0/12.5), pyrexia (20.0/0), stomatitis 
(20.0/0), AST increased (17.5/5.0), blood creatinine increased (15.0/2.5), chills (15.0/0) and 
hypomagnesemia (15.0/0). 
Combination of encorafenib and binimetinib  
An ongoing Phase 3 (COLUMBUS study - CMEK162B2301), 2- part, randomized, open -label, 
multicenter study = compared the efficacy and safety of the combination of binimetinib + 
encorafenib to single- agent vemurafenib and single -agent encorafenib in patients with BRAF 
V600-
mutant locally advanced unresectable or metastatic melanoma (Stage IIIB, IIIC and IV per the American Joint Committee on Cancer [AJCC]) untreated or have progressed on or afte r first line 
immunotherapy . 
In Part 1 of the study ( Dummer R et al, 2016 ), patients were to be randomized in a 1:1:1 ratio to 1 
of the 3 treatment arms: binimetinib 45 mg BID + encorafenib 450 mg QD (Combo 450) or single -
agent encorafenib 300 mg QD or single -agent vemurafenib 960 mg BID. In Part 2 of the study  
Dummer R et al, (part 2) , patients were to be randomized in a 3:1 ratio to 1 of the 2 treatment 
arms: (1) binimetinib 45 mg BID + encorafenib 300 mg QD (Combo 300) or (2) single -agent 
encorafenib 300 mg QD.  
Enrollment is complete, with a total of 921  patients (577 in Part 1 [192 Combo 450, 194 
encorafenib, 191 vemurafenib] and 344 in Part 2 [258 Combo 300, 86 encorafenib) randomized to 
treatment. A total of 911 patients ( 577 in Part 1 [192 Combo 450, 192 encorafenib, 186 
vemurafenib] and 344 in Part 2 [257 Combo 300, 84 encorafenib] ) received at least 1 dose of study 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  63/234 
  treatment (Combo 450, Combo 300, encorafenib or vemurafenib). The most frequently reported 
AEs (≥ 10.0% of patients in either population) are summarized by preferred term and treatment 
population in Table 5 . 
Table 5: Adverse Events Regardless of Causality Reported in ≥ 10.0% of Patients by 
Preferred Term (Pooled Data from Studies of Combo 450 and CMEK162B2301 Part 2 Data 
for Combo 300 in Patients with Melanoma) 
 Pooled Data * Study CMEK162B2301 Part 2 
 Combo 450  
N = 274  
n (%)  Combo 300  
N = 257  
n (%)  
Preferred term  All Grades  
n (%)  Grade 3/4  
n (%)  All Grades  
n (%)  Grade 3/4  
n (%)  
Any AE  271 (98.9)  168 (61.3)  252 (98.1)  120 (46.7)  
Nausea 114 (41.6)  7 (2.6)  70 (27.2)  4 (1.6)  
Diarrhoea  104 (38.0)  9 (3.3)  73 (28.4)  4 (1.6)  
Fatigue  85 (31.0)  6 (2.2)  57 (22.2)  2 (0.8)  
Vomiting  77 (28.1)  6 (2.2)  39 (15.2)  1 (0.4)  
Arthralgia  74 (27.0)  2 (0.7)  57 (22.2)  3 (1.2)  
Blood CK increased  74 (27.0)  16 (5.8)  51 (19.8)  14 (5.4)  
Constipation  66 (24.1)  0 43 (16.7)  0 
Headache  57 (20.8)  4 (1.5)  30 (11.7)  1 (0.4)  
Anaemia 51 (18.6)  13 (4.7)  24 (9.3)  7 (2.7)  
Pyrexia  47 (17.2)  7 (2.6)  43 (16.7)  0 
Abdominal pain  47 (17.2)  5 (1.8)  27 (10.5)  3 (1.2)  
Asthenia  43 (15.7)  3 (1.1)  38 (14.8)  2 (0.8)  
Vision blurred  43 (15.7)  1 (0.4)  26 (10.1)  1 (0.4)  
GGT increased  40 (14.6)  23 (8.4)  36 (14.0)  12 (4.7)  
Alopecia  38 (13.9)  0 33 (12.8)  0 
Myalgia  38 (13.9)  1 (0.4)  35 (13.6)  1 (0.4)  
Hyperkeratosis  37 (13.5)  1 (0.4)  25 (9.7)  0 
Muscle spasms  37 (13.5)  1 (0.4)  18 (7.0)  1 (0.4)  
ALT increased  36 (13.1)  13 (4.7)  29 (11.3)  12 (4.7)  
Dry skin  36 (13.1)  0 21 (8.2)  0 
Oedema peripheral  35 (12.8)  3 (1.1)  28 (10.9)  0 
Dizziness  34 (12.4)  4 (1.5)  21 (8.2)  0 
Rash  34 (12.4)  2 (0.7)  18 (7.0)  2 (0.8)  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  64/234 
   Pooled Data * Study CMEK162B2301 Part 2 
 Combo 450  
N = 274  
n (%)  Combo 300  
N = 257  
n (%)  
Preferred term  All Grades  
n (%)  Grade 3/4  
n (%)  All Grades  
n (%)  Grade 3/4  
n (%)  
Hypertension  31 (11.3)  15 (5.5)  21 (8.2)  9 (3.5)  
Back pain  30 (10.9)  2 (0.7)  36 (14.0)  2 (0.8)  
Nasopharyngitis  30 (10.9)  0 23 (8.9)  0 
Pain in extremity  29 (10.6)  4 (1.5)  27 (10.5)  2 (0.8)  
Abdominal pain upper  26 (9.5)  2 (0.7)  32 (12.5)  1 (0.4)  
*pooled data from 3 clinical studies of the combination of binimetinib + encorafenib (CMEK162X2110 [Phase 1b/2], CLGX818X2109 
[Phase 2] and CMEK162B2301 Part 1 [Phase 3])  
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK = creatinine phosphok inase; 
Combo =  encorafenib plus binimetinib; GGT = gamma -glutamyl transferase; n or N = number  
Preferred terms are sorted in descending frequency of the Combo 450 column  
Data cutoff date CMEK162B2301 (Parts 1 and 2) 09 Nov 2016; CLGX818X2109 30 Dec 2016; CMEK162X2110 31 Dec 2016   
 
 
1.2.3.  CETUXIMAB  
Chemical and pharmaceutical characteristics  
Cetuximab is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically 
to the extracellular domain of human EGFR on both normal and tumor cells, and inhibits receptor 
activation by competing with the epidermal growth factor and other ligands. In vitro and in vivo 
assays have shown that binding of cetuximab to the EGFR blocks its dimerization and 
phosphorylation and its consequent activation, resulting in an inhibition of cell growth, induction 
of apoptosis, and decreased matrix metalloproteinase and vascular endothelial factor production. Cetuximab exhibits clinical activity as a monotherapy or in combination with chemotherapy and/or 
radiation in head and neck cancer and  mCRC ( Cunningham D et al, 2 004; Baselga J et al, 2005; 
Bonner JA, et al 2006).  
Cetuximab is approved in about 100 countries for the treatment of patients with epidermal growth factor receptor (EGFR) -expressing, RAS wild- type metastatic colorectal cancer  
• in combination with irinotecan -based chemotherapy,  
• in first -line in combination with FOLFOX,  
• as a single agent in patients who have failed oxali platin - and irinotecan- based therapy and 
who are intolerant to irinotecan (see the locally applicable cetuximab label).  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  65/234 
   
Nonclinical data  
Following the recommended dose regimen (400 mg/m2 initial dose; 250 mg/m2 weekly dose), 
concentrations of cetuximab re ach steady -state levels by the third weekly infusion. Cetuximab has 
a long elimination half -life with values ranging from 70 to 100 hours at the target dose . Although 
the US label for Erbitux® indicates that US -licensed cetuximab (Erbitux®) provides approximately 
22% greater exposure relative to cetuximab which is approved in the European Union (EU), the 
dosing and administration guidelines are consistent between the regions. 
 
Clinical data  
In subjects with mCRC whose disease had progressed during or within 3 months after treatment 
with an irinotecan -based regimen, treatment with single -agent cetuximab resulted in an objective 
response rate of 11% and a median time to progression of 1.5 months ( Cunningham D et al,  2004) . 
In subjects with EGFR -expressing mCRC treated with cetuximab in combination with irinotecan in 
the second -line setting, the median PFS was 4.0 months (95% confidence interval [CI], 3.24.1  
months) and OS was 10.7 months (95% CI, 9.6 -11.3 months) ( Sobrero AF et al, 2008).  
In general, cetuximab is well tolerated and does not exacerbate the side effects of irinotecan or oxaliplatin. The main side effects are skin  reactions, particularly an acne -like rash that is 
characteristic of treatment with many EGFR inhibitors. Such skin reactions are generally manageable. Other less frequently observed side effects associated with cetuximab treatment are 
diarrhea, fatigue, and hypomagnesemia ( Tabernero J et al, 2008).  
The approved dosing regimen of cetuximab, both as monotherapy and in combination with chemotherapy, is an initial i.v. infusion of 400 mg/m
2 on day 1 with subsequent weekly doses of 
250 mg/m2.Regarding the first -line treatment, cetuximab plus FOLFIRI, as compared with 
FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer patients with  KRAS 
wild-type tumors ( Van Cutsem E et al, 2009). 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  66/234 
   
Combination of encorafenib, binimetinib, and cetux imab.  
This triple combination is currently being evaluated in the Phase III BEACON  CRC study. A total 
of 30 patients were treated with encorafenib 300 mg QD , binimetinib 45 mg BID and cetuximab 
400 mg/m2 initial dose followed by 250 mg/m2 IV weekly in the Safety Lead- in portion of the study. 
Overall, the observed AEs ( Van Cutsem E et al, 2018 – Table 6 ) were consistent with known 
BRAF, MEK and EGFR inhibitor toxicities. Grade 3/4 adverse events reported in ≥  10% of patients 
were fatigue, CK  increased, AST increased and urinary tract infection (3 patients [10%] each), all 
of which were grade 3 events except for a single grade 4 AST elevation. The only grade 3/4 skin-
related AE reported was rash (grade 3) in 1 patient (3%).  
This rate of severe toxicity is lower than generally observed for cetuximab alone or in combination 
with standard chemotherapy for mCRC ( Erbitux® USPI ).  
 
Table 6: ARRAY-818- 302 (BEACON CRC study) Safety Lead -in: summary of adverse 
events regardless of causality occurring in ≥15% of patients (N=30)  
Event, n (%)  Any grade  Grade 3/4  
Any AE  30 (100)  19 (63.3)  
Diarrhea  23 (76.7)  1 (3.3)  
Dermatitis acneiform  20 (66.7)  0 
Fatigue  19 (63.3)  4 (13.3)  
Nausea 19 (63.3)  2 (6.7)  
Vomiting  15 (50.0)  2 (6.7)  
Dry skin  14 (46.7)  0 
Anemia  11 (36.7)  2 (6.7)  
Blood creatine phosphokinase increased  11 (36.7)  3 (10.0)  
Decreased appetite 11 (36.7)  2 (6.7)  
Abdominal pain  10 (33.3)  1 (3.3)  
Dyspnea  10 (33.3)  2 (6.7)  
Constipation  9 (30.0)  0 
Pyrexia  9 (30.0)  0 
Arthralgia  8 (26.7)  0 
Blood creatinine increased  8 (26.7)  0 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  67/234 
  Event, n (%)  Any grade  Grade 3/4  
Vision blurred  8 (26.7)  0 
Skin fissures  7 (23.3)  0 
Aspartate aminotransferase increased  6 (20.0)  3 (10.0)  
Asthenia  6 (20.0)  0 
Palmar -plantar erythrodysesthesia syndrome  6 (20.0)  0 
Rash maculopapular  6 (20.0)  0 
Dizziness  5 (16.7)  0 
Malaise  5 (16.7)  1 (3.3)  
Myalgia  5 (16.7)  0 
Edema peripheral  5 (16.7)  0 
Peripheral sensory neuropathy  5 (16.7) 0 
Urinary tract infection  5 (16.7)  3 (10.0)  
 
The Triplet combination dose used in the randomized Phase 3 portion of the study for US and EU 
patients (encorafenib 300 mg QD, binimetinib 45 mg BID and cetuximab 400 mg/m2 initial dose 
followed by 250 mg/m2 IV weekly) was subsequently administered to 7 patients enrolled in the 
Japanese Safety Lead -in (JSLI), which was initiated in February 2017. After all patients had 
completed at least 1  cycle of treatment the DMC reviewed the safety from the JSLI and agreed that 
Japanese patients may participate in the randomized portion of the study at the same Triplet regimen 
doses.  Ten Japanese sites have been participating in the randomized Phase 3 portion of the st udy 
in June 2018.  
1.3. STUDY RATIONALE  
BRAF mutations, which lead to constitutive activation of BRAF kinase and sustained 
RAS/RAF/MEK/ERK pathway signaling resulting in increased cell proliferation and survival occur in approximately 10% (range, 5 –22%) of the unselected colorectal cancer (CRC) population   
(Rozek LS et al, 2010, Shaukat A et al, 2010; Sorbye et al, 2015)  with lower prevalence in more 
advanced subject populations. 
The presence of a BRAF mutation is considered a marker of poor prognosis in subjects with mCRC 
and is associated with a median survival of approximately 12 to 14 months relative to 21 to 25 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  68/234 
  months for subjects with BRAFwt tumors ( Van Cutsem E et al, 2011;  Sorbye et al, 2015 ). These 
data suggest that improved therapies are urgently needed for pat ients with BRAFV600E mutant mCRC 
in the first line setting.  
Non clinical experiments have provided compelling evidence that combining a BRAF inhibitor with 
an EGFR inhibitor results in greater anti -tumor effects than either agent alone in BRAFV600E CRC 
cells (Corcoran RB et al, 2012; Prahallad A et al, 2012). Consistent with these observations, the 
combination of the selective BRAF inhibitor, encorafenib and cetuximab resulted in a strong 
synergistic antitumor activity (as shown in Table 1 ). 
Clinical data  
Consistent with nonclinical data in human CRC cell models (Array data on file), early clinical data 
suggest that the triple combination BRAF + MEK + EGFR inhibitor s may result in greater activity 
than a dual combination BRAF + EGFR inhibitor in subjects wi th BRAFV600E mutant mCRC as 
described below . 
Triple combinations in the second or later line of therapy for the metastatic setting  
The ongoing multicentric, randomized phase III BEACON  CRC study ([STUDY_ID_REMOVED]) is 
evaluating encorafenib + binimetinib +  cetux imab vs encorafenib + cetuximab compared with 
Investigator’s choice of irinotecan + cetuximab or FOLFIRI + cetuximab in subjects with 
BRAFV600E  mutant mCRC whose disease has progressed after 1 or 2 prior regimens in the 
metastatic setting.  A total of 30 subjects were treated in the SLI, all of whom received encorafenib (300 mg QD) + binimetinib (45 mg BID) + cetuximab (400 mg initial dose then 250 mg/m
2 QW). 
Among the 29 subjects with BRAFV600E mutated tumors (one patient had a BRAF non-V600E 
mutated tumor) the confirmed overall response rate (ORR) was 48% (14/29) including a complete 
response in 3/29 patients. The ORR was 62% (including 8 PR and 2 CR) i n patients with one 
previous line of therapy and 31% including 3 PR and 1 CR in those with two prior lines of therapy. 
Of the 29 patients with a BRAFV600E mutation, the median time on study treatment was 7.9 
months (range, 1.0–11.9 months), and 10 (33%) pa tients remained on study treatment at the time of 
data cutoff. Preliminary estimate of median PFS is 8.0 months (95% CI, 5.6 –8.5 months), with 7 of 
29 patients (24%) still in follow -up and progression- free. Progression -free survival was similar 
between pat ients who had 1 vs 2 previous regimens (median, 95% CI, 7.6 [4.0–8.3] vs  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  69/234 
  8.1 [4.1–10.8] months) ( Van Cutsem E et al, 2018) . The confirmed ORR of 48% and median PFS 
of 8.0 months with the triple combination of encorafenib + binimetinib + cetuximab exceeds 
historical standard -of-care and exceeds the ORR of 22% in a phase II trial of the doublet of  
encorafenib + cetuximab ( Tabernero J et al, 2016). The BEACON CRC SLI results are also 
improved compared with other recent triple combination including dabrafenib plus trametinib plus 
panitumumab, in which the ORR was 21% (Corcoran RB et al, 2016) and irinotecan, vemurafenib, 
cetuximab, in which the ORR (confirmed plus unconfirmed) was 16% ( Kopetz S el al,  2017) in 
patients with previously treated BRAF mutant CRC.  In addition, to being better than other triple 
combinations, the efficacy data from the BEACON CRC SLI is also superior to the ORR of 4% and 
PFS of 2.0 months in patients treated with the irinotecan plus cetuximab, a combination accepted 
as current standard -of-care ( Kopetz S el al, 2017).  
The preclinical data and the encouraging preliminary efficacy results observed in the SLI part of the BEACON CRC study justify the evaluation of combination of encorafenib, binimetinib and 
cetuximab in the first- line setting of this subject population, which represents a high- unmet medical 
need.  
BRAF inhibition as first line treatment for the metastatic disease in BRAFm mCRC subjects  
Data from retrospective series and post hoc analyses of randomised trials reveal that stand ard first -
line regimens, including a chemo- doublet and a biologic agent, lead to poor results in terms of PFS, 
ranging from 4 to 6 months ( Ince WL et al, 2005
). 
BRAF mutation status is a strong predictor for overall survival not only in the metastatic setting but 
also in earlier -stage diagnoses. The BRAF mutation is an early event in the CRC disease 
progression, which is involved in the transformation of epithelia  into Traditional Serrated 
Adenomas (TSAs) or Sessile Serrated Adenomas (SSAs). BRAF mutation has also been identified 
as a potential mechanism of resistance to EGFR blockade. Therefore, it could be hypothesized that 
the introduction of a treatment combination including a BRAF inhibitor as first line might be 
effective 1) because of the early onset of the BRAF mutation and 2) as a strategy to prevent the 
resistance to EGFR inhibition.   
On the other hand, less “targeted’ strategies such as an intensive firs t-line regimen combining 
FOLFOXIRI with bevacizumab, seem to be effective in counteracting BRAF- mutant tumors’ 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  70/234 
  aggressiveness, as it was shown by Cremolini et al in the TRIBE study. It is important to note that 
this treatment combination is reserved to “fit” and young patients and not all patients might be 
eligible to receive such an aggressive treatment. Indeed, ( Loupakis F et al, 2014) have reported 
that the treatment combination of FOLFOXIRI and bevacizumab was associated with a significant increase in the rates of grade 3 or 4 neurotoxicity, stomatitis, diarrhea, and neut ropenia in 
comparison to FOLFIRI and bevacizumab. Therefore new treatment combinations are highly 
awaited for this population in the first line setting.  
The current study is designed in light of the promising non- clinical and early clinical data of the 
combination of encorafenib, binimetinib  and cetuximab in subjects with BRAF
V600E mCRC who 
have a poor clinical outcome. 
1.4. OVERALL RISK AND BEN EFIT ASSESSMENT  
An independent data monitoring committee (DMC) regularly reviews the safety of the combination 
of binimetinib, encorafenib, and cetuximab in the Safety Lead- in and Phase 3 portions of the 
BEACON CRC trial.   The DMC has not identified any unexpected toxicities and has determined 
that the triple combination data is indicative of an acceptable and manageable tolerability profile . 
The safety profiles of each drug were described ( in Section 1.2). Laboratory assessments as well as  
clinical procedures will be performed throughout the conduct of the current study to ensure the 
subjects’ safety.  
The benefit/risk assessment for this phase II study that will be conducted in compliance with the protocol, Good Clinical Practices ( GCP ) and the applicable regulatory requirements, appears 
acceptable for subjects with such an aggressive disease as BRAFm mCRC.  
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  71/234 
   
2. STUDY OBJECTIVE AND ENDPOINTS  
2.1. PRIMARY OBJECTIVE  
The primary objective of the study is: 
To evaluate the antitumor activity of the combination of  encorafenib , binimetinib and cetuximab by 
assessing the confirmed overall response rate (cORR) by local radiologist/investigator assessment 
in adult subjects with previously untreated BRAFV600E -mutant ( BRAFV600E) metastatic colorectal 
cancer (mCRC).  
2.2. SECONDARY OBJECTIVE S  
The secondary objectives of the study are: 
• To evaluate the cORR by central radiologist assessment.  
• To evaluate the ORR (for confirmed + unconfirmed responses) by local 
radiologist/investigator and central assessment.  
• To assess the effect of the combination of encorafenib, binimetinib and cetuximab on the duration of response (DOR).  
• To assess the effect  of the combination of encorafenib, binimetinib and cetuximab on other 
time-related efficacy parameters: time to response (TTR), progression -free survival (PFS) 
and overall survival (OS). 
• To characterize the safety and tolerability of the combination of encorafenib, binimetinib 
and cetuximab.  
• To assess the effect on quality of life (QoL). 
• To explore health care resource utilization.  
• To describe the pharmacokinetics (PK) of encorafenib, binimetinib, a metabolite of 
binimetinib (AR00426032) and cetuximab. 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  72/234 
   
2.3. EXPLORATORY OBJECTIV ES 
 
• To assess the relationship between changes in tumor markers (carcinoembryonic antigen 
[CEA] and carbohydrate antigen 19- 9 [CA19-9]) and radiographic response to tr eatment.  
• To assess BRAFV600 E status in blood circulating tumor DNA (ctDNA) at baseline. 
• To assess the  potential predictive significance of the microsatellite instability (MSI) status 
in subject s with BRAFV600E mutant mCRC.  
• To assess blood- and tissue -based predictive biomarkers of activity.  
2.4. PRIMARY ENDPOINTS  
• cORR as assessed by local radiologist/investigator review  as per Response Evaluation 
Criteria in Solid Tumors (RECIST 1.1).  
2.5. SECONDARY ENDPOINTS  
• cORR as assessed by central radiologist review as per RECIST 1.1. 
• ORR (for confirmed and unconfirmed responses) as per local radiologist/investigator and 
central assessment.  
• DOR assessed based on local radiologist/investigator and central review.  
• TTR assessed based on local radiologist/investigator  and central review.  
• PFS assessed based on local radiologist/investigator and central review.  
• OS. 
• Type and severity of adverse events (AEs) and serious adverse events (SAEs), changes in hematology and chemistry values, physical examinations, vital signs, e lectrocardiogram 
(ECGs) and echocardiogram (ECHO)/ multi -gated acquisition (MUGA) scans and 
ophthalmological examinations graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events v4.03 (NCI-CTCAE v4.03). 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  73/234 
  • Change from baseline in the European Organization for Research and Treatment of Cancer 
(EORTC) Quality of Life Questionnaire for Cancer subjects (QLQ -C30), EuroQol -5D-5L 
(EQ-5D-5L), and Patient Global Impression of Change (PGIC). 
• Resource utilization focused on hospit alizations occurring during the study treatment phase . 
• Plasma concentrations of encorafenib, binimetinib and the active metabolite of binimetinib 
(AR00426032) and serum concentration of cetuximab. 
2.6. EXPLORATORY ENDPOINT S: 
• Changes from baseline in blood CEA and CA19 -9 at the beginning of each cycle and at the 
end of treatment. 
• BRAF V600E mutation status in ct- DNA at baseline.  
• MSI status in formalin -fixed paraffin -embedded (FFPE) samples via established PCR 
assays in tumor sample versus germline control at screening . 
• Genomic and proteomic analysis of tumor tissue at baseline and at end of treatment (optional tumor tissue sample at end of treatment). 
• Genomic and proteomic analysis of blood samples at baseline. 
3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY  
Some of the ethical considerations that lead to an acceptable risk -assessment have already been 
described in Section 1.2, in the encorafenib and binimetinib Investigator’s Brochure s and in the  
Cetuximab  Summary Of Product Characteristics  (SPC ). The study will be conducted on the basis 
of appropriate clinical and non- clinical data.  
In this study, the treatment will be administered to subjects with mCRC who have received no 
systemic treatment for metastatic disease. They will be included only after they have received 
detailed and complete information about the risks and constraints related to their participation and give their written consent for participation in the study. 
They will remain un der medical control throughout the duration of the study: as described in the 
assessment and procedures sections. Potential AEs will be reported during all treatment periods, 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  74/234 
  allowing the Investigator to decide whether the subjects can continue to receive study treatment . In 
addition, verification of vital signs, as well as ophthalmologic and dermatologic examinations will 
be performed to detect any safety signals.  
The study will be carried out in accordance with the Declaration of Helsinki and its subseque nt 
modifications (the latest in 2013 – Fortaleza) , the recommendations for Good Clinical Practice 
(GCP) (ICH E6 , R2), and any applicable local regulatory requirement(s).  
The clinical study will start upon receipt of approval from both the relevant independe nt Ethics 
Committee (IEC) / Institutional Review Board (IRB) and the Competent Authorities . 
4. STUDY DESIGN  
4.1. OVERALL DESCRIPTION  
This two -stage phase II trial will be conducted as a multinational, multicenter , open- label, single -
arm study in 90 subjects. In the first stage 40 subjects will be treated , and an additional 50 subjects 
will be treated  during the second stage. Subjects in whom the presence of BRAFV600E is not 
confirmed by central laboratory will be replaced. The second stage may be initiated as soon as confirmed responses are observed in at least 12 subjects.  
As it may take several treatment cycles for subjects to achieve a confirmed response, if 12 confirmed 
responses are not observed at the time the 40
th subject is treated  in Stage 1 a limited number of 
subjects  (maximum 12) from stage 2 may be treated while waiting for all subjects in the initial 
cohort of 40 subjects in Stage 1 to be evaluable for a  confirmed response  providing no safety 
concern was raised by the iDSMC . These additional subjects will not count towards responses in 
Stage 1 but will be included as part of the Stage 2 cohort, should the study move forward into Stage 
2. 
If at any time it becomes evident that the threshold of 12 responses is unlikely to be met, then 
additional subjects  may not be recruited (eg: 6 or fewer responses among 35 subjects  with sufficient 
followup [potential for at leat 2 assessments]).  If the study continues to the second stage, 50 
additional subjects will be treated for a total of 90 . Subjects in whom the presence of BRAFV600E is 
not confirmed by central laboratory will be replaced. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  75/234 
  An iDSMC will review the available safety information at regular intervals to en sure that the overall 
safety remains acceptable during the Main study period (see section  11.5. i DSMC ). 
 
For the Main Study period, the treatment will be administered by cycles of 28 days until disease 
progression, unacceptable toxicity, withdrawal of consent, initiation of subsequent anticanc er 
therapy or death. In each 28- day cycle, subjects will receive:  
From Day 1 to Day 28: Encorafenib: 300 mg PO (oral capsule 4X 75 mg) once daily (QD). From Day 1 to Day 28: Binimetinib: 45 mg PO (oral tablet 3X 15 mg) twice daily (BID). 
Initial cetuximab dose Cycle 1, Day 1 400 mg/m
2 administered as a 120 -min IV infusion followed 
by a 250 mg/m2 dose administered as a 60 -min IV infusion once weekly (QW) thereafter until week 
28. Then, 500mg/m2 IV Q2W from week 29 (Cycle 8 day 1).  
Since implementation of th e  Urgent Safety Measure on 26 M ar 2020, i n order to ensure the 
subjects’  safety in the clinical trial by decreasing the number of clinic visits  in the context of 
COVID- 19 pandemic, Cetuximab infusions can be given every two weeks at the dose of 500 mg/m2 
administered as a 120 -min IV infusion (i.e. on D1 and D15 of each cycle) regardless of  the cycle  
number , after the investigator has evaluated the benefi t/risk ratio for the subjec t with regards to 
Covid-19 pandemic. 
If there was a dose modification prior to switching to the biweekly schedule, the total dose per cycle 
should be maintained (i.e. 200mg/m2 QW, may be changed to a 400mg/m2 Q2W).  
From 28 Dec 2020, access to study treatment will be provided through a Study extension to all 
subjects whom the investigator considers are continuing to benefit from study treatment (i.e. do not 
experience unacceptable toxicities and none of the treatment discontinuation criteria are met)  until:   
• the last ongoing subject will discontinue study treatments (including 30- day Safety Follow -
Up visit)  for any reason (unacceptable toxicity, progression of disease, subject’s decision, 
withdrawal of consent, initiation of subsequent anticancer therapy or death),  
• or binimetinib/encorafenib are commercially avail able in the first line setting of BRAF V600E 
mutated mCRC,   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  76/234 
  • or the binimetinib/encorafenib development program is stopped, whichever comes first.  
The same study treatment doses and schedule as for Main study period will be applicable for the 
Study extension period (including dose modification recommendations). 
After discontinuation of study treatment  (during Main s tudy or Study e xtension periods) , there will 
be a 30- day safety follow -up period. Subjects will then enter a survival follow -up period until the 
End of the Study. 
 
BRAF TESTING:  
Because time to treatment initiation is critical for untreated BRAFV600E mCRC subjects , will be 
eligible for the study based on identification of a tumoral BRAFV600E mutation  as determined by 
local laboratory result obtained at any time prior to Screening. Only polymerase chain reaction 
(PCR) and next generation sequencing (NGS)- based local assays results will be acceptable.  
The BRAF mutation status must be confirmed by the central laboratory no later than 30 days after 
the first dose of study treatment. In cases where there is discordance between the local assay and 
central laboratory results, or if the central laboratory is not able to confirm presence of a BRAFV600E 
mutation due to inadequate or poor sample condition or insufficient amount of tumor cells in sample 
within 30 days of initiating study therapy, subject s may only continue treatment if there is no clinical 
indication of deterioration or disease progression and the Investigator determines that the subject  is 
deriving benefit. In such instances, s ubject s must be informed that the BRAF mutation status is 
unconfirmed and must sign a separate informed consent  form  (ICF) that  includes this information  
and describes  alternative  treatment  options.  
Central laboratory BRAF  mutation tests with a definitive  result (positive or negative) cannot be 
repeated to resolve a discordant result. Subject s whose sample is determined to be inadequate or 
who have an indeterminate result on central testing should have samples (archival material only ) 
resubmitted for testing  until a definite result can be obtained ; however, in some cases , the BRAF 
status may remain indeterminate after several attempts to conduct the central test.  
If at any time there is lack of confirmation of the BRAFV600E mutation in a total of 6 su bjects (≥ 6% 
of the total targeted 90 treated subjects) or discordance between the local assay and the central 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  77/234 
  laboratory in 3 subjects (≥ 3% of the total targeted 90 treated subjects ), all subsequent subjects will 
be required to have BRAFV600E determined by the central laboratory prior to study treatment 
assignment (i.e., local BRAF testing will no longer be accepted for trial eligibility). Information 
regarding sites and laboratories associated with discordant results will be maintained and results 
from l aboratories with more than 1 prior discordant result will not be accepted for further subject 
enrollment. It means that further subjects will be treated in this site on the basis of the central 
laboratory only. 
4.2. DISCUSSION OF THE ST UDY DESIGN 
4.2.1.  Choice of the Study Population  
Refer to S ection  1 
4.2.2.  Choice of the Study Design  
In clinical practice, the number of mCRC patient s receiving therapy (as well as the treatment 
efficacy) decreases with subsequent lines of therapy ( Bokemeyer C et al, 2011;  Maughan TS et 
al, 2011). Patients with BRAFm mCRC have limited treatment options and currently no targeted 
therapy  blocking BRAF has been approved in this patient population.  Standard of C are treatment 
options provi de limited  number of  responses t o treatment. As outlined in Section 1, the data from 
retrospective series and post hoc analyses of randomised trials reveal that standard first- line 
regimens, including a chemo- doublet and a biologic  agent , lead to poor results in terms of ORR, 
PFS, and OS compared to BRAFwt  patients, even when more aggressive and les s “targeted” 
approaches are used  (Cremolini C et al, 2015). The available data from the SLI of the BEACON 
CRC study provides evidence that the triple combination of encorafenib , binimetin ib and cetuximab 
is likely to be at least as effective as the current standard of care in the first line setting.  
The objective and advantage of the current study design is to evaluate the antitumor effect while 
limiting the number of subjects exposed to t he triple combination in the frontline setting. The two -
stage design allows for this by providing an opportunity to stop the study early due to futility. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  78/234 
  4.2.3.  Choice of the Dose and Administration Modalities  
In order to optimize the potential for benefit while limiting the potential for toxicity, the dose of 
encorafenib chosen for this study is 300 mg QD, corresponding to its single-agent RP2D.  
The proposed 300 mg dose represents an active dose of encorafenib that has been shown in clinical 
studies to result in  tumor  regression and clinical responses as a single agent ( Dummer R et al, 
2013 ; Gomez -Roca CA et al, 2014 ). Non- clinical in vitro and in vivo studies using BRAFV600E 
human melanoma and colon cancer cell lines and xenograft models exploring the relationship 
between dose and efficacy also provide evidence in support of 300 mg being an appropriate starting 
dose in subject s. Using the human melanoma xenograft model A375, which expresses BRAFV600E, 
a 20 mg/kg dose was estimated to reduce tumor volume by 85% compared to untreated animals.  
Based on relative free fraction exposure, the 20 mg/kg steady- state mouse exposure is equivalent to 
the average exposure for subject s receiving 300 mg QD dosing. This is also consistent with the 
observed inhibitory effects of encorafenib in combination with cetuximab using a BRAFV600E CRC 
cell-based system. Inhibition was 70% when studied at a free encorafenib concentration that was 
equivalent to the average daily concentration in subject s receiving 300 mg QD dosing. 
The dose of binimetinib that was chosen corresponds to the single- agent RP2D (45 mg BID) . 
The dose of cetuximab corresponds to the approved dose in the US Product Information, Summary 
of the Product Characteristics for Erbitux® and Package Insert  respectively in the US , Europe and 
Japan . 
Regarding the use of cetuximab as a biweekly schedule: Tabernero et al . (Tabernero J et al, 2016  
and Tabernero J et al, 2010) showed preliminary pharmacokinetic, pharmacodynamic, effic acy, 
and safety evidence that every -2-weeks administration of cetuximab at a dose of 500 mg/m2 may 
be a potentially convenient alternative to the approved weekly dosing regimen of 250 mg/m2 
(following an initial dose of 400 mg/m2 ) in the treatment of mCRC . In regards to efficacy, an every-
2-weeks dose of 500 mg/m2 of cetuximab in combination with irinotecan gave a strikingly similar 
response rate (23%) and median TTP (4.8 months) (Pfeiffer P et al, 2007) to those of the approved 
dosing regimen plus irinotecan (23% and 4.1 months, respectively) ( Cunningham D et al, 2004 ), 
in patients who had progressed on previous chemotherapy. Based on the pharmacokinetic 
similarities of the two dosing regimens in the first- line setting  (Taberno J et al, 2006) , it is 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  79/234 
  reasonable to anticipate that the efficacy and safety of the every -2-weeks dosing regimen will also 
be similar to that observed with the approved dosing re gimen  (Tabernero J et al, 2010). 
The justification to switch to a biweekly schedule is to provide a more convenient schedule of 
administration to subject s who would stay on treatment (and who have not presented any signs of 
PD) for a period of time equivalent as the median PFS reported wi th SoC in the first line setting. 
Although cetuximab has not been approved for a Q2W dosing schedule, there are several key studies 
supporting the clinical use of this schedule for patients which metastatic CRC in the first line 
(Tabernero J et al, 2010;  Bouchahd a M et al, 2011) as well as the second and third line setting 
(Roca JM et al, 2010;  Martin -Martorell P et al, 2008; Pfeiffer P et al, 2008 ; Carneiro BA et al, 
2012; Mrabti H et al, 2009; Shitara K et al, 2012).  
Since implementation of the Urgent Safety Measure on 26 M ar 20 20, in order to ensure the subjects’ 
safety in the clinical trial by decreasing the number of clinic visits  in the context of COVID -19 
pandemic , Cetuximab infusions can be given every two weeks at the dose of 500 mg/m2 
administered as a 120 -min IV infusion (i.e . on D1 and D15 of each cycle) regardless of  the cycle  
number , after  the investigator has  evaluated the benefi t/risk ratio for the subjec t with regards to 
Covid-19 pandemic.   
As described by Tabernero and colleagues, this change in the  Cetuximab  administration  regimen 
should not impact the  pharmacokinetic, pharmacodynamic, efficacy, and safety of Cetuximab in the 
treatment of mCRC  (Tabernero J et al, 2016 and  Tabernero J et al, 2010). 
In regards to the triple combination, t he DMC of BEACON CRC study reviewed the data after the 
first 88 randomized patients , and these have not indicated any safety concerns . The doses of th e 
study treatment administered in BEACON CRC study were the same as those that will be used in 
this study. Given that there were no new safety concerns among the 88 subject s randomized , the 
use of the same doses of study treatment in this study is justified. 
4.2.4.  Choice of sample size  
Taking into consideration the study primary objective, the study sample size with 40 treated subject s 
with a centrally confirmed BRAFV600E mutation in stage 1, and 50 in stage 2 ( if study does not stop 
for futility after stage 1) , is considered sufficient to evaluate the antitumor activity of the study 
treatment ( see Section  13.3 for more detail s).  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  80/234 
  5. STUDY POPULATION  
Subject s fulfilling all of the inclusion criteria and none of the exclusion criteria will be eligible.  
5.1. INCLUSION CRITERIA  
 
1. Provide a signed and dated informed consent document. 
2. Male or female ≥ 18 years of age at time of informed consent.  
3. Histologically or cytologically confirmed CRC that is metastatic and unresectable at time of 
study entry (i.e. not suitable for complete surgical resection at screening).  
4. Presence of BRAFV600E mutation in tumor tissue previously determined by a local assay at any 
time prio r to screening. 
Notes:  
a. Only PCR and NGS-based local assays results will be acceptable.  
b. If at any time there is lack of confirmation of the BRAFV600E mutation in a total of 6 subjects 
(≥ 6% of the total targeted 90 treated subjects ) or discordance between the local assay and 
the central laboratory in 3 subjects (≥ 3% of the total targeted 90 treated subjects ), 
discordance or impossibility to confirm the BRAFV600E mutation in 3 subjects, all subsequent 
subjects will be required to have BRAFV600E determined by the central laboratory prior to 
study treatment assignment. 
c. Central testing cannot be repeated to resolve discordances with a local result once the 
central laboratory delivers a definitive result (positive or negative). 
d. If the result from the central la boratory is indeterminate or the sample is deemed inadequate 
for testing, additional samples should be submitted (archival material only). 
e. If more than 1 discordant result from any local laboratory leads to subject enrollment, subsequent results from this local laboratory  will not be accepted for further subject 
enrollment. 
 5. Eligible to receive cetuximab per locally approved label with regards to tumor RAS status.  
e.g.: In agreement with EU label, evidence of wild type RAS (KRAS and NRAS) in EU 
countries. 
 6. Able to provide a sufficient amount of representative tumor specimen ( primary or metastatic, 
archival or newly obtained) for  testing of BRAF and RAS mutation status
(a). 
(a) FFPE tumor tissue block or a minimum of 10 slides, optimally up to 15 slides.  7. Evidence of measurable disease, as per RECIST 1.1. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  81/234 
  Note: Lesions in areas of prior radiotherapy or other loco-regional therapies are considered 
measurable only if progression has been documented in the region following therapy.  8. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 
 
9. Adequate bone marrow function at screening and baseline:  
i. Absolute neutrophil count (ANC) ≥ 1.5 x 10
9/L. 
ii. Platelets ≥ 100 x 109/L. 
iii. Hemoglobin ≥ 9.0 g/dL. 
Note: Blood transfusions are allowed provided that the subject has not received more than 2 units 
of red blood cells in the 4 weeks prior to achieve the minimum required hemoglobin level.  
 10. Adequate renal function at screening and baseline. 
i.  Serum creatinine ≤ 1.5x upper limit of normal (ULN) or 
ii. Calculated creatinine clearance (CrCl) ≥ 50 mL/min  by Cockroft -Gault formula  
 11. Adequate electrolytes at screening and baseline, defined as serum potassium and magnesium 
levels within institutional normal limits.  
Note: replacement treatment to achieve adequate electrolytes will be allowed 
 
12. Adequate hepatic function at screening and baseline:  
i. Serum total bilirubin ≤ 1.5 x ULN and < 2 mg/dL. Note: Total bilirubin > 1.5 x ULN is 
allowed if direct (conjugated) bilirubin is ≤ 1.5 x ULN  (and indirect (unconjugated) 
bilirubin is ≤ 4.25 x ULN – Only applicable for France). 
ii. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x 
ULN, or ≤ 5 x ULN in the presence of liver metastases. 
13. Adequate cardiac function at screen ing:  
i. Left ventricular ejection fraction (LVEF) ≥ 50% as determined by MUGA scan or 
ECHO.  
ii. Mean triplicate QT interval corrected for heart rate according to Fridericia’s formula (QTcF) value ≤ 480 msec. 
14. Subject able to take oral medications.  
15. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  82/234 
  16. Female subjects are either postmenopausal for at least 1 year, are surgically sterile for at least 
6 weeks, or must agree to take appropriate precautions to avoid pregnancy. 
Notes:  
(a) Precautions to avoid pregnancy must be conducted from screening through 6 months after the 
last dose of cetuximab or through 30 days after the last dose of encorafenib or binimetinib, 
whichever is later if of childbearing potential. 
(b) Permitted methods of contraception as provided (in Section 5.3.1) should be communicated to 
the subjects and their understanding confirmed. For all females, the pregnancy test must be negative at screening and baseline. 
 17. Male subject must agree to take appropriate precautions to avoid fathering a child.  
Notes:  
(a) from screening through 6 months after the last dose of cetuximab or through 90 days after the 
last dose of encorafenib or binimetinib, whichever is later. 
(b) permitted methods of contraception as provided (in Section 5.3.1) should be communicated to 
the subjects and their understanding confirmed.  
 18. Subjects  under guardianship or partial guardianship will be eligible unless prohibited by local 
laws or by local/central ethic committees.  
Note: where allowed, all procedures prescribed by law must be followed.  19. Affiliated to a social security system, or is a beneficiary (if app licable in the national 
regulation). 
5.2. EXCLUSION CRITERIA  
 1. Prior systemic therapy for metastatic disease . 
Note: previous adjuvant/neoadjuvant therapy is allowed provided that 1) the interval from the end of chemotherapy to relapse is >6 months OR 2) in the case of neoadjuvant therapy, complete surgical resection was achieved and the interval from the end of chemotherapy to relapse is >12 months. Prior locoregional radiotherapy is allowed.  2. Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti- EGFR 
treatment.  
 3. Symptomatic brain metastasis.  
Note: subjects previously treated or untreated for these conditions who are asymptomatic in the absence of corticosteroid and anti-epileptic therapy are allowed. Brain metastases must be stable for ≥ 4 weeks with imaging (e.g. brain magnetic resonance imaging [MRI] or computed 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  83/234 
  tomography [CT] demonstrating no current evidence of progressive brain metastases at 
screening).  
 4. Leptomeningeal disease.  
 5. History or current evidence of R etinal V ein O cclusion (RVO) or current risk factors for RVO . 
Note: Risk factors for RVO are uncontrolled glaucoma or ocular hypertension, history of hyperviscosity syndrome or hypercoagulability syndrome.  6. Use of any herbal medications/supplements or any medications or foods that are moderate or  
strong inhibitors or inducers of CYP3A4/5 ≤ 1 week prior to the start of treatment. 
Note: However, subjects who either discontinue moderate or strong inhibitors or inducers of CYP3A4/5 or switch to another medication at least 7 days prior to starting study treatment are eligible.  
 7. Known history of acute or chronic pancreatitis within 6 months prior to the start of the 
treatment.  
8. History of chronic inflammatory bowel disease or Crohn’s disease requiring medical intervention (immun omodulatory or immunosuppressive medications or surgery) ≤ 12 months 
prior to first dose. 
 
9. Impaired cardiovascular function or clinically significant cardiovascular diseases, including 
any of the following: 
i. History of acute myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft (CABG), coronary angioplasty or stenting) ≤ 6 
months prior to start of study treatment. 
ii. Symptomatic congestive heart failure (Grade 2 or higher), history or current evidence 
of clinically significant arrhythmia and/or conduction abnormality ≤ 6 months prior to start of study treatment, except rate controlled atrial fibrillation and paroxysmal 
supraventricular tachycardia. 
 
10. Uncontrolled hypertension defined as persistent elevation of systolic blood pressure ≥ 150 
mmHg or diastolic blood pressure ≥ 100 mmHg despite optimal therapy.  
 
11. Impaired hepatic function, defined as Child-Pugh class B or C. 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  84/234 
  12. Known history of Gilbert's syndrome or is known to have any of the following genotypes: 
UDP glucoronosyl transferase (UGT)1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28. No 
more applicable from Protocol V6.0/Amendment PA03 
 
13. Impaired gastrointestinal function or disease* which may significantly alter the absorption of 
encora fenib or binimetinib  or recent changes in bowel function suggesting current or 
impending bowel obstruction. 
*eg. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection.  
 14. Previous or concurrent malignancy* within 5 years of study. 
*except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in- situ of the cervix  or any other malignancy that has been 
adequately treated and has not recurred within 3 years prior to study entry.   15. History of thromboembolic* or cerebrovascular events ** ≤ 6 months prior to starting study 
treatment.   
*excluding venous thrombosis related to indwelling catheters and treated with low -grade 
anticoagulants **including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli.  16. Concurrent neuromuscular disorder that is associated with the potential of elevated Creatine 
Kinase (CK) . 
Note: e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal 
muscular atrophy.  17. Residual CTCAE ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of 
Grade 2 alopecia or Grade 2 neuropathy. 
 
18. Known history of human immunodeficiency virus (HIV) infection. 
Note: HIV testing will only be conducted in jurisdictions specifically requiring it.  19. Active hepatitis B or hepatitis C infection.  
 20. Known contraindication to receive cetuximab at the planned doses. Refer to the most recent 
cetuximab summary of product characteristics (SPC) or local label as applicable.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  85/234 
   
21. Subjects who have any medical condition that would, in the Investigator’s judgment, prevent 
the subject’s participation in the clinical study due to safety concerns or compliance with 
study procedures. 
 
22. Any medical or psychiatric condition or laboratory abnormality that may increase the risk  with 
study participation or study drug administration or that may interfere with the interpretation of 
study. 
 
23. Pregnancy, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test 
result, or breastfeeding. 
 
24. Is a family member of the Investigator or any associate, colleague, or employee assisting in 
the conduct of the study (secretary, nurse, technician ). 
 
25. Is in a position likely to represent a conflict of interest. 
 26. Participation in a clinical study with administration of an investigational product within 4 weeks 
or five times the half -life of the investigational product, whichever is longer, before the first 
dose of study treatment.  
 
27. Is mentally unable to understand the nature, objectives and possible consequences of the trial; 
or he/she refuses to its contraints.  
5.3. LIFESTYLE GUIDELINES 
5.3.1.  Contraception  
Female subjects who  are postmenopausal for at least 1 year or are surgically sterile for at least 6  
weeks are considered to be of non-childbearing potential.  
Female subjects of childbearing potential must agree to take appropriate precautions to avoid pregnancy from screening through 6 months after the last dose of cetuximab or t hrough 30 days 
after the last dose of encorafenib or binimetinib, whichever is later. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  86/234 
  Male subjects must agree to take appropriate precautions to avoid fathering a child and prevent 
exposure of seminal fluid to the partner from screening through 6 months a fter the last dose of 
cetuximab or through 90 days after the last dose of encorafenib or binimetinib, whichever is later .  
The following methods are permitted under this protocol for use by the subject  and his/her partner. 
These methods are listed below and should be communicated to the subjec ts and their understanding 
confirmed . 
Methods that have been determined to be highly effective (i.e., can achieve a failure rate < 1% per 
year when used consistently and correctly) according to the  CTFG 2014 ( Clinical Trials 
Facilitation Group ) include: 
• Complete abstinence from heterosexual intercourse during the entire period of risk 
associated with the study treatments; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject  
• Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: 
− Oral 
− Intravaginal 
− Transdermal  
• Progestogen-only hormonal contraception associated with inhibition of ovulation: 
− Oral 
− Injectable  
− Implantable 
• Intrauterine device (IUD)  
• Intrauterine hormone- releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomised partner (considered highly effective provided the vasectomized male h as 
received medical assessment of surgical success and that the male is a female subject’ s sole 
sexual partner) 
Acceptable birth control methods that result in a failure rate of more than 1% per year (CTFG 2014) 
include: 
• Progestogen- only oral hormonal contraception, where inhibition of ovulation is not the 
primary mode of action 
• Male or female condom with or without spermicide 
• Cap, diaphragm or sponge with spermicide 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  87/234 
  NOTE: Due to the potential of encorafenib to induce CYP3A4, hormonal agents (including but not 
limited to birth control patch, vaginal ring, oral, injectable, or implanted contraceptives) are 
permissible only when combined with other highly effective or acceptable methods of 
contraception.  
5.3.2.  Photosensitivity 
Subject s should avoid extended exposure  to ultraviolet light and , when outdoors, should wear 
occlusive clothing, sunscreen and sunglasses while receiving encoraf enib or cetuximab  and for 2 
months following the last dose of each agent . 
5.4. NUMBER OF SUBJECTS  
The target of 90 subjects   with centrally confirmed BRAFV600E  will be treated in two stages: 
• First stage: 40 subjects  will be treated  
• Second stage: if there are at least 12 confirmed responders in the first stage, 50 additional 
subjects will be treated in this second stage .  
In case of discordance in the results between the local assay and the central laboratory (potential 
false-positive local result), or lack of BRAFV600E confirmation, subject will be replaced. 
5.5. RECRUITMENT MODALITI ES 
Subjects  with confirmed BRAFV600E  mCRC and who have not received any prior systemic therapy 
for the metastatic disease and who fulfill all inclusion and none of the exclusion criteria will be 
recruited.  
Where  authoriz ed by local/national regulation, some specific materials may be used to improve 
recruitmen t including: leaflets , advertising in oncology journals, websites, mailing (paper or e -mail) 
to doctors, subject  association s, and subject  advocacy groups . Before use of such materials, they 
will be reviewed and approved by the Sponsor and submitted to and approved by the appropriate 
IECs /IRBs . 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  88/234 
  5.6. SUBJECTS I DENTIFICATION  
The Subject’s code will contain 8 digits, corresponding to the country number, the centre number 
and the Subject’s number according to chronological order (once having signed t he written 
informed consent). 
5.7. SUBJECT DISCONTINUATION REAS ONS  
The reasons for a subject’s premature discontinuation from the study may be the following (i n all 
cases, available data will be retained for the safety analysis ): 
5.7.1.  Treatment Discontinuation for Individual Subject   
Subjects may decide to stop participating in the study at any time for any reason without prejudice to their future medical care by the physician or at the institution. Wherever possible, the tests and 
evaluations listed for the End of Treatment visit and Safety Follow -up visit  should be carried out 
and an effort should be made to continue follow-up. 
If a subject decides to discontinue study treatment, he/she should be asked if he/she is willing to be 
contacted by telephone for monitoring of survival.   
If a subject withdraws consent, the s ubject ’s data collected up to the date of consent withdrawal will 
be included in the analyses. The date, stated reason for and level of consent withdrawal should be 
documented. Any blood or tissue samples collected up to the date of withdrawal of consent will be 
analyzed , unless explicitly prohibited  by the subject . 
The Sponsor should be notified of all subjects’ decision to discontinue study treatment and all study withdrawals through the designated e- CRFs in a timely manner.  
Subject s meeting any of the following criteria must discontinue study drug treatment: 
• Subject decision  to discontinue study treatment  (but reque st agreement to return for end 
of treatment assessments, safety follow -up assessments and/or survival follow-up). 
• Withdrawal of consent : no further participation  
• Lost to follow up : A subject will be considered as lost to follow up, if he/she did not attend 
a scheduled visit and for whom no news can be obtained after three documented attempts  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  89/234 
  with a minimum of 15 days between the first and the last attempt. This status must be dated 
at the latest as the database lock . 
• Investigator decision  in the subject’s interest if an SAE occurs and is considered by the 
Investigator liable to threaten the health of the subject or if a serious disease occurs and 
necessitates the prescription of a medication incompatible with the pursuit of the study. The 
Sponsor should immediately be informed by phone or fax or email and a report explaining 
the discontinuation will be forwarded to him as soon as possible. 
•  Progressive disease:  at any time (to be taken into account only for treatment 
discontinuation).  
• Unacceptable AE o r toxicity  (related or not to the study treatment) or failure to tolerate 
the study treatment. 
• Dose interruption  of >  28 consecutive days in administration of encorafenib or 
binimetinib, or noncompliance with study drug administration consisting of > 4 mis sed 
consecutive doses of cetuximab due to an AE or clinically significant laboratory 
abnormality, unless judged by the Investigator and Sponsor Medical Contact or designee to 
be in the best interest of the subject to continue treatment. 
• Death . 
• Female subject becomes pregnant, or begins breastfeeding,  
• Significant protocol deviation  that, in opinion of the investigator and/ or sponsor, renders 
the subject unsuitable for further study drug administration.  
• Termination of the study by the sponsor.  
Subjects meeting any of the following criteria may be discontinued from study drug treatment if, 
during the course of the study: 
• Is found to have a tumor that is BRAFwt by the central laboratory. 
• Is noncompliant with study procedures or study drug administration in the opinion of the 
investigator. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  90/234 
  5.7.2.  Study Discontinuation for individual Subject   
The subject  may be considered discontinued from the study for the following reasons: 
• Withdrawal o f consent . 
• Lost to follow-up. 
• Death . 
• Termination of the study by the Sponsor. 
5.8. STUDY DISCONTINUATIO N 
This study may be discontinued at any time due to safety concerns, failure to meet expected 
enrollment goals, administrative reasons or at the discretion of the Sponsor. Should the study be 
terminated prematurely, the Sponsor will provide written notification to all Investigators and 
regulatory authorities and will specify the reason(s) for early termination. The Sponsor/Investigator 
must inform the EC/ IRB promptly and provide the reason(s) for the termination. 
The Competent Authority (CA) may suspend or prohibit the study if it considers that the conditions 
of authorisation are not being met or has doubt about the safety or scientific validity of the study. 
5.9. REPLACEMENT OF  SUBJECTS  
Withdrawn subjects will not be replaced. 
Subjects with unconfirmed BRAFV600E mutation will be replaced.  
5.10. POST -STUDY EXCLUSION PERIOD  
A post-study exclusion period is not required in this protocol. 
5.11.  SUBJECT CARD 
As soon as consent is signed, t he subject will receive from the Investigational Cent er a personal 
card to be kept throughout the study duration, which provides  the following information: subject's 
name, Sponsor's name, study code, (if applicable) EudraCT number, complete address of the 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  91/234 
  Investigating Centre with the name and emergency phone number of the Investigator and a Sponsor 
24/7 phone contact number (French and English languages). 
The delivery date of the card to the study subject will be documented in the electronic case report 
form (e -CRF) . 
The preferred contact  for the subject in case of need is in all cases the Investigator or his team. The 
card includes  the name of the Investigator and the phone number which allows direct contact by the 
subject or the caregiver in case of need.  
 
The card, features an additional phone number which allows, should the need arise, a contact with 
a Sponsor representative able to address any medical and urgent issues. 
The subject is informed that, if a call is necessary, this call will be answered in English / French, 
which allows th e subject to take any appropriate measures.  
6. STUDY TREATMENT(S)  
In Europe (EU),  the Investigational Medicinal Product Management Service of the Institut de Recherche Pierre Fabre ( IRPF) will supply the investigational centers  with labeled and packaged 
encorafenib, binimetinib and cetuximab units necessary for the conduct of the trial.
 
In the United States (US), labeled and packaged binimetinib and encorafenib will be supplied to 
investigational centers by Array BioPharma. Cetuximab supply withi n the US will be supplied 
either locally or by Array BioPharma. Array BioPharma will employ a licensed company specializing in packaging, labeling, and distribution of investigational medicinal products. 
In Japan (JAP), labeled and packaged binimetinib, encorafenib and cetuximab will be supplied to 
investigational centers by Array BioPharma via a licensed company specializing in packaging, 
labeling, and distribution of investigational medicinal products via a warehouse facility located in 
Japan.  
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  92/234 
   
6.1. SOURCE,  PRESENTATION AND CO MPOSITION OF 
INVESTIGATIONAL PROD UCT(S) AND ASSOCIATE D 
PRODUCT(S)  
6.1.1.  Encorafenib 75 mg hard capsule  
Encorafenib will be prepared in oral hard capsules. 
 
Code and name:  W0090-Encorafenib for Europe , LGX818 -Encorafenib  for US  and Japan.  
Enco rafenib may also be known as ONO -7702 in  Japan . 
Pharmaceutical presentation:  hard  capsule of 75 mg 
 
Composition:  
• Hard capsule 
− Active ingredient:  Encorafenib  
− List of Excipients: copovidone, Poloxamer 188, cellulose microcrystalline, succinic acid, 
crospovidone, silica colloidal anhydrous, magnesium stearate of vegetable origin. 
Capsule shell (gelatin, titanium dioxide (E171), iron oxide red (E172), iron oxide yellow 
(E172), iron oxide black (E172), ink capsule shell (Pharmaceutical Glaze, iron oxide  black 
(E172), Propylene glycol). 
6.1.2.  Binimetinib 15 mg film-coated tablet  
Binimetinib will be prepared in film- coated tablets for oral use.  
 
Code and name:  W0074 - Binimetinib  for Europe, MEK162 - Binimetinib for US  and Japan.  
Binimetinib may also be known as ONO -7703 in  Japan . 
Pharmaceutical presentation:  film-coated tablet of 15 mg 
 
Composition:  
• Film-c oated tablet  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  93/234 
  − Active ingredient:  Binimetinib  
− List of e xcipients:  lactose monohydrate, microcrystalline c ellulose , croscarmellose s odium, 
magnesium s tearate, colloidal silicon dioxide/s ilica colloidal anhydrous , OPADRY® 
yellow 85F92213 (polyvinyl a lcohol – part hydrolyzed, macrogol / PEG 3350, titanium 
dioxide, talc, iron oxide yellow E172, iron oxide black E172)  
 
 
6.1.3.  Cetuximab solution for infusion  
Cetuximab is available under different formulations:  
- 1 formulation for Europe and Japan  
- 1 formulation for US 
 
• Europe and Japan formulation: ERBITUX® 5 mg/mL solution for infusion 
Cetuximab solution for infusion will be supplied in labelled packages : s ingle- use vial of 500 mg 
cetuximab (5 mg/mL  solution) – vial of 100 mL 
Cetuximab is a colorless solution administer ed intravenously. 
Cetuximab is a chimeric monoclonal IgG1 antibody produced in a mammalian cell line (Sp2/0) by 
recombinant DNA technology. 
 
Composition: 
−  Active ingredient: Cetuximab 5  mg/mL  
− List of excipients : Sodium chloride , Glycine , Polysorbate 80, Citric acid monohydrate , 
Sodium hydroxide, Water for injection . 
Cetuximab does not contain any antimicrobial preservative or bacteriostatic agents . From a 
microbiological point of view, the product should be used immediately after opening. If not used 
immediately, in -use storage times and conditions prior to use are the responsibility of the user and 
would normally not be longer than 24 hours at 2 to 8ºC, unless opening has taken place in controlled 
and validated aseptic conditions. 
• US formulation 
Erbitux®(cetuximab) in the US is commercially available and is supplied at a concentration of 2 
mg/mL as  a 100 mg/50 ML, single -use vial or as a 200 mg/100 mL, single -use vial as a sterile 
injectable liquid containing no preservatives. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  94/234 
  Composition: 
Cetuximab is formulated in a solution with no preservatives, which contains: 
− Active ingredient: Cetuximab 2 mg/ mL 
−  List of excipients: sodium chloride, sodium phosphate dibasic heptahydrate, sodium 
phosphate monobasic monohydrate, and Water for Injection 
 
6.2. PACKAGING AND LABELL ING  
In Europe, t he treatment units will be packed and labelled by the Investigational Medic inal Product 
Management Service of IRPF  according to the European Directive,  local requirements  and local 
languages. 
In US, the treatment units will be packed and labelled within US  by the s ponsor designee  and 
comply with the legal requirements of the US . 
In Japan, the treatment units will be packed and labelled by sponsor designee  and comply with the 
legal requirements of Japan.  
6.2.1.  Packaging 
6.2.1.1.  Encorafenib 75 mg capsule  
 
• Europe  formulation 
- Primary packaging  
70 hard capsules will be packaged in a bottle 175 cc (HDPE, white, opaque, square) closed 
with a cap (38 mm, polypropylene ( PP), white, child- resistant design, cap with induction seal 
liner) and containing a 2 grams silica gel  desiccant .  
- Secondary packagi ng (only for Europe) 
The bottle will be packaged in a sealed box . 
• US and Japan formulation 
- Primary packaging  
70 hard capsules will be packaged in a bottle 175 cc (HDPE, white, opaque, square) closed 
with a cap (38 mm, PP, white, child- resistant design, cap with induction seal liner and opening 
seal ring) and containing a desiccant.  
(Tyvek soft packet, 2 gram sil ica Gel Desiccant).  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  95/234 
  - Secondary packaging  
No secondary packaging.   
 
6.2.1.2.  Binimetinib 15 mg film coated tablet  
 
• Europe  formulation 
- Primary packaging  
70 film coated tablets will be packaged in a 120 cc bottle  (HDPE, without dessicant, white, 
opaque, square) closed with a cap (38 mm, Polypropylene (PP), white, child- resistant design, 
cap with induction seal liner). 
 
- Secondary packaging   
The bottle will be packaged in a sealed box. 
 
• US and Japan formulation 
- Primary packaging  
70 film c oated tablets will be packaged in a 120 cc bottle (HDPE, without desiccant, with 
induction seal, and child- resistant cap)  
 
- Secondary packaging  
No secondary packaging. 
 
 
6.2.1.3.  Cetuximab ERBITUX® 5 mg/mL solution for infusion  
• Europ e and Japan formulation: Cetuximab ERBITUX® 5 mg/mL solution for infusion  
- Primary packaging  
100 mL of solution in a vial (Type I glass) with a stopper (halobutyl rubber) and a seal (aluminium/polypropylene ). 
 
- Secondary packaging  
Sealed box of 1 vial: 500 mg. 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  96/234 
  • US formulation: Cetuximab ERBITUX® 2 mg/mL solution for infusion 
Erbitux®(cetuximab) in the US is commercially available.  Commercially available vials are 
packed into cartons.   
 
6.2.2.  Labelling  
 
• Labelling for Europe Supply : 
Investigational Products will be labelled in compliance with local requirements, according to the 
following rules: 
 
I. Treatment unit box labelling:  
The secondary packaging box label (green for binimetinib and white for encorafenib and cetuximab) 
contains the following information: 
(a) Name and address of Sponsor 
(b) Pharmaceutical dosage form, route of administration, quantity of dosage units, the 
name/identifier and strength/potency 
(c) Packaging batch number 
(d) Trial reference code allowing identification of the study (protocol number and EudraCT 
number) 
(e) Treatment number  
(f) Name of the Investigator ( will be added when preparing to send)  
(g) Directions for use (reference may be made to the investigator brochure or other explanatory document intended for the trial subject or person administering the product) 
(h) “For clinical trial use only”  
(i) Storage conditions 
(j) Expiry date as month/year (MM/YYYY) 
(k) “Keep out of reach and sight of children” except when the product is for use in trials where the product is not taken home by subjects  
The box labelling contains a tear -off flap (also green for binimetinib and white for encorafenib and 
cetuximab ) with the following information:  
- Protocol number 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  97/234 
  - Packaging batch number 
- Treatment  number 
- The name/identifier and strength/potency  
Additional mentions will be added according to local authority requirements. 
Symbols or pictograms may be included to clarify certain information mentioned above. Additional 
information, warnings and/or handling instructions may be displayed. 
 
II. Treatment bottle/vial labelling:  
The product is supplied in a primary packaging and a secondary packaging which are intended to remain together. T he following information is included on the label of the primary package  
bottle/vial (green for binimetinib and white for encorafenib and cetuximab):  
(a) Name of Sponsor 
(b) Pharmaceutical dosage form, route of administration (may be excluded for oral solid dose forms), quantity of dosage units, the name/identifier and strength/potency 
(c) Packaging batch number 
(d) Trial reference code allowing identification  of the study (protocol number) 
(e) Treatment number  
(f) Expiry date as month/year (MM/YYYY) 
• Labelling  for US and Japan Supply  
For both encorafenib and binimetinib supplied within the US  and Japan , each bottle will be labelled, 
at a minimum, with a unique identifier (medication number), the lot number, contents (number of tablets), dosage strength, storage conditions and the name and address of the Sponsor  designee . 
Both encorafenib and binimetinib labels will be in the local language and comply with the legal requirements of the US  and Japan. Site personnel will add the subject number to the label. 
In the US, cetuximab will be supplied either locally or by the Sponsor designee, Array BioPharma.  
If the US cetuximab is locally supplied, then the cetuximab does not require specific labelling. Each 
unit of cetuximab supplied for Japan by the Sponsor designee will be labelled, at a minimum, with a unique identifier (medication number), the lot number, contents (number of tablets), dosage 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  98/234 
  strength, storage conditions and the name and address of the Sponsor designee. Cetuximab labels 
will be in local language and comply with the legal requirements of Japan.  
 
6.3. DISTRIBUTION TO CENTE RS AND STORAGE  
Before the start of the study, the sponsor or designee  will supply the Investigational Centre with the 
necessary treatment units for the study using Interactive Response Technology (IRT).  
Additional treatment supplies will be shipped to the Investigational Centre upon request via IRT 
and according to needs. 
Acknowledgement of receipt of all shipments should be managed according to Pharmacy manual 
process and timelines.  
The Clinical Research Associate (CRA) will ensure during the initiation visit that trial medications 
have been received in good condition and the acknowledgment of receipt has been adequately 
completed  and returned. 
In cases of undue delay in study execution, the Pharmacist or Investigator should ensure that the expiry date has not been exceeded. If the date has been exceeded, new treatment units  will be 
supplied to the investigational center. 
Labeled, packaged encorafenib , binimetinib and cetuximab will be shipped to each centre by the 
Sponsor or designee, as described in the Pharmacy Manual.  The Investigator or an approved representative (e.g., registered pharmacist) will ensure that all 
encorafenib , binimetinib and cetuximab is stored as outlined in the Pharmacy Manual and in 
accordance with applicable regulatory requirements. The drug storage area at the site must be secure, with access limite d to authorized personnel. 
Storage conditions will be described on the medication label. Detailed instructions for storage and handling of encorafenib and binimetinib will be provided in the Pharmacy Manual. Cetuximab 
should be stored according to the locally approved prescribing information.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  99/234 
   
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO 
SUBJECT S  
All subjects who sign an informed consent will be assigned a unique subjec t number and will be 
able to start screening. A subject will be assigned for study treatments via the IRT system if he/she  
meet s all eligibility requirements .  
According to GCP, all eligibility  criteria will be checked during the registration procedure. 
Assignment of treatment number  will be implemented via IRT.  All information regarding this 
process is described in the IRT manual.  
Throughout the Treatment Period (Main study and Study extension periods) the Investigator will 
dispense to the s ubject the b ox indicated by IRT (Day 1 of each cycle).  
6.5. TREATMENT ADMINISTRATION 
6.5.1.  Duration of Treatment  
During the Main study period, study treatment will be  administered  until unacceptable toxicity, 
progression of disease, subject ’s decision, withdrawal of consent, initiation of subsequent 
anticancer therapy or death. During the Study extension period (from 28 Dec 2020), access to study treatment will be provided 
through a Study extension to all subjects who m the investigator considers are continuing to benefit 
from stu dy treatment (i.e. do not experience unacceptable toxicities and none of the treatment 
discontinuation criteria are met) until:  
• the last ongoing subject will discontinue study treatments (including 30- day Safety Follow -
Up visit) for any reason (unacceptable toxicity, progression of disease, subject’s decision, 
withdrawal of consent, initiation of subsequent anticancer therapy or death),  
• or binimetinib/encorafenib are commercially availabl e in the first line setting of BRAF 
V600E 
mutated mCRC,   
• or the binimetinib/encorafenib development program is stopped, whichever comes first.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  100/234 
   
Dose Schedule  
The investigational products in this study are e ncorafenib  and binimetinib  in combination with 
cetuximab . Dose schedule is described  in Table 7 . 
 
Table 7: Dose and Treatment Schedule  
Study treatment  Pharmaceutical form and 
route of administration Dose  Frequency  
Encorafenib  4 × 75 mg oral capsule  300 mg  QD 
Binimetinib  3 × 15 mg oral film -coated 
tablet 45 mg  BID 
Cetuximab  IV infusion  400 mg/m2 initial 
dose (120- minute 
infusion),  then 250 
mg/m2 (60-minutes 
infusion)  QW for the first 2 8 
weeks  
500 mg/m2 (120-
minute infusion)  Q2W (from week 2 9 - 
C8D1 ) 
Since implementation of 
the Urgent Safety Measure on 26  Mar 
2020, in order to ensure the subjects’ safety in the 
clinical trial by 
decreasing the number of clinic visits  in the 
context of COVID -19 
pandemic , Cetuximab 
infusions can be given 
every two weeks (i.e. on  
D1 and D15 of each 
cycle) regardless of the cycle number, after the investigator has evaluated the benefit/risk 
ratio for the subjec t with 
regards to Covid -19 
pandemic . 
QD: once daily; BID: twice daily; QW, once weekly ; Q2W, every 2 weeks  
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  101/234 
   
6.5.2.  Route and Conditions of Administration of Encorafenib and 
Binimetinib  
Encorafenib will be administered with a QD schedule and binimetinib will be administered with a 
BID schedule, both PO as a flat-fixed dose, not by body weight or body surface area (BSA ).  
Binimetinib and encorafenib can be taken without regard to food. Subjects should be instructed to 
swallow the capsules /tablets whole and not to chew or crush them. Both oral study drugs are to be 
taken together in the morning and only the BID administered drug (binimetinib) is to be taken in 
the evening without regard to food. 
• QD dosing: subject s should be instructed to take encorafenib capsules daily with a large  
glass of water (~250 mL) in the morning (together with the morning intake of binimetinib) 
at approximately the same time every day. Doses of encorafenib that are omitted for AEs or 
any other reason can be taken up to 12 hours prior to the next dose; if less than 12 hours to 
the next dose, the regular dosing schedule must continue and subjec t should be instructed 
to check with the study doctor. It is forbidden to double the next dose. 
• BID dosing: subject s should be instructed to take binimetinib tablets 12 ± 2 hours apart with 
a large glass of water (~250 mL) in the morning and in the evening at approximately the 
same times every day. Doses of binimetinib that are omitted for AEs or any other reason 
should not be made up later in the day, or at the end of the dosing period and it’s forbidden 
to double the next dose. 
On days when a blood collection is scheduled at the investigational site, subject s will take the  
morning dose of encorafenib and binimetinib  at the site under the supervision of the Investigator or 
designee , after any required blood sample  collections . The time of dosing and the time of PK 
samples should be recorded on these clinic visit dates. O n all other days, subject s will take 
encorafen ib and binimetinib at home.  
If a subject vomits at any time after dosing, the dose of study drug should not be re- administered.  
Subject s are prohibited to consume grapefruit, pomegranates, star fruits, Seville oranges or products 
containing the juice of any of these items throughout  the entire study and for 7 days before the first 
dose of study drugs, due to potential CYP3A4 interaction with the study drugs. Orange juice is allowed.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  102/234 
  Encorafenib and binimetinib will be administered at least 30 minutes prior to cetuximab  without 
regard to when cetuximab premedications are administered.  
The Investigator or responsible site personnel will ensure that the appropriate dos e is dispensed and 
will provide the subject with at least the appropriate number of encorafenib capsules and binimetinib 
tablets for the number of doses to be taken prior to the next scheduled visit. The site personnel will 
train the subject  and/or the subject ’s caregiver on dosing procedures for the study drug. 
Subjects will receive a diary to document self -administered dosings of encorafenib and binimetinib 
for each cycle to include the dose of study drug taken, the date of dosing (and times if applicable ), 
and if any doses were missed and the reason for the missed dose. One diary will be provided per cycle. Subject s will be instructed to return unused encorafenib and binimetinib and the subject  diary 
to the center at the end of each cycle. Drug accountabi lity must be performed on a regular basis. 
The Investigator or responsible site personnel should instruct the subject  to take encorafenib and 
binimetinib as per protocol ( i.e., promote compliance). The dosage prescribed and dispensed to the 
subject  and all  dose changes and all missed doses during the study must be recorded in the e- CRF .  
6.5.3.  Route and Condition of Administration of Cetuximab  
Cetuximab will be administered IV weekly on Days 1, 8, 15 and 22 (±3 days) of every 28- day cycle 
at the study center for the first 28 weeks then every two weeks from week  29 ( Table 7 ) according 
to institutional standards.  
The initial cetuximab dose on Day 1 of Cycle 1 is 400 mg/m2 administered as a 120 -minute IV 
infusion followed thereafter by a 250 mg/m2 dose administered  as a 60 -minute IV infusion at each 
cycle. Subjects who remain on treatment for 28 weeks will be treated with cetuximab 500 mg/m2 
administered as a 120 -min IV infusion once every 2 weeks from week 29 (Cycle 8 day 1).  
Since implementation of the Urgent Saf ety Measure on 26  Mar 2020, in order to ensure the subjects’ 
safety in the clinical trial by decreasing the number of clinic visits  in the context of COVID -19 
pandemic , Cetuximab infusions can be given every two weeks at the dose of 500 mg/m2 
administered as a 120 -min IV infusion (i.e. on D1 and D15 of each cycle) regardless of  the cycle  
number , after the investigator has evaluated the benefi t/risk ratio for the subjec t with regards to 
Covid-19 pandemic. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  103/234 
  If there was a dose modification prior to switching to the biweekly schedule, the total dose per cycle 
should be maintained (i.e. 200mg/m2 QW, may be changed to a 400mg/m2 Q2W).  
The infusion rate should be consistent with local labelling but should not exceed 10 mg/min  (the 
first infusion rate should not exceed 5mg/min). Close monitoring is required during the infusion 
and for at least 1 hour after the end of the infusion. If an infusion reaction occurs while cetuximab 
is being administered, the infusion should be stopped immediately, and the subjects should be 
closely monitored and treated in line with institutional standards. Any re -challenge with cetuximab 
following an infusion reaction should be first discussed with the Sponsor.  
Pre-medication for routine cetuximab infusions may be used in accordance with the label and with 
the national and/or institutional standards, but should preferably be based on a combination of an 
H1 antagonist (e.g., diphenhydramine) and dexamethasone (10 mg IV) . This combination is 
mandatory for the  first infusion . Pre-medication should be administered no sooner than 1 hour after 
administration of encorafenib and binimetinib (if applicable) and 30 minutes prior to cetuximab 
infusion. According to cetuximab labelling instructions, medications such as corticosteroids and 
antihistamines may be administered at the discretion of the Investigator to treat an existing infusion 
reaction, or as premedication for a subject who has previously experienced an infusion reaction. Predose PK samples for cetuximab analysis should be collected just prior the beginning of the 
cetuximab infusion. 
Doses of cetuximab that are omitted for AEs or any other reason should not be made up. If 
cetuximab is discontinued, the frequency of study visits may be decreased after discussion with 
Sponsor.  
6.5.4.  Dose Modification  
Subject s will be monitored for AEs. The severity of AEs will be evaluated using the NCI -CTCAE 
v.4.03. 
If a subject  develops toxicity, the dose should be modified as outlined in Table 14 and Table 15, 
which  include criteria for interruption and reduction of encorafenib, binimetinib  and cetuximab . All 
dose modifications should be based on the worst preceding toxicity. All dosing interruptions and 
modifications must be recorded in the e- CRF . 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  104/234 
  If a subjec t permanently discontinues binimetinib due to an AE or clinically significant laboratory 
value, they may continue to receive encorafenib in combination with cetuximab.  
Due to the lack of efficacy of binimetinib, encorafenib, or cetuximab when used as single agents in 
subject s with BRAF- mutant mCRC, subject s who cannot tolerate these agents in combination with 
at least one other agent, should discontinue study treatment altogether, complete the end of treatment visit and continue to be followed for survival (and disease progression, if applicable). 
Cetuximab may be reduced by 2 dose levels to a minimum of 150 mg/m
2, due to AEs or laboratory 
abnormalities ( Table 8 ). When a dose reduction is required because of an AE, no subsequent dose 
re-escalation of cetuximab will be permitted for that subject  for the d uration of study treatment. If 
after resolution of an AE, treatment is resumed at the same dose, and the same toxicity reoccurs 
with the same severity, any re -initiation of treatment must be at the next lower dose level 
irrespective of duration, with some exceptions for skin toxicity.  In addition, a subject  must discontinue study treatment if, after treatment is resumed at a lower 
dose of cetuximab, the same toxicity reoccurs with the same or worse severity.  
If a subject miss es > 28 consecutive days of encorafenib or binimetinib, or > 4 consecutive 
cetuximab doses as the result of an AE or clinically significant laboratory abnormality, then the 
respective agent (s) should be discontinued.  
Subject s who discontinue study treatment for a study- related AE or an abnormal laboratory value 
must complete the end of treatment visit and continue to be followed for survival (and disease 
progression). 
 
 
 
  
 
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  105/234 
  Table 8: Dose Levels for Dose Modification  
 Encorafenib  
(mg QD)  Binimetinib  
(mg BID)  Cetuximab  
WEEKLY 
(mg/m2)   
 Cetuximab  
BI-WEEKLY 
(mg/m2)  
 Starting from C8D1 
week 29  Or at any cycle 
since implementation of 
the Urgent Safety 
Measure on 26  Mar 20 20 
Starting Dose  300 45 400 mg/m2 cycle 1 day 1   
then 250 mg/m2 
thereafter  500 
Dose level -1 225 30 200   400 
Dose level -2 150 15 150 300 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  106/234 
   
6.5.4.1.  Dose  Modification for Encorafenib and/or Binimetinib  
Doses of encorafenib and/or binimetinib may be adjusted for AEs throughout the study as described 
inTable 14. In general, doses should not be reduced or interrupted for Grade 1 AEs other than for  
specific ocular AEs referred  to in Tab le 13 , but treatment to control symptoms should be provided 
as appropriate, if applicable.  
An individual subject may have their dose of encorafenib and/or binimetinib reduced to the dose 
levels specified in  Table 8 . 
The lowest permitted dose level of encorafenib is 150 mg QD and the lowest permitted dose level of binimetinib is 15 mg BID. 
If the AE causing a dose reduction improves to the subject’s Basel ine level and remains stable for 
a minimum of 14 days, the dose can be re -escalated to the next dose level at the discretion of the 
Investigator, provided there are no other concomitant toxicities that would prevent drug re -
escalation. There is no limit to  the number of times the subject can have their dose reduced or re 
escalated (in increments specified in  Table 8).  
• No dose re -escalation of encorafenib i s allowed after a dose reduction due to prolonged 
QTcF ≥ 501 msec  
• No dose re -escalation of binimetinib is allowed after a dose reduction due to LVEF 
dysfunction or prolonged QTcF ≥ 501 msec  
• No dose re -escalation of binimetinib or encorafenib is allowed after a dose reduction due to 
retinal toxicity ≥ Grade 2. 
Refer to Table 14 for recommended dose modifications for encorafenib and/or binimetinib, if 
applicable, based on the occurrence of treatment- related AEs.  
Eye disorders that cannot be specifically graded according to modified NCI-CTCAE, v.4.03, should 
be graded according to  Table 9. Serous detachment of the retina should be graded according to 
Table 10.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  107/234 
   
Uveitis sh ould be graded according to NCI -CTCAE, v.4.03 as described in Table 11, Hand-foot 
skin reactions (HFSR) should be graded according to NCI -CTCAE, v.4.03 as described in Table 
12. Diarrhea should be graded according to modified NCI -CTCAE, v.4.03 as described in Table 
13. Furthermore, please refer to  Section 17.1 for additional supportive care recommended 
guidelines for the management of: cetuximab- induced, encoraf enib-induced and/or binimetinib-
induced skin reaction (Section 17.1),  encorafenib -induced HFSR ( Section 17.2) , binimetinib -
induced diarrhea (Section 17.3) and binimetinib -associated interstitial lung disease/pneumonitis 
(Section 17.7).  
Table 9: Modified NCI CTCAE, Version 4.03 Grading of Eye Disorders 
Grade  Description  
1 Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated  
2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental activities of daily living  
3 Severe or medically significant but not immediately sight threatening; hospitalization or 
prolongation of existing hospitali zation indicated; disabling; limiting self -care activities of daily 
living  
4 Sight -threatening consequences; urgent intervention indicated; blindness (20/200 or worse) in the 
affected eye  
  
 
Table 10: NCI CTCAE, Version 4.03 Grading of Serous Detachment of the Retina  
Grade  Description  
1 Asymptomatic (but with findings in ocular coherence tomography, fundoscopy and/or slit lamp 
biomicroscopy)  
2 Symptomatic with moderate decrease in visual acuity (20/40a or better); limiting instrumental 
activities of daily living  
3 Symptomatic with marked decrease in visual acuity (worse than 20/40a); limiting self -care activities 
of daily living   
4 Blindness (20/200a or worse) in the affected eye  
Note: For rhegmatogenous retinal detachment, grade according to NCI -CTCAE v.4.03 Retinal Detachment.  
a Please refer to (Section  17.3). 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  108/234 
  Table 11: NCI CTCAE, Version 4.03 Grading of Uveitis 
Grade  Description  
1 Asymptomatic; clinical or diagnostic observations only  
2 Anterior uveitis; medical intervention indicated  
3 Posterior or pan- uveitis  
4 Blindness (20/200a or worse) in the affected eye  
a Please refer to ( Section  17.3 ). 
 
Table 12: NCI CTCAE, Version 4.03 Grading of Hand- foot Skin Reaction (HFSR)a  
Grade  Description  b 
1 Minimal skin changes or dermatitis (e.g., erythema, edema, numbness, dysesthesia, paresthesia, 
tingling or hyperkeratosis) without pain  
2 Skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting 
instrumental ADL  
3 Severe skin changes (e.g., peeling, ulceration, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self -care ADL  
Abbreviations: ADL=activities of daily living.  
a. HFSR or palmar -plantar erythrodysesthesia syndrome, a disorder characterized by redness, marked discomfort, 
swelling, and tingling in the palms of the hands or the soles of the feet;  
b. More specific examples for Grade 1 and Grade 3 are added to facilitate proper grading (from the sorafenib 
package insert ; West Haven, CT: Bayer Pharmaceuticals Corporation; 2007).  
 
Table 13: Modified NCI CTCAE, Version 4.03 Grading of Diarrhea 
Grade  Description  
1 Increase of < 4 stools per day over Baseline; mild increase in ostomy output compared to Baseline  
2 Increase of 4 -6 stools per day over Baseline; moderate increase in ostomy output compared to 
Baseline  
1/2 complicated  Definition as above (Grade 1/2) with the following complicating signs/symptoms:  
• Moderate to severe cramping  
• Grade ≥ 2 nausea/vomiting  
• Decreased performance status  
• Fever  
• Sepsis  
• Neutropenia  
• Frank bleeding  
• Dehydration  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  109/234 
  Grade  Description  
• Unresolved diarrhea after 48 hours of treatment with loperamide (including high -dose 
adminis tration) and initiation of second -line treatment  
3 Increase of ≥ 7 stools per day over Baseline; incontinence; hospitalization indicated; severe 
increase in ostomy output compared to Baseline; limiting self -care activities of daily living  
4 Life threatening consequences; urgent intervention indicated  
 
Table 14: Recommended dose modifications for Encorafenib -related and/or Binimetinib 
related AEs  
 
Worst toxicity  
CTCAE, v.4.03 Grade  
(unless otherwise specifieda) Dose Modification for Encorafenib and for Binimetinib  
Eye Disorders - Retinal Events (including serous detachment of the retina),  
Note: Results and images of ocular coherence tomography (OCT) must be made available upon request.  
Any visual acuity impairment at screening should be documented and should be considered as baseline.  
Grade 1  Maintain dose levels of encorafenib and binimetinib and repeat ophthalmic monitoring 
including visual acuity assessment and OCT within 10 days . 
• If subject  remains asymptomatic (Grade 1), maintain dose level of encorafenib 
and binimetinib and continue the schedule of visual assessments established per 
protocol . 
• If subject  becomes symptomatic (blurred vision, photophobia, etc.) or visual 
acuity assessment sho ws Grade 2, follow Grade 2 dose guidelines below . 
Grade 2  Interrupt dosing of encorafenib and binimetinib and repeat ophthalmic monitoring 
including visual acuity assessment and OCT within 10 days . 
• If resolved to baseline or Grade ≤ 1, resume treatment at  current dose level of 
encorafenib and binimetinib and continue the schedule of visual assessments 
established per protocol . 
• If not resolved to baseline or Grade ≤ 1, resume treatment at 1 reduced dose 
levelb of encorafenib and binimetinib and continue the  schedule of visual 
assessments established per protocol . 
Grade 3  Interrupt dosing of encorafenib and binimetinib and repeat ophthalmic monitoring 
including visual acuity assessment and OCT within 10 days:  
• If resolved to baseline or Grade ≤ 2, resume treatment at 1 reduced dose levelb of 
encorafenib and binimetinib and continue the schedule of visual assessments 
established per protocol . 
• If not resolved to baseline or Grade ≤ 2, continue the interruption and repeat the ophthalmic assessment in 1 0 days.  
. If resolved to baseline or Grade ≤ 2, resume treatment at 1 reduced 
dose levelb of encorafenib and binimetinib and continue the 
schedule of visual assessments established per protocol  
. If remains Grade 3, permanently discontinue encorafenib and 
binimetinib . 
Grade 4  Permanently discontinue binimetinib and immediate follow -up with ophthalmic 
monitoringc. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  110/234 
  Worst toxicity  
CTCAE, v.4.03 Grade  
(unless otherwise specifieda) Dose Modification for Encorafenib and for Binimetinib  
Eye Disorders - Posterior Uveitisc 
Note: Results and images of ocular coherence tomography (OCT) must be made available upon request.  
Any visual acuity impairment at screening should be documented and should be considered as baseline.  
Grade 1  Maintain dose levels of encorafenib and binimetinib and repeat ophthalmic monitoring 
including visual acuity assessment and OCT within 10 days.  
• If subject remains asymptomatic (Grade 1), maintain dose level of encorafenib 
and binimetinib and continue the schedule of visual assessments established per 
protocol.  
If subject becomes symptomatic (blurred vision, photophobia, etc.) or visual acuity 
assessm ent shows Grade 2, follow Grade 2 dose guidelines below.  
Grade 2  Interrupt dosing of encorafenib and binimetinib and repeat ophthalmic monitoring 
including visual acuity assessment and OCT within 10 days.  
• If resolved to baseline or Grade ≤ 1, resume treat ment at current dose level of 
encorafenib and binimetinib and continue the schedule of visual assessments established per protocol.  
• If not resolved to baseline or Grade ≤ 1, resume treatment at 1 reduced dose 
level
b of encorafenib and current dose of binim etinib and continue the schedule 
of visual assessments established per protocol.  
If posterior uveitis lasts > 6 weeks, permanently discontinue binimetinib and 
encorafenib.  
Grade 3  Interrupt dosing of encorafenib and binimetinib and repeat ophthalmic moni toring 
including visual acuity assessment and OCT within 10 days:  
 
• If resolved to baseline or Grade ≤ 2, resume treatment at 1 reduced dose levelb of 
encorafenib and current dose of binimetinib and continue the schedule of visual 
assessments established per protocol.  
• If not resolved to baseline or Grade ≤ 2, continue the interruption and repeat the 
ophthalmic assessment in 10 days.  
• If remains Grade 3, permanently discontinue encorafenib and binimetinib.  
Grade 4  Permanently discontinue encorafenib and binimetinib and immediate follow -up with 
ophthalmic monitoringc. 
Eye Disorder - RVOc(Retinal Vein Occlusion)  
Note: Results and images of ophthalmic examinations should be made available upon request. This includes 
scans/images of fluorescein angiography should a subject be assessed using this technique.  
RVO of any grade  Permanently discontinue binimetinib and immediately follow -up with ophthalmic 
monitoringc. 
Other Eye Disorders (i.e., Non-Retinal Events)  
Grade 1 – 2 Maintain dose level of encorafenib and binimetinib and increase frequency of 
ophthalmic monitoring to at least every 14 days until stabilization or resolution.  
Grade 3  Interrupt dosing of encorafenib and binimetinib and refer subject to ophthalmologist 
within 7 daysc: 
• If resolved to Grade ≤ 1 in ≤ 21 days, resume treatment at 1 reduced dose levelb 
of encorafenib and binimetinib.  
• If not resolved to Grade ≤ 1 in ≤ 21 days, permanently discontinue encorafenib  
and binimetinib and close follow -up with ophthalmic monitoring until 
stabilization or resolutionc. 
Grade 4  Permanently discontinue encorafenib and binimetinib and immediate follow -up with  
ophthalmic monitoring until stabilization or resolutionc 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  111/234 
  Worst toxicity  
CTCAE, v.4.03 Grade  
(unless otherwise specifieda) Dose Modification for Encorafenib and for Binimetinib  
Liver -Related Adverse Events  
Grade 1  
AST or ALT  
> ULN to 3 × ULN  Maintain dose level of encorafenib and binimetinib.  
Grade 2  
AST or ALT  
> 3 to 5.0 × ULN or  
3 × baseline valued AND  
blood bilirubing  
≤ 2.0 × ULN  
 
 
 
  Maintain dose level of encorafenib and interrupt dosing of binimetinib until resolved to 
Grade  ≤ 1 (or Grade ≤ 2 in case of liver metastasis), then:  
• If resolved in ≤ 14 days, maintain dose level of encorafenib and binimetinib.  
• If not resolved in ≤ 14 days, interrupt dose of encorafenib (in addition to prior 
binimetinib) until resolved to Grade ≤ 1 (or Grade ≤ 2 in case of liver metastasis), then resume treatment at current dose level of encorafenib and 1 reduced dose level
b of binimetinib.  
If additional occurrence:  
• Interrupt dos ing of encorafenib and binimetinib until resolved to Grade ≤ 1 (or 
Grade ≤ 2 in case of liver metastasis), then resume treatment at 1 reduced dose level
b of encorafenib and binimetinib.  
Treatment with encorafenib and binimetinib may be resumed sequentially at the 
Investigator’s discretion, with encorafenib being resumed alone for one week before 
resuming binimetinib treatment.  
  
 
AST or ALT  
> 3.0 to 5.0 × ULN AND  
blood bilirubing 
 > 2.0 × ULN  Interrupt dosing of encorafenib and binimetinib until resolved to Grade ≤ 1, then:  
• If resolved in ≤ 7 days, resume treatment at 1 reduced dose levelb of encorafenib 
and binimetinib.  
• If not resolved in ≤ 7 days, permanently discontinue encorafenib and binimetinib.  
Treatment with encorafenib and binimetinib may be resumed sequentially at the 
Investigator’s discretion, with encorafenib being resumed alone for one week before 
resuming binimetinib treatment.  
Grade 3  
AST or ALT  
> 5.0 to 8.0 × ULN)  
AND  
blood bilirubing  
≤ 2.0 × ULN  
  Interrupt dosi ng of encorafenib and binimetinib until resolved to Grade ≤ 1 (or Grade ≤ 
2 in case of liver metastasis), then:  
• If resolved in ≤ 14 days, resume treatment at current dose level of encorafenib 
and binimetinib.  
• If not resolved in ≤ 14 days, resume treatment at 1 reduced dose levelb of 
encorafenib and binimetinib.  
Treatment with encorafenib and binimetinib may be resumed sequentially at the 
Investigator’s discretion, with encorafenib being resumed alone for one week before resuming binimetinib treatment.  
 If additional occurrence:  
• Interrupt dosing of encorafenib and binimetinib until resolved to Grade ≤ 1 (or 
Grade ≤ 2 in case of liver metastasis), then resume treatment at 1 reduced dose 
level
b of encorafenib and binimetinib.  
AST or ALT  
>8 × ULN  
AND blood bilirubing  
≤ 2.0 × ULN  Permanently discontinue encorafenib and binimetinib.  
AST or ALT  
> 5.0 × ULN  
AND  blood bilirubin
g  
> 2.0 ×  ULN  Permanently discontinue encorafenib and binimetinib.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  112/234 
  Worst toxicity  
CTCAE, v.4.03 Grade  
(unless otherwise specifieda) Dose Modification for Encorafenib and for Binimetinib  
Grade 4  
AST or ALT  
> 20.0 × ULN  Permanently discontinue encorafenib and binimetinib.  
Cardiac Disorders - Left Ventricular Systolic Dysfunctiona (Dose Adjustment for Binimetinib ONLY).  
Asymptomatic  
absolute decrease of > 10% in 
LVEF compared to baseline and 
the LVEF is below the 
institution’s LLN (e.g., a decrease of 60% to 48% is an absolute decrease of 12%)  Interrupt dosing of binimetinib and repeat evaluation of LVEF within 2 weeks.  
• If the LVEF recovers (defined as LVEF ≥ 50% or ≥ lower limit of normal (LLN) 
and absolute decrease ≤ 10% compared to baseline) ≤ 21 days, resume treatment 
at 1 reduced dose levelb of binimetinib after approval of the Sponsor’s Medical 
Monitor. Monitor LVEF 2 weeks after resuming binimetinib, every 4 weeks for 12 weeks and subsequently as per protocol . 
• If LVEF does not recover in ≤ 21 days, permanently discontinue binimetinib. Closely monitor LVEF until resolution or for up to 16 weeks.  
Grade 3 – 4 Permanently discontinue binimetinib. Closely monitor LVEF until resolution or up to 
16 weeks.  
Note: Copies of ECHO and/or MUGA scans could be requested for subjects to be 
available to the Sponsor for subjects with absolute decrease of >10% in LVEF 
compared to baseline and LVEF < 50% or LLN.  
CK Elevation  
Grade 1 -2 Maintain dose of encorafenib and binimetinib. Ensure subject is adequately hydrated. 
Closely monitor CK and serum creatinine.  
• If total CK ≥ 3 × ULN, measure CK isoenzymes and myoglobin in blood or 
urine.  
Grade 3  
> 5.0 - 10.0 x ULN without   
renal impairment (i.e., serum 
creatinine < 1.5 × ULN or  
1.5 × baseline)  If asymptomatic, maintain dosing of encorafenib and binimetinib. Ensure subject is 
adequately hydrated. Monitor and measure isoenzymes and myoglobin in blood or urine and serum creatinine.  
 If symptomatic (muscle pain/spasms/muscle weakness), maintain dosing of encorafenib 
and interrupt dosing of binimetinib until resolved to CTCAE Grade ≤ 1 and monitor 
closely, then:  
• If resolved in ≤ 21 days, maintain dose of encorafenib and resume treatment at 
1 reduced dose level
b of binimetinib.  
• If not resolved in ≤ 21 days, maintain dose of encorafenib and permanently 
discontinue binimetinib.  
Grade 4  
without   
renal impairment (i.e., serum 
creatinine < 1.5 × ULN or  
1.5 × baseline)  If asymptomatic, maintain dose of encorafenib  and interrupt dosing of binimetinib. 
Ensure subject is adequately hydrated. Monitor and measure isoenzymes and myoglobin in blood or urine and serum creatinine.  
• If resolved in ≤ 21 days, maintain dose of encorafenib and resume treatment at 
1 reduced dose levelb of binimetinib.  
• If not resolved in ≤ 21 days, maintain dose of encorafenib and permanently 
discontinue binimetinib.  
If symptomatic (muscle pain/spasms/muscle weakness), maintain dose of encorafenib 
and permanently discontinue binimetinib.  
Grade 3 o r 4  
with   
renal impairment  
(i.e., serum creatinine ≥ 1.5 × 
ULN or  
1.5 × baseline)  Interrupt dosing of encorafenib and binimetinib until resolved to CTCAE Grade < 1 or 
baseline level. Ensure subject is adequately hydrated. Monitor closely and measure isoenzymes and myoglobin in blood or urine and serum creatinine, then:  
• If resolved in ≤ 21 days, consider resuming treatment at 1 reduced dose levelb of 
encorafenib and binimetinib.  
• If not resolved in ≤ 21 days, permanently discontinue encorafenib and 
binimeti nib. 
2nd occurrence:  
• Permanently discontinue encorafenib and binimetinib.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  113/234 
  Worst toxicity  
CTCAE, v.4.03 Grade  
(unless otherwise specifieda) Dose Modification for Encorafenib and for Binimetinib  
Cardiac Investigation – Prolongation of QT interval QTcF value  
QTcF > 500 ms during treatment 
and change from pre -treatment 
value remains ≤ 60 ms  Subjects should have regular ECG monitoring (continuous where appropriate) until an 
adequately trained physician (such as a cardiologist or internist) has reviewed the data. 
Electrolyte abnormalities including magnesium should be corrected and cardiac risk 
factors for QT prolo ngation (e.g., congestive heart failure, bradyarrhythmias) should be 
controlled.  
1st occurrence:  
• Temporarily interrupt dosing of encorafenib and binimetinib until QTcF <  500 
ms. Then resume treatment at 1 reduced dose levelb of encorafenib and 
binimetinib . 
2nd occurrence:  
• Temporarily interrupt dosing of encorafenib and binimetinib treatment until 
QTcF < 500 ms. Then resume treatment at 1 reduced dose levelb of encorafenib 
and binimetinib. If a subject restarts binimetinib and encorafenib following 
resoluti on of Grade 3 QTcF prolongation event, the subject should be evaluated 
with triplicate predose ECGs on Day 1 of the next cycle, followed by a single postdose ECG and a single predose ECG on Day 15, as well as single predose ECG and a single postdose ECG on Day 1 of the subsequent cycle (2nd cycle 
after the Grade 3 QT prolongation event).  
3
rd occurrence:  
• Permanently discontinue encorafenib and binimetinib.  
QTcF increase during treatment 
is both > 500 ms and > 60 ms 
change from - pretreatment values  Subjects should have regular ECG monitoring (continuous where appropriate) until an 
adequately trained physician (such as a cardiologist or internist) has reviewe d the data. 
Electrolyte abnormalities including magnesium should be corrected and cardiac risk 
factors for QT prolongation (e.g., congestive heart failure, bradyarrhythmias) should be controlled.  
• Permanently discontinue encorafenib and binimetinib.  
Rash [ see cetuximab dose modifications ( Table 15) and  (Section 17.1). 
Grade 1  Maintain dose level of encorafenib and binimetinib.  
Initiate Initial Rash Treatment Regimen (see Section 17.1. if it was not already started 
and rash should be closely monitored ). 
Grade 2  1st occurrence:  
• Maintain dose level of encorafenib and binimetinib  
• Initiate Initial Rash Treatment Regimen if it was not already started and rash 
should be closely monitored  
• Reassess within ≤ 14 days. If rash worsens or does not improve, interrupt dosing 
of encorafenib and binimetinib until resolved to Grade  ≤ 1. Then resume 
treatment at current dose level of enco rafenib and binimetinib. For dermatitis 
acneiform, treatment with encorafenib may be maintained if, in the judgment of 
the Investigator, the rash is considered to be unrelated to encorafenib. If treatment with encorafenib was maintained and no improvement within 8 days, interrupt dosing of encorafenib.  
2
nd occurrence:  
• Reassess within ≤ 14 days. If rash worsens or does not improve, interrupt dosing 
of encorafenib and binimetinib until resolved to Grade  ≤ 1. Then resume 
treatment at current dose level of enco rafenib and 1 reduced dose levelb of 
binimetinib. For dermatitis acneiform rash, treatment with encorafenib may be 
maintained if, in the judgment of the Investigator, the rash is considered to be unrelated to encorafenib. If treatment with encorafenib was maintained and no improvement within 8 days, interrupt dosing of encorafenib.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  114/234 
  Worst toxicity  
CTCAE, v.4.03 Grade  
(unless otherwise specifieda) Dose Modification for Encorafenib and for Binimetinib  
Grade 3  1st occurrence:  
• Interrupt dosing of encorafenib and binimetinib until resolved to Grade  ≤ 1. 
Reassess weekly. Then resume treatment at current dose level of encorafenib 
and binimetinib.  
• Consider referral to dermatologist and manage rash per dermatologist’s 
recommendation.  
2nd occurrence:  
• Interrupt dosing of encorafenib and binimetinib until resolved to Grade ≤ 1. Then resume treatment at 1 reduced dose level
b of encorafenib and binimetinib.  
Resume treatment with encorafenib at the same dose level if, in the judgment of 
the Investigator, the rash is considered to be unrelated to encorafenib.  
• Consider referral to dermatologist and manage rash per dermatologist’s  
recommendation.  
Grade 4  Permanently discontinue encorafenib and binimetinibf 
Hand -foot Skin Reaction (HFSR)/Palmar -plantar Erythrodysesthesia Syndromee (Dose Adjustment for Encorafenib 
ONLY) (See  Section 17.2 and Table 12 ) 
Grade 1  Maintain dose of encorafenib. Promptly institute supportive measures, such as topical 
therapy, for symptomatic relief. Give instruction on life -style modifications.  
Grade 2  1st occurrence:  
• Maintain dose of encorafenib and HFSR should be closely monitored. Promptly institute supportive measures, such as topical therapy, for symptomatic relief. Give instruction on life -style modifications.  
• If no improvement ≤ 14 days, interrupt dosing of encorafenib until resolved to 
Grade ≤ 1. Resume treatment wit h encorafenib at current dose level. Continue 
supportive measures, such as topical therapy, for symptomatic relief. Give 
instruction on life -style modifications.  
Additional occurrence:  
• Treatment with encorafenib may be maintained or interrupted based upon  the 
Investigator’s discretion. Continue supportive measures, such as topical therapy, for symptomatic relief. Give instruction on life -style modifications.  
• If interrupted dosing of encorafenib per Investigator’s judgment, interrupt until resolved to Grade  ≤ 1. Resume treatment with encorafenib at the same dose level 
or 1 reduced dose level
b based upon the Investigator’s discretion.  
Grade 3  1st or additional occurrence:  
• Interrupt dosing of encorafenib until resolved to Grade ≤ 1. Promptly initiate supportive  measures, such as topical therapy, for symptomatic relief. Give 
instruction on life -style modifications. Reassess the subject weekly.  
Then resume treatment at one reduced dose level
b of encorafenib  
• Consider referral to dermatologist and manage H FSR per dermatologist’s 
recommendation.  
> 3nd occurrence:  
• Interrupt dosing of encorafenib until resolved to Grade ≤ 1, decision to resume 
treatment with encorafenib at one reduced dose levelb or permanently 
discontinue encorafenib should be based upon the Investigator’s discretion.  
SCC, KA and any Other Suspicious Skin Lesion (Dose Adjustment for Encorafenib ONLY)  
Grade ≤ 3  Maintain dose of encorafenib (dose interruptions or modifications are not required). 
Treatment of SCC, KA, and any other suspicious skin lesion (eg, new primary 
melanoma) should occur based upon institutional practice.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  115/234 
  Worst toxicity  
CTCAE, v.4.03 Grade  
(unless otherwise specifieda) Dose Modification for Encorafenib and for Binimetinib  
Diarrhea (See Section 17.3). 
Uncomplicated  
Grade 1 -2 Maintain dose of encorafenib. Consider temporary interruption of binimetinib until 
resolved to Grade ≤ 1. Then resume treatment at current dose level of binimetinib.  
Complicated  
Grade 1 -2 Consider temporary interruption of encorafenib until resolved to Grade ≤ 1. Then 
resume treatment at current dose level of encorafenib  
Interrupt dosing of binimetinib until resolved to Grade ≤ 1. Then resume treatment at 
1 reduced dose levelb of binimetinib.  
Grade 3 -4 Interrupt dosing of encorafenib and binimetinib until resolved to Grade ≤ 1. Then 
resume treatment at current dose level of encorafenib if, in the judgment of the 
Investig ator, the toxicity is considered to be unrelated to encorafenib, or at one reduced 
dose levelb. Resume treatment at 1 reduced dose levelb of binimetinib.  
Nausea/Vomiting  
Grade 1 -2 Maintain dose level of encorafenib and binimetinib. Promptly institute antiemetic 
measure.  
Grade 3  Interrupt dosing of encorafenib and binimetinib until resolved to Grade ≤ 1. Then 
resume treatment at 1  reduced dose levelb of encorafenib. Resume treatmen t with 
binimetinib at the current dose if, in the judgment of the Investigator, the toxicity is 
considered to be unrelated to binimetinib, or at 1 reduced dose levelb. 
Note: Interrupt dosing of encorafenib and binimetinib for ≥ Grade 3 vomiting or Grade 3 nausea only if the vomiting or nausea cannot be controlled with optimal antiemetics 
(as per local practice).  
Grade 4  Permanently discontinue encorafenib and binimetinibf. 
Interst itial lung disease/pneumonitis  - Section  17.7 
Grade 1  Maintain dose level of encorafenib and binimetinib. Monitor weekly.  
Grade 2  Maintain dose of encorafenib. Withhold binimetinib for up to 3 weeks.  
If improved to Grade 0 or 1, resume treatment at 1 reduced dose level of binimetinib.  
If not resolved within 3 weeks, permanently discontinue binimetinib.  
Grade 3 -4 Permanently discontinue binimetinib.  
All Other Adverse Events (Suspected To Be Related To Encorafenib and/or Binimetinib)  
Grade 1 -2 If the event is a persistent Grade 2 AE not responsive to a specific therapy, consider 
interruption or reduction of encorafenib and binimetinib, as applicable  
Grade 3  Interrupt dosing of encorafenib and binimetinib until resolved to Grade ≤1 or to 
pretreatment/baseline level. If the event resolves ≤ 21 days, then study drug may be 
resumed at 1 reduced dose levelb based upon the Investigator’s discretion.  
Grade 4  Permanen tly discontinue encorafenib and binimetinibf 
 
a : Not according to NCI -CTCAE  
b : Dose reduction below 150 mg QD for encorafenib, and below 15 mg BID for binimetinib is not allowed.  
c : Ophthalmic monitoring mandated for retinal events, posterior uveitis, RVO: further evaluation with specialized retinal imaging (e.g. 
ocular coherence tomography, fluorescein angiography). Any diagnosis of retinal events must be supported by presence or absen ce of 
symptoms, visual acuity assessment and findings in OC T. 
d : For subjects enrolled with liver metastases and baseline LFT elevations.  
e : Disorder  characterized  by redness, marked  discomfort,  swelling,  and tingling  in the palms  of the hands  or the soles  of the 
feet. 
f : A subject with a Grade 4 AE may resume treatment at the lower dose level if the AE recovers to Grade ≤ 1 within 28 days of 
discontinuing drug and, if in the opinion of the Investigator and Sponsor Medical Monitor, the event is not life -threatening and the subject 
can be managed and monitored for recurrence of AE. Any subjects requiring a treatment interruption of duration > 28 days must 
discontinue study drug permanently.  
g : Refers to total bilirubin.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  116/234 
   
6.5.4.2.  Dose  Modifications for Cetuximab  
Recommended dose modifications for cetuximab based on the occurrence of cetuximab treatment -
related AEs are summarized in  Table 15. Section 17.1 contains recommended guidelines for 
prophylactic and symptomatic treatment of cetuximab -induced rash.   
 
Table 15: Recommended dose modifications for Cetuximab during a cycle of therapy  
Worst toxicity  
CTCAE, v.4.03 Grade   
Dose Modification for Cetuximab During a Cycle of Therapy 
Infusion Reaction If an infusion reaction occurs while cetuximab is being infused, the infusion 
should be stopped immediately and the subject  should be evaluated.  
Grade 1 or 2  
 Restart and complete the disrupted infusion at the discretion of the 
Investigator. The infusion must be restarted at a reduced rate. Additional pre-medications such as antihistamines or low -dose systemic corticosteroids 
may be administered when the infusion is restarted per inst itutional 
standards.  
All subsequent infusions must also be administered a t the reduced rate.  
Grade 3 or 4  Permanently discontinue cetuximab  
Rash : see encorafenib and/or binimetinib dose modifications  (Table 14 )] 
Grade 1 or 2  Maintain dose level; consider initiating appropriate therapy (such as 
antihistamines, topical corticosteroids, and low -dose systemic 
corticosteroids)  
Grade 3, despite therapy  Omit dose until resolved to ≤  Grade 2, then:  
• If resolved in ≤ 7 days (or ≤  14 days for acneiform rash), then 
maintain dose level  
• If not resolved in ≤ 7 days despite appropriate skin toxicity therapy 
(or ≤  14 days for acneiform rash), then permanently discontinue 
cetuximab  
Grade 3 recurrent  Omit dose until resolved to ≤ Grade 2, then:  
• If resolved in ≤ 7 days (or ≤  14 days for acneiform rash), then 
decrease 1 dose level  
• If not resolved in ≤ 7 days despite appropriate skin toxicity therapy 
(or ≤ 14 days for acneiform rash), then permanently discontinue 
cetuximab  
• Permanently discontinue cetuximab after 3rd recurrence ( i.e., upon 
4th occurrence)  
Grade 4, despite skin toxicity 
therapy  Permanently discontinue cetuximab  
Interstitial lung disease - Section 17.7: in case of ILD, for all grades, cetuximab must be discontinued  
 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  117/234 
   
6.6. REPLACEMENT PROCEDURE  
Not Applicable  
6.7. BLIND BREAKING PROCESS  
Not Applicable  
6.8. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF 
INVESTIGATIONAL PROD UCT(S) AND ASSOCIATE D 
PRODUCT(S)  
The Investigator should maintain accurate written records of treatment received, dispensed, returned 
and any remaining treatment units, on the treatment accountability form. These records should be 
made available for CRA monitoring. The packaging of the medication should remain intact until 
just before the dispensation. 
At each visit, the Investigator will record the number of  capsu les and tablets  returned by each 
subject.  
At the end of the study, all used and unused treatments including packaging should be noted, and 
will be destroyed at the center (or local warehouse if not possible at the center ). A copy of the 
treatment accountability form should be provided by the Investigator to the CRA and a destruction certificate should be received by Sponsor. 
6.9. RECALL OF INVESTIGAT IONAL PRODUCT(S) AND  RESCUE 
MEDICATION 
In cases of recall of investigational products (decided by the Competent Authorities or the Sponsor), 
the Investigato r will be immediately informed by the Sponsor. 
The Investigator , in collaboration with the S ponsor representatives (Study Manager, CRA) must 
urgently: 
• stop the delivery of the concerned investigational products to the subjects , 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  118/234 
  • inform the concerned subjects  that they must immediately stop taking these investigational 
products and return them to the center . 
The Study Manager/CRA will organiz e the return of the recalled products to the sponsor or 
designee, or will insure the destruction of the recall products at site  under the investigator’s 
responsibility (destruction certificate to be obtained). 
7. CONCOMITANT THERAPY AND THERAPEUTIC / DI AGNOSTIC 
PROCEDURE S 
Any existing concomitant therapies ( at screening), any new concomitant therapies or change in the 
dosage of an existing concomitant therapy during the course of the study must be recorded on the 
e-CRF  (as describe in the e- CRF  completion guideline). All non- essential therapies must be stopped 
at screening.  
All medications, whether prescription or nonprescription, and non- drug therapies (e.g., blood 
transfusions) taken within 4 weeks prior to the first administration of study treatment , and all 
concomitant therapy administered during the study must be recorded on the Prior/Concomitant 
Therapies e-CRF  page up to 30 days after the last study treatment administration. 
All medications (other than study treatment) and significant non- drug therapies (including physical 
therapy, and blood transfusions) administered during the study must be listed on the concomitant 
therapies  e-CRF  page.  
For all concomitant therapies taken during the study, the following information must be noted in the relevant section (s) of the e- CRF : 
• The name of the treatment / therapy  
• The reason for prescription 
• The route of administration 
• The dose 
• The frequency  
• The duration (start date and end date) 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  119/234 
  Any therapeutic and diagnostic procedures such as endoscopic examinations, diagnosti cs tests, 
ablation, surgical procedures etc. not planned by the study protocol must also be noted in the e-
CRF . These procedures may be associated with events , in which case  the condition that leads to the 
procedure must be reported in the appropriate sect ion of the e- CRF  (AEs, medical history).  
For all such procedures that occur during the study, the following information must be noted in the 
relevant section(s) of the e- CRF : 
• The name of the procedure 
• The indication 
• The duration (start date and end date) 
7.1. PROHIBITED THERAPY A ND THERAPEUTIC /DIAGNOSTIC  
PROCEDURES  
None of the  concomitant therapies and therapeutic/diagnostic procedures  listed below are allowed 
during the study period  ( except those listed in S ection 7.2): 
• Anticancer agents such as cytotoxic chemotherapy small -molecule targeted agents, biological 
agents, immune response modifiers or hormonal therapy, 
• Local therapies w hich could interfere with treatment (e .g.  surgical excision or ablation of 
lesions are not permitted  without Sponsor approval while subject s are receiving study 
treatment ), 
• Investigational drugs (other than study drugs) and devices , 
• Radiation therapy (not including palliative radiotherapy at focal sites that covers ≤  10%  of the 
bone marrow reserve), 
• Herbal preparations/medications. Subject s should stop using herbal medications 7 days prior 
to first dose of study treatment, 
• Concomitant moderate or strong systemic CYP3A4 inhibitors  or inducers which are  likely  to 
significantly increase or decrease respectively  encorafenib exposure and thus should not be 
used during this study (see Section 17.5).  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  120/234 
  If another therapy and/or therapeutic / diagnostic procedure has to be prescribed in the interest s of 
the subject’ s health, the decision to discontinue the subject from the study should be taken by the 
Investigator. 
 
7.2. AUTHORIZED THERAPY, THERAPEUTIC  AND DIAGNOSTIC 
PROCEDURE S 
In general, the use of any concomitant medication/therapies deemed necessary for the care of the subject  is permitted, unless otherwise specified. Additional information regarding concomitant 
medications/therapies is provided in the Investigator’s Brochures for encorafenib and binimetinib and the cetuximab locally approved label ling. 
Subjects receiving any of the medications listed  in Section 17.5 must be  used with caution carefully 
monitored for potentiati on of toxicity due to any individual concomitant medication and may 
require dose titration of the drug substance. Investigators should use caution when prescribing concomitant medications, as clinical experience with these compounds in subject s with cancer is 
often limited. Investigators should contact the Sponsor or designee when they are unsure whether a 
drug should be prescribed to a subject  in the clinical study. All concomitant medications/therapies, 
transfusions, procedures and dietary supplements must be documented in the e- CRF .  
7.2.1.  Skin Toxicity Treat ments 
Subjects should be treated for cetuximab- induced, encorafenib -induced and/or binimetinib-induced 
skin toxicity following the supportive care recommended guidelines for the management of these 
toxicities and prophylaxis measures refer red to in Section 17.1.  
7.2.2.  Hand -Foot Skin Reaction Treatment  
HFSR has been reported for encorafenib, so it is recommended that subjects are informed prior to 
starting study treatment to avoid activities that can cause friction to the hands and/or feet. In 
addition, supportive measures for prevention and/or management of HFSR should be instituted. Clinical judgment and experience of the treating physician should guide the management plan of 
each subject. Subject s receiving encorafenib should be treated for encorafenib- induced HFSR 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  121/234 
  following the supportive care recommended guidelines for the management of these toxicities 
(Section  17.3).  
7.2.3.  Anti -Diarrheal  
Subjects should be treated for diarrhea as per institutional guidelines, and/or as indicated in the 
locally approved prescribing information, or for subjects receiv ing binimetinib, per the supportive 
care recommended guidelines for the management of binimetinib-induced diarrhea ( Section  17.3).  
7.2.4.  Antiemetics  
Prophylactic antiemetics should only be administered if the subject experiences nausea or vomiting 
and at the discretion of the Investigator. It is recommended that subject s use drugs that do not cause 
QT prolongation. Note that some antiemetics have a known risk for Torsade de Pointes (TdP) 
(Section 17.5). 
7.2.5.  Permitted Conco mitant Therapy requiring Caution and/or  Action  
7.2.5.1.   CYP and UGT Substrates and Inhibitors  
Encorafenib is a reversible inhibitor of CYP2B6, CYP2C9, CYP3A4 and UGT1A1. It is also a time -
dependent inhibitor of CYP3A4. Likewise, b inimetinib is also a reversible inhibitor of CYP2B6. 
Permitted medications to be used with caution in this study include those that are sensitive substrates of CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and UGT1A1 or those substrates that have 
a narrow therapeutic index  (Section  17.5). 
There is a potential for encorafenib to induce CYP3A4, which may reduce the effectiveness of  
hormonal contraception methods. Therefore, the  use of at least one form of non-hormonal 
contraception is required during participation in this study ( See Section 5.3 for use of contraception 
methods required for this study) . Caution should be used in subject s receiving concomitant 
treatment with other drugs that are substrates of CYP3A4 as the efficacy of these drugs could be reduced when administered with encorafenib. 
Encorafenib has been ident ified in vitro to be metabolized by CYP3A4 and to a lesser extent by 
CYP2C19. The use of strong inhibitors of CYP3A4 is prohibited. Concomitant use of moderate 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  122/234 
  CYP3A4 inhibitors while on study should be avoided. If use of moderate CYP3A4 inhibitors is 
unavoidable and no alternatives are available, short -term use (≤ 30 days) following discussion with 
the Sponsor may be permitted with accompanying dose reduction to one- half of the encorafenib 
dose prior to use of moderate CYP3A4 inhibitors (or as close as can be achieved without exceeding 
the target dose). The encorafenib dose that was taken prior to initiating the CYP3A4 inhibitor may 
be resumed after the inhibitor has been discontinued for 3 to 5 elimination half lives. S trong 
inhibitors of CYP2C19 should be used with caution when co-administered with encorafenib.  
Binimetinib has been identified to be primarily metabolized by glucuronidation. It is advised that 
strong inhibitors of UGT1A1 should be used with caution when co- administered with binimetinib 
(Section  17.5).  
Subject s should be closely monitored for the occurrence of AEs. 
7.2.5.2.  Transporter Substrate and Inhibitors  
In vitro data showed that both encorafenib and binimetinib are substrates of the transporter P -
glycoprotein (P -gp). Binimetinib is also a substrate of BCRP. Encorafenib is a BCRP inhibitor. 
Thus, the use of drugs that are known to inhibit or induce P -gp or  BCRP should be used with caution. 
Encorafenib is also a potent inhibitor of the renal transporters, organic anionic transporter OAT1, 
OAT3 and organic cationic transporter ( OCT) 2, and the hepatic transporter organic anion-
transporting peptide ( OATP1 )B1 and OATP1B3. The co- administration of drugs that are known to 
be sensitive or narrow therapeutic index substrates of BCRP, P -gp, OAT1, OAT3, OC T 2, 
OATP1B1 and OATP1B3 should be used with caution ( Section 17.5).  
 
7.2.5.3.  Drugs with a Conditional or Possible Risk to Prolong the QT Interval 
and/or Induce Torsade de Pointes  
Investigators should use caution when administering encorafenib or binimetinib with concomitant 
medications with a known, conditional or possible risk to prolong the QT interval and/or induce TdP ( Section 17.5). Subject s receiving such medications must be carefully monitored for 
potentiation of toxicity due to any individual concomitant medication, and may require dose 
titration of the concomitant medication.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  123/234 
  8. ASSESSMENTS  
8.1. EFFICACY ASSESSMENTS  
Tumor response will be evaluated locally by  the Investigator according to RECIST, v1.1 ( Section 
17.6). 
All potential sites of tumor lesions will be assessed at screening, the following should be performed: 
• A CT scan with IV contrast of chest, abdomen and pelvis is the preferred technique. If there 
is concern about radiation exposure, an MRI may be used instead of a CT. 
• In subject s with a history of asymptomatic brain metastases , a brain MRI or CT scan  
• If clinically indicated, a whole -body bone scan (i.e., if bone metastases are suspected or 
known at baseline). A whole -body bone imaging method may be used per local standard of 
care (e.g., Tc99m bone scan, fluorodeoxyglucose -posit ron emission tomography [FDG -
PET], sodium fluoride -positron emission tomography [NaF PET] scan or whole -body bone 
MRI).  
Skeletal lesions identified on a whole -body bone scan at baseline, which are not visible on the chest, 
abdomen, or pelvis CT (or MRI) scan should be imaged at baseline using localized CT, MRI, or X -
ray.  
As far as possible, the same method of assessment of each lesion should be used at screening and 
for all visits,  for consistent comparison. 
During the Main study period, a ll post- screenin g assessments should be performed every 6 weeks 
(±7 days) from the first dose for the first 12 weeks of treatment; except for first tumor evaluation 
for which the time -window allowed is day 42 +7 days from first dose. T hen, every 8 weeks 
thereafter until d isease progression, subjec t decision, withdrawal of consent, initiation of 
subsequent anticancer therapy, subject is lost to follow -up, death or defined end of study as 
described in S ection  5.7. 
During the Study extension period, all assessments should be performed every 12 weeks (±7 days) , 
until disease progression, subject decision, withdrawal of consent, initiation of subsequent 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  124/234 
  anticancer therapy, subject is lost to follow -up, death or defined end of study as described in Section 
5.7. 
 
If a subject  discontinues study treatment for reasons other than disease progression, tumor 
assessments must continue to be performed (as per local and central review) every 6 weeks (first 12 
weeks) then every 8 weeks during the Main s tudy period and every 12 weeks during the Study 
extension period  (as per local review) , until the start of new anti- cancer therapy, disease 
progression, death, lost to follow-up, subject  decision or withdrawal consent. 
Regardless of whether study treatment is discontinued, the following should be performed: 
• Chest, abdomen, and pelvis CT (or M RI) scans  
• Brain MRI or CT scan, if metastases were documented at baseline  
• Skeletal lesions identified at baseline should continue to be imaged at subsequent scheduled 
visits using localized CT, MRI, or X -ray (using the same method used at baseline for all  
visits for any given lesion). After baseline, whole body bone scans need not be repeated, 
unless clinically indicated.  
• Additional imaging evaluations may be performed if there is symptomatic evidence 
suggesting the possibility of disease progression based on clinical symptoms or physical 
examination at any time.  
If off- schedule imaging evaluations are performed or if progression is suspected, every effort should 
be made to perform subsequent imaging evaluations in accordance with the original imaging 
sched ule.  
All CT scans should be performed with IV contrast. If a subject  is known to have a medical 
contraindication to the contrast agent or develops a contraindication during the study, a CT scan 
without IV contrast of the chest and MRI with IV contrast, if possible, of the abdomen and pelvis 
may be performed. A CT scan of the brain, preferably with IV contrast, may be performed if MRI 
is contra- indicated.  
Chest X -ray or ultrasound should not be used for tumor response assessments in this study. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  125/234 
  Any lesions that have been subjected to loco- regional therapies (e.g., radiotherapy, ablation, etc.) 
should not be considered measurable, unless they have clearly progressed since that therapy. 
Previously treated lesions that have not progressed should be considered non- measurable and 
therefore, assessed as non -target lesions.  
While FD G-PET scans are not required for this study, sites may perform combined PET/CT scans 
per their local standard of care, provided the CT is of similar diagnostic quality as a CT scan 
performed without PET, including the use of oral and IV contrast media. If acquired according to 
local standard of care, FDG -PET may be relied upon to document progressive disease ( PD) in 
accordance with RECIST.  
When possible, each center should have a designated radiologist responsible for the interpretation 
of scans and response evaluations for study subject s. At a minimum, a single radiologist should 
perform all evaluations for an individual subject . 
Transmission for central review  
All imaging data acquired for efficacy purposes during the Main study period will be transmitted  to 
an imaging vendor for central review. Image transmission to the imaging vendor should be 
accomplished according to the imaging vendor manual.  Full details of the central reading process 
are included in the Independent Review Charter.  
8.2. PHARMACOKINETICS  ASSESSMENT  
8.2.1.  Blood Samples  Collection  
8.2.1.1.  Collection Schedule  
Blood sample s (4 mL /time point) for determination of encorafenib, binimetinib and the active 
metabolite of binimetinib (AR00426032) plasma levels will be collected, during Cycle 1 and C ycle 
2, at the following times.  
Cycle 1:  
• Day 1: T2h (±10 min) and T6h (±30 min) post encorafenib/ binimetinib dose.   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  126/234 
  Dosing and sampling information will consist of the date and time of the first encorafenib and 
binimetinib dose, the encorafenib and binimetinib dose amount administered, and exact date and 
time of the PK samples; 
Cycle 2:  
• Day 1: predose (T0) (just prior to the dose of encorafenib/ binimetinib), T2h (±10min) post 
encorafenib/ binimetinib dose.  
Dosing and sampling information will consist of: 
− For predose sample:  
. date and time of the last two previous binimetinib doses (morning/evening) and the 
current day’s binimetinib dose, including the dose amounts taken and exact date and time of the PK samples.  
. date and time of the last previous encorafenib dose and the current day’s encorafenib dose, including the dose amounts taken and exact date and time of the PK samples  
 
− For T2h sample:  
. date and time of the current day’s first encorafenib and binimetinib dose, including the dose amounts administered, and exact date and time of the PK samples.
 
Blood sample s (4 mL per time point) for determination of cetuximab serum levels will be collected, 
during Cycle 1 and Cycle 2, only at the following times:  
Cycle 1:  
• Day 1: T2h (± 10 min) and T6h (± 30 min) after the beginning of cetuximab infusion.  
− Post dose infusion information should include date, dose, start time, and infusion duration. 
Any eventual infusion interruptions should also be documented. 
Cycle 2:  
• Day 1: predose (T0) (just prior the infusion), T2h (± 10 min) after the start of cetuximab 
infusion.  
Dosing and sampling information will consist of: 
− Predose sample: collection should occur before the beginning of cetuximab infusion. 
Information should include date, dose, start time, and infusion duration of the last previous dose of cetuximab a nd exact date and time of the PK sample.
 
− For T2h: include the current day’s date, dose, start time, and infusion duration of the infusion and exact date and time of the PK sample.  Any eventual infusion interruptions 
should also be documented. 
Blood sample collection time s are presented in ( Table 16) and ( Table 17):  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  127/234 
   
Table 16: Pharmacokinetic sampling times for Encorafenib, Binimetinib and AR0042603 
 Cycle 1 Day 1  Cycle 2 Day 1  
Time after encorafenib/ binimetinib dosing 
on designated dosing days (h)  
 2 6 0 
(Pre-dose)  2 
PK sample for encorafenib , binimetinib 
and AR00426032 (4 mL  per time point ) 
 x x x x 
Abbreviations: h = hours; PK = pharmacokinetic  
PK samples will be collected on Cycle 1 Day 1 postdose (encorafenib/binimetinib) at 2 h (± 10 min) and 6 h (± 30 min). PK sam ples will be 
collected on Cycle 2 Day 1 predose (just prior to encorafenib/binimetin ib dose) and postdose at 2 h (± 10 min). Blood samples for 
encorafenib/binimetinib PK will be processed to  collect  plasma. 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  128/234 
   
Table 17: Pharmacokinetic sampling times for Cetuximab 
 
 Cycle 1 Day 1  Cycle 2 Day 1  
Time after  the start of  
cetuximab infusion on 
designated dosing days (h)  2 6 0 
(Pre-infusion) 2 
PK sample for cetuximab (4 mL per time point ) x X x X 
Abbreviations: h = hours; PK = pharmacokinetic  
PK samples will be collected on Cycle 1 Day 1 post -infusion (cetuximab) at 2 h (± 10 min) and 6 h (± 30 min). PK samples will be collected on 
Cycle 2 Day 1 pre -infusion (just prior to infusion of cetuximab) and post -infusion at 2 h (± 10 min). Blood sample s for cetuximab PK will be 
processed to obtain serum.  Time points are based on the start of infusion . 
 
The total number of blood samples for analytical determination will be 8 per subject , making t he 
total volume of collected blood for pharmacokinetics approximately 32 mL per subject . 
If a subject  receiving any of the treatments defined in this protocol experiences an AE that results 
in an unscheduled visit or meets the criteria for an SAE, a blood sample for measurement of 
concentrations of drug -related analytes should be collected, if feasible, if less than 24 hours have 
elapsed since the last dose of study drug. 
Study visits for PK sampling should be scheduled in the morning so that correct  predose and 
postdose PK blood samples can be collected. On the PK visit days, the morning doses of encorafe nib 
and binimetinib, if applicable, should be taken at the study site, only after collecting the predose 
PK sample  (for cycle 2). A graphic representation of blood PK sampling for plasma and serum is 
provided in Figure 1.   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  129/234 
   
Figure 1: Graphic representation for pharmacokinetic sampling plan * 
 
*Predose PK samples for cetuximab analysis should be collected just prior the beginning of the cetuximab infusion, 
regardless of the pre -medication that may be used prior to cetuximab i nfusion. 
If a vomiting episode occurs within the first 4 hours post -dosing of  binimetinib and encorafenib 
during the day of the last dose prior to collection of PK samples , the exact time (whenever possible) 
must be noted i n the e -CRF . In addition, on Day 1 of cycles 1 and 2 when postdose PK samples are 
collected, if vomiting occurs, the exact time of the first vomiting episode within the first 4 hours  
post-dosing on that day must be noted.  
 
8.2.1.2.  Technical Handling  
Complete instructions for sample processing, handling and shipment will be provided in a separate 
Laboratory Manual. 
Each blood sample will be drawn by direct venipuncture or via an indwelling ca theter. Each  sample 
will be 4 mL (according t o the Collection Schedule Table 16, Table 17).  
Important points for blood collection:  
• Blood sampling from a central venous line is not allowed if this line was used to infuse 
cetuximab , 
• If an indwelling catheter is used for blood collection, approximately 1 mL will be  drawn 
and discarded before sampling, 
• Blood samples must be collected from the body side contralateral to the site of the  cetuximab 
infusion, 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  130/234 
  • Care must be taken to collect blood slowly without causing hemolysis 
 
8.2.2.  Samples Handling and shipping  
Complete instructions for sample labelling, handling, storage and shipping to the central laboratory  
will be provided in a separate Laboratory Manual . The samples will be stored in the central 
laboratory until transfer to the bioanalytical center for analytical determination.  
8.2.3.  Analytical determination  
Analytical determination of  encorafenib, binimetinib and the active metabolite of binimetinib 
(AR00426032) in plasma will be carried out at a designated CRO  laboratory  using validated 
LC/MS -MS methods. 
Analytical determination of cetuximab in serum will be carried out at a designate d CRO laboratory 
using a validated method. 
8.2.4.  Sample Storage  
Biological samples dedicated to analytical determination will not be discarded before the final 
clinical study report (CSR) is released and without prior notification to the study manager and 
authorization of the head of the PK/PD Department of IRPF.  
8.3. SAFETY ASSESSMENT  
8.3.1.  Adverse Events  
At screening, any concomitant disease s will be reported as medical history i n the e- CRF . At each 
subsequent visit, the occurrence of AEs since the last visit will be dete rmined by the subject’s 
spontaneous reporting, the Investigator’s non-leading questioning and his/her clinical evaluation.  The severity of AEs will be evaluated using the NCI-CTCAE, v.4.03. 
All AEs that occur after signature of informed consent through 30 days after the last dose of study 
drug must be recorded on the AE e -CRF , irrespective of their etiology and relationship to study 
treatment. Assessment and reporting of AEs is described in detail in Section 10 and will be 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  131/234 
  completed at the time points specified in the study flow chart  (Main study period and Study 
extension period flow charts) . 
 
8.3.2.  Clinical Safety Laboratory Assessment s  
The local clinical  center ’s laboratory will analy ze and report all laboratory safety tests performed 
at the cent er to the Investigator who will ensure they are entered in the e -CRF . Clinical laboratory 
tests will be performed according to the laboratory procedures and the latest updated references . 
Ranges from the laboratory will be used to identify abnormal values.  
Assess ment s including clinical chemistry, hematology, urinalysis, coagulation, and pregnancy test s 
do not have to be repeate d if performed within 72 hours prior to the first dose  on Cycle 1 Day 1 .  
Additional clinical laboratory tests may be obtained at any time during the study at the Investigator’s 
discretion. 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  134/234 
   
8.3.2.2.  Parameters 
Table 20: Summary of Clinical Laboratory Tests _Main study period 
Hematology  Chemistry  Urinalysis  Coagulation  
Basophils  
Eosinophils  
Hematocrit  
Hemoglobin  
Lymphocytes  
Monocytes  
Neutrophils/ANC  
Platelets  
RBC  
WBC  ALT  
AST  
Bilirubin [total and direct 
(and indirect – only 
applicable for France)]a 
Albumin  
Alkaline phosphatase  
Bicarbonate ( HCO3) 
BUN/urea  
Calcium  
Chloride  
CKb 
Creatinine  
Glucose  
LDH 
Magnesium  
Potassium  
Sodium  
Total protein  
Troponin I or T  
Uric acid  
Lipase  
Amylase  
Serum CK isoenzyme s b 
Myoglobinb Blood  
Glucose  
Ketones  
Leukocytes  
pH 
Protein  
Myoglobinb PT or INR  
aPTT  
Other  
At Screening only:  
• Hepatitis B surface 
antigen  
• Hepatitis C antibody  
• CRP  
• Calculated creatinine 
clearance (Cockroft -
Gault formula)  
• LH, FSH and/or estradiol (if 
applicable)  
• HIV (if required)  
• At Screening and EOT  
• Serum pregnancy test (if applicable)  
 
Abbreviations: ALT = alanine aminotransferase;  ANC = absolute neutrophil count; AST = aspartate aminotransferase;  BUN = blood urea 
nitrogen; CK  = creatine kinase; CRP = C -reactive protein; FSH = follicle -stimulating hormone; INR = International Normalized Ratio; LDH = 
lactate dehydrog enase; LH = luteinizing hormone; pH = hydrogen ion concentration; PT = prothrombin time; aPPT = activated partial 
thromboplastin time; RBC = red blood cell(s); WBC = white blood cell(s) ; HIV = Human  Immuno deficiency Virus.  
a Direct bilirubin (and indirec t – only applicable for France ) will be measured at screening only if total bilirubin values are abnormal; for the 
purposes of determining eligibility to participate in the study.  
b For Grade 2 total CK that is also > 3 × ULN or asymptomatic Grade 3 total  CK: measure CK, CK isoenzymes and myoglobin in blood or 
urine weekly for 3 weeks. If total CK remains above the grade that led to the increased monitoring, continue to assess CK, CK  isoenzymes and 
myoglobin, along with regularly scheduled clinical chemist ry assessments, until normalization or improvement to Grade 1. When CK is 
elevated, ensure the subject  is adequately hydrated.  
 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  135/234 
   
Table 21: Summary of Clinical Laboratory Tests_Study extension period  
Hematology  Chemistry  Urinalysis  Other  
 
Basophils  
Eosinophils  
Hematocrit  
Hemoglobin  
Lymphocytes  
Monocytes  
Neutrophils/ANC  
Platelets  
RBC  
WBC  ALT  
AST  
Bilirubin [total and 
direct  (and indirect – 
only applicable for 
France )] 
Albumin  
Alkaline phosphatase  
Calcium  
Chloride  
Creatinine  
Glucose  
Magnesium  
Potassium  
Sodium  
Total protein  
 Blood  
Glucose  
Ketones  
Leukocytes  
pH 
Protein  
 At EOT  
Serum pregnancy test (if 
applicable)  
 
 
Abbreviations: ALT = alanine aminotransferase;  ANC = absolute neutrophil count; AST = pH = hydrogen ion concentration; RBC = red blood 
cell(s); WBC = white blood cell(s)  
 
 
 
 
Hematology, Coa gulation and Clinical Chemistry : 
Blood samples for the hematology, coagulation and chemistry laboratory tests listed in Table 
Summary of Clinical Laboratory Tests  (Table 20) will be collected at the time points specified in 
Table Laboratory Schedule ( Table 18) for Main study period. 
For the Study e xtension period, blood samples for the hematology a nd chemistry laboratory tests 
listed in Table Summary of Clinical Laboratory Tests (Table 21) will be collected at the time points 
specified in Table Laboratory Schedule ( Table 19 ). 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  136/234 
  Blood sample collections occurring on dosing days must be performed prior to study drug 
administration. Laboratory test results required to make decisions regarding potential dose 
modifications (as specified in Section 6.5.4) should be reviewed prior to study treatment 
administration.  
Additional tests may be done at the Investigator’s discretion, in the subjects ’ best interest.  
Urinalysis  
Urine samples for the laboratory tests listed in Summary of Clinical Laboratory Tests (Table 20) 
for Main study period will be collected at the time points specified in Table Laboratory Schedule  
(Table 18). 
Urine samples for the laboratory tests for the Study extension period listed in Summary of Clinic al 
Laboratory Tests ( Table 21) will be collected at the time points specified in Table Laboratory 
Schedule ( Table 19).  
 
All urine collections occurring on dosing days must be performed prior to study treatment 
administration.  
Pregnancy and Assessment of Fertility 
For Main s tudy and Study extension periods, all females of childbearing potential are required to 
undergo a local serum pregnancy assessment at Screening and end of treatment ( EOT ) and local 
urine pregnancy assessments at time points specified in Table Laboratory Schedule  (Table 18 and 
Table 19)  
Any positive pregnancy tests will result in immediate cessation of study treatment 
administration. Female subject s of non-childbearing potential (as defined in Section 5.3) do not 
require pregnancy tests.   
8.3.3.  Physical Examination  
A physical examination will be carried out for each body system  at the screening visit and on Day 
1 of ever y cycle (for Main study and Study extension periods) . 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  137/234 
  At Screening, the physical examination should include general appearance, skin, neck (including 
thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular 
and neurological. If indicated based on medical history and/ or symptoms, rectal, external genitalia, 
breast and pelvic examinations will be performed; body weight  will be measured as part of the 
physical examination. Height will only be measured at Screening . 
For subsequent visits, the physical examinations should be targeted as clinically indicated . 
The physical examination will be globally evaluated prior to study drug administration as 
“normal/abnormal”. Further target inspection will be undertaken for any abnormal finding and will 
be recorded as AEs.  
 
8.3.4.  Vital Sign s  
8.3.4.1.  Schedule  
Vital signs include Heart Rate (HR), systolic and diastolic blood pressure (SBP, DBP), respiration 
rate, and temperature. They will be assessed at the time points indicated in the study flow chart  
(please refer to the flow -chart corresponding to the current period: Main study or Study extension) . 
8.3.4.2.  Technical Procedure and Parameters  
 
SBP and DBP, expressed in mmHg,and HR expressed in beat per minute (bpm) will be measured  
per institutional standards.  
Limits for abno rmal values for SBP and DBP should be graded according to NCI -CTCAE, v.4.03 
as described in tables below  (Table 22 and Table 23).  
 
 
 
  
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  138/234 
   Table 22: Modified NCI CTCAE, Version 4.03 Grading for Hypertension   
Grade  Description  
Grade 1  Prehypertension (systolic BP 120- 139 mm Hg or diastolic BP 80- 89 mm Hg  ) 
Grade 2  Stage 1 hypertension (systolicBP 140 - 159 mm Hg or  
diastolic BP 90 - 99 mm Hg);  medical intervention indicated; 
recurrent or persistent (>=24hrs); symptomatic increase by>20 mm Hg 
(diastolic) or to>140/90 mm Hg if previously  
WNL ; monotherapy indic ated  
Grade 3  Stage 2 hypertension (systolic BP >=160 mm Hg or diastolic  
BP >=100 mm Hg);  
 Medical intervention indicated; more than one drug or more intensive 
therapy than previously used indicated  
Grade 4  Life-threatening consequences (e.g., malignant hypertension,  
Transient or permanent neurologic deficit, hypertensive crisis) ; urgent 
intervention indicated  
 
Definition: A disorder characterized by a pathological increase in blood pressure; a repeatedly elevation in the blood pressu re exceedi ng 140 over 
90 mm Hg . 
 
 
Table 23: Modified NCI CTCAE, Version 4.03 Grading for Hypotension 
Grade  Description  
Grade 1  Asymptomatic, intervention not indicated  
Grade 2  Non-urgent medical intervention indicated  
Grade 3  Medical intervention or hospitalization indicated  
Grade 4  Life-threatening and urgent intervention indicated  
 
Definition: A disorder characterized by a blood pressure that is below the normal expected for an individual   in a given environment . 
 
An institutional thermometer will be used to measure body temperature.  
All vital sign measurements occurring on dosing days must be performed prior to study treatment 
administration . 
Any treatment -emergent abnormal findings will be recorded as AEs.  
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  139/234 
  8.3.5.  Electrocardiogram (ECG) and Echocardiogram/Multi -gated 
Acquisition Scans (ECHO/MUGA)  
8.3.5.1.  Schedule  
ECG and ECHO/MUGA will be assessed as indicated in the study flow chart  (please refer to the 
flow-chart corresponding to the current period: Main study or Study extension). 
ECGs for which abnormal results are collected after study treatment initiation should be repeated 
until the values return to normal or to a stable status. The frequency with which such checks should 
be made wi ll be defined by the Investigator according to the degree of abnormality.  
 
8.3.5.2.  Technical Procedure and Parameters  
• Electrocardiogram  
An ECG will be recorded as described on the flowchart (please refer to the flow -chart corresponding 
to the current period: Main study or Study extension) using the internationally recogni zed 12 -lead 
cardiograph. An institutional cardiograph will be used.  
Prior to performing the 12- lead ECG, subject s should r est in the supine position for at least 5 
minutes. The ECG measurement performed at the Screening Visit will be used to determine 
eligibility. The mean of the triplicate ECG measurements recorded pre -dose on Cycle 1 Day 1 will 
serve as the subject ’s Baseli ne value for all postdose comparisons. The ECG measurement at any 
time point should be used for AE grading and recommended dose modifications. 
When an ECG is to be performed at the same time point as a blood collection, the ECG is to be  
performed first.  
Interpretation of the tracing, Heart R ate (HR), QT cF interval  (Fridericia’s correction formula), PR 
and QRS  complex  should be made by a qualified physician and evaluated as normal or abnormal . 
All data should be documented in the e- CRF .  
Clinically significant abnormalities present when the subject  signed the Screening informed consent 
should be reported in the e -CRF . New or worsened clinically significant findings occurring after 
the informed consent must be recorded in the e- CRF .  
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  140/234 
   
• Echocardiogram/Multi -gated Acquisition Scans  
Cardiac ejection fraction will be assessed by transthoracic ECHO or MUGA scans as described on 
the flowchart  (please refer to the flow -chart corresponding to the current period: Main study or 
Study extension). The same method should be used throughout the study.  
Subject s who develop signs/symptoms of congestive heart failure at any point during the study are 
required to have an evaluation of LVEF measurement by ECHO or MUGA.  
 
8.3.6.  Opht halmic Assessment s 
During the M ain study period, visual assessment must be performed by investigator, to assess 
general inspection of the eyes, examination of motility and alignment, visual disturbance including 
diminished central vision, blurred vision or loss of vision at each Day 1, if clinically indicated at 
D8, D15, D22 during treatment and at 30- days follow -up visit.  
During the Study e xtension period, visual assessment must be performed by investigator, to assess 
general inspection of the eyes, examination of motility and alignment, visual disturbance including diminished central vision, blurred vision or loss of vision at each Day 1, if clinically indicated at 
D15 during treatment and at 30-days follow-up visit. 
At screening, EOT, if clinically indicated, during treatment, and at safety 30  day-follow- up visit in 
case of ocular clinical event at EOT visit, a full ophthalmic examination will be performed by an 
ophthalmologist (during Main study and Study extension periods).  
The full ophthalmic examination includes:   
• Best corrected visual acuity for distance testing, slit lamp examination, intraocular pressure 
and dilated fundoscopy ( with attention to retinal abnormalities, especially retinal pigment 
epithelial detachment (RPE D), serous detachment of the retina and RVO ).  
• OCT  will be performed systematically at screening and if clinically indicated during 
treatment and at EOT.  
• Fluorescein angiography  will be performed only if clinically indicated from screening to 
EOT.  
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  141/234 
  For al l subject s, ophthalmic assessments may be performed more frequently per standard of care or 
if clinically indicated for evaluation of any visual signs or symptoms . Subject s with clinical 
suspicion of retinal abnormalities (i.e., RPED, posterior uveitis, se rous detachment of the retina, 
RVO, photopsia, metamorphopsia, impairment of visual acuity, etc.), must complete at least one of 
the following additional assessments: 
• For non- vascular abnormalities: OCT of the macula (spectral domain OCT recommended) . 
• For vascular abnormalities: fluorescein angiography of the central 30 degrees.  
Images/results of the ophthalmic examinations (at a minimum, OCT and/or fluorescein 
angiography) should be sent to the study site and be maintained in the subject ’s source document  
file. These images/results may be requested to be sent to the Sponsor or designee.  
8.3.7.  Dermatologic Evaluation s  
Dermatologic evaluations will be performed at the site by the Investigator to monitor for the 
possible development of keratoacanthoma (KA) and/or  squamous cell carcinoma (SCC), as these 
have been reported to occur with selective BRAF inhibitor treatment. This assessment can be done 
predose or postdose and will be performed at the time points specified in the Flowchart  (please refer 
to the flow-chart corresponding to the current period: Main study or Study extension).  
In case of occurrence of KA or SCC, subject s will undergo complete surgical excision of the skin 
lesion following institutional standards. The  evaluation  can be done by the dermatologist if 
clinically indicated . 
It is recommened that dermatological examination should be performed every two months for up to 
6 months following discontinuation of encorafenib.  
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  142/234 
   
8.3.8.  ECOG Performance Status  
Assessment of ECOG PS will be performed at the time points specified in the Flow Chart (please 
refer to the flow -chart corresponding to the current period: Main study or Study extension) . ECOG 
PS should be obtained on the scheduled day, even if study treatment is being held (se e Table 24). 
 
Table 24: Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 
0 Fully active, able to carry on all predisease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary 
nature, e.g., light housework, office work.  
2 Ambulatory and capable of all self -care but unab le to carry out any work activities. Up and about more than 
50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair.  
5 Dead  
 
 
8.4.  TISSUE AND BLOOD BIOMARKER ASSESSMENTS  
All tissue and blood biomarker assessments are described in Table 25 for the Main study period . 
All tissue and blood biomarker assessments are described in Table 26 for the Study extension 
period  
8.4.1.   Tumor  Biomarker Assessments  
 
- BRAF testing  
Subject s will be eligible for the study based on identification of a BRAFV600E mutation in the tumor 
as determined by local laboratory result obtained any time prior to Screening. Only PCR and NGS -
based local assays results will be acceptable. The BRAF mutation s tatus must be confirmed by the 
central laboratory no later than 30 days from first dose of study treatment.  
In cases where there is discordance between the local assay and central laboratory results, or if the 
central laboratory is not able to confirm pre sence of a BRAFV600E mutation due to inadequate or 
poor sample condition or absence of available material within 30 days of initiating study therapy, subject s may only continue treatment if there is no clinical indication of deterioration or disease 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  143/234 
  progre ssion and the Investigator determines that the subject  is deriving benefit. In such instances, 
subject s must be informed that the BRAF mutation status is unconfirmed (negative or indeterminate) 
and must sign a separate informed consent form (ICF) that includes this information and describes 
alternative treatment options.  
If the result from the central laboratory is indeterminate or the sample is deemed inadequate for 
testing, additional samples should be submitted (archival material only) . 
This analysis will be performed on an archival FFPE tumor sample  or fresh biopsy provided at 
screening and may also be performed on an optional biopsy obtained at End of Treatment. 
 
- Other assessments in tumor tissue samples 
The tissue source submitted to the central laboratory will also be used for retrospective testing of  
MSI status and RAS  mutation status. Information regarding tissue specimen requirements, sample 
handling and shipment will be provided in the Laboratory Manual.  
This test will analyze tumor mutations representative of the mutational load. Germline DNA 
obtained via a blood sample (MSI germline control) will also be required (10mL)  for the Main study 
period (see Table 25). These biomarker analysis will be exploratory and will not be part of the CSR. 
 
8.4.2.   Blood Biomarker Assessments  
8.4.2.1.  C-reactive protein  
A blood sample ( 3.5 mL) for analysis of C -reactive protein (CRP), a biomarker of inflammation,  
will be collected during  Screening . Complete instructions for sample collection, processing, 
handling and shipment to the central laboratory will be provided in the Laboratory Manual. 
8.4.2.2.  Tumor markers  
Blood samples (10 mL  of each ) for analysis of tumor markers CEA and CA 19 -9 will be collected 
at screening , predose on day 1 of cycle 1 i f more than 72 hours after screening and pre -dose on day 
1 of each subsequent cycles, and at the EOT  visit  (Main study period). This measurement will 
provide a surrogate marker of response to treatment. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  144/234 
  During the Study e xtension period, blood samples (10 mL of each) for analysis of tumor markers 
(CEA and CA 19-9) will be collected at  pre-dose on day 1 of each cycle,and at the EOT visit, only 
if as per routine clinical practice. 
The analysis of these blood samples will be performed by the local laboratory. 
 
 
8.4.2.3.  Circulating DNA  (ct-DNA)  
ctDNA will be analy zed at baseline i n a plasma sample (2 blood samples of 10 mL). BRAFV600 E 
mutational status will be explored and compared to the BRAFV600 E mutational status observed in the 
local test used for inclusion and for retrospective tumor mutation analysis. In addition to BRAFV600 E, 
other cancer genes may be explored in order to identify biomarkers for sensitivity or resistance to treatment.  
All blood biomarker analysis will be exploratory and will not be part of the CSR. 
 
8.4.3.   Predictive Biomarkers of Activity  
Further exploratory biomarker research may be conducted on collected blood and tumor samples. 
These studies would extend the search for other potential biomarkers relevant to the effects of the 
drugs given in combination in this study, and/or prediction of these effects, and/or resistance to the 
treatment, and/or safety, and these additional investigations would be dependent upon clinical 
outcome, reagent and sample availability. Samples used for these analyses will be: 
- Remaining tumor tissue ( Section  8.4.1): retrospective analyses may include and not limited to: 
expression of proteins by immunohistochemistry or gene expression by RNA analysis 
(RNAs eq, nanostring, RT- Q PCR, etc).  
- Remaining blood samples ( Section  8.4.2.3): remaining blood sample s collected at baseline may 
be analyzed for potential genomic or proteomic predictive markers of activity.  
Complete instructions for sample collection, processing, handling and shipment to the central 
laboratory will be provided in the Laboratory Manual.  
These analyses will be exploratory and will not be part of the CSR. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  145/234 
  8.4.4.   Optional t umor biopsy 
If the subject consents, optional fresh tumor samples may be collected at the time of progression  in 
subject s with accessible lesions. Accessible lesions are defined as tumor lesions which are easily 
biopsied w ith minimum risk to the subject . Lesions with the greatest change in dimensional size are 
the recommended lesions to be excised at the time of PD. Whenever possible, biopsies at 
progression should be performed within 3 days of study drug discontinuation (during the Main study 
or Study e xtension periods) . The tissue from these biopsies will be used to determine possible 
mechanisms of resistance. Subject s will be asked (in a specific section of the main ICF) if they 
agree to provide this tumor sample.  
All blood biomarker analysis will be exploratory and will not be part of the CSR. 
 
Table 25: Biomarker samples _Main study period 
 
(a)  
Optional tumor sample will be requested only for subjects that discontinue study due to disease progression.  
 
           Cycle/Period
Visit ScreeningC1                   
D8C1                  
D15C1                  
D22Cn                   
D1Cn                          
D8Cn                 
D15Cn                  
D22End of 
treatment Safety Follow-
Upq (EOS)Survival
(Every x Months)
Cycle  Days D-28 to D- 1 D8 D15 D22 D1 D8 D1 5 D22 Dxx Dxx Dxx
Epochs FOLLOW-UPLONG-TERM 
FOLLOW-UP
Pre-Dose Post-Dose
Procedures
Bl ood s a mpl e for tumor ma rkers  (CEA, 
CA19-9)X X X X
A tumour  sample (ar chiv al or  fr esh) 
should be send to central laboratory to test   for BRAFV600E and RASwt status and MSI testing X
Blood samples for  ctDNA analy sis (i.e. 
BRAFV600)X
Blood sample for MSI testing (control) X
Tumor biopsy (optional) XaSubsequent Cycles Cycle 1
C1
D1
D1
SCREENING TREATMENT 
± 3-day window for procedures/assessments
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  146/234 
  Table 26: Biomarker samples _Study extension period  
Cycle/Period  Subsequent Cycles during study 
extensiona,b       
Visit  CnD1  CnD15  End of treatment  Safety Follow -Up  
(EOS)m Survival  
(Every 3 Months)  
Cycle Days  D1 D15 Dxx Dxx Dxx 
Epochs  TREATMENT  FOLLOW -UP LONG- TERM 
FOLLOW -UP 
Procedures    
Blood sample for tumor 
markers (CEA, CA19 -9)a X   X   
  
Tumor biopsy (optional) b     X   
  
 
(a) 
(b) Blood sample for tumor markers (CEA, CA19 -9) should be collected only if performed as per routine clinical practice  
Optional tumor sample will be requested only for subjects who discontinue study due to disease progression.  
 
  
8.4.5.   Retention of Samples for Future Analysis  
If the subject  agrees, and in accordance with local laws, any tumor (archival or fresh) , blood and 
plasma samples remaining after determination of BRAFV600E status may be stored for up to 10 years 
after the final CSR  of the study is released. The samples may be further analyzed to address 
scientific questions and/or development of biological tests related to administration of encorafenib 
+ cetuximab + binimetinib and/or cancer. The decision to perform such exploratory biomarker 
research studies would be based on outcome data from this study or from new scientific findings related to the drug class or disease, as well as reagent and assay availability.  
The Sponsor will be the exclusive owner of any data and discoveries resulting from this study. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  147/234 
   
8.5. CONCOMITANT THERAPY AND THERAPEUTIC / DI AGNOSTIC 
PROCEDURE ASSESSMENT  
Concomitant therapies and therapeutic / diagnostic procedures will be evaluated at  each cycle at 
D1, D8, D15, D22 and starting Cycle 8, at D1 and D15 and at EOT/ 30-day Safety F ollow Up (Main 
study period).  
Since implementation of the Urgent Safety Measure on 26 Mar 2020, in order to ensure the subjects’  
safety in the clinical trial by decreasing the number of clinic visits  in the context of COVID -19 
pandemic , Cetuximab infusions can be given every two weeks at the dose of 500 mg/m2 
administered as a 120 -min IV infusion (i.e. on D1 and D15 of each cycle) regardless of  the cycle  
number, after the investigator has  evaluated the benefi t/risk ratio for the subjec t with regards to 
Covid-19 pandemic.  
For the subjects  moving to this eve ry two weeks regimen before C8D1, c oncomitant therapies and 
therapeutic / diagnostic procedures will be evaluated at  each cycle at D1 and D15  and at EOT/30-
day Safety Follow Up.  During the Study extension period, concomitant therapies and therapeutic / diagnostic procedures 
will be evaluated at  each cycle at D1  and D15  and at EOT/30 -day Safety Follow Up. 
Require ments relating to  subject’ s concomitant therapies and therapeutic / diagnostic procedures 
before entry or  throughout the trial can be found in Section 7.  
8.6. QUALITY OF LIFE ASSESSMENT  
Patient reported outcome (PRO) assessments will be collected during Main study period using the 
QoL questionnaires EORTC QLQ -C30 ,EQ -5D- 5L and Patient Global Impression of Change 
(PGIC)  at the time points specified in Study Flow Chart (Main study period Flow Chart).  
These questionnaires will be used to explore PRO  measures of health -related QoL, functioning, 
cancer symptoms, and treatment- related side effects.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  148/234 
  The QLQ -C30 EQ -5D-5L and PGIC  are recognized reliable and valid measures in the treatment of 
cancer subject s.  
The questionnaires should be administered to subject s in the subject s’ local language at the 
beginning of the study visit prior to receiving any study treatment, prior to any other study 
assessment or consultation with the Investigator, and prior to being informed of their current disease 
status.  
Attempts should be made to collect all questionnaires for all subject s, including those who 
discontinue prior to the EOT  visit. However, if the subject  refuses to complete the questionnaires, 
this should be documented in study source records. Subject  refusal to complete study questionnaires 
is not a protocol deviation. Subject s should be given sufficient space and time to complete all study questionnaires, and all 
administered questionnaires should be reviewed for completeness. If missing responses are noted, 
subject s should be encouraged to complete any missing responses. 
Completed questionnaires, including both responses to the questions and any unsolicited comments written by the subject , should be reviewed by the Investigator or designee to ensure every question 
has been answered and that there is only one response for each question. If omissions or double 
responses occur, they should be brought to the attention of the subject . Investigators must not 
encourage the subject to change responses reported in questionnaires.  
In addition, the completed questionnaires should be reviewed and assessed by the Investigator for 
responses which may indicate potential AEs or SAEs. This review should be documented in study 
source records .  
8.7. HEALTHCARE RESOURCE UTILI ZATION  
Hospitalization data of interest will focus on those hospitalizations reported as Serious Adverse Events as required in S ection 10.2.1 
Healthcare resource util ization data regarding hospitalizations should be captured continuously 
through- out the Main study period treatment phase starting on the date of first study treatment 
administration until 30 days after the last administration dose, as described in  the Study Flow Chart  
(during the Main study period only).  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  149/234 
  Information related to the length of stay, hospital facilities used, reasons for hospitalization, and 
hospital discharge information will be evaluated. 
 
 
8.8. COMPLIANCE  
The subject  will be reminded regularly to bring back to the site at each study visit any remaining 
encorafenib and binimetinib blister s and  boxes  (used or unused). 
Compliance will be evaluated at each cycle on Day 1 and at EOT by review ing subject  diary entries, 
accou nting of returned study drug and subject  interviews  (Main study and Study extension periods). 
Cetuximab will be administered intravenously per protocol in the clinic by study personnel. 
Information regarding individual study drug infusions is to be documented as described in Section  
6.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  150/234 
  9. STUDY PROCEDURES  
Details of schedule, technical procedures and parameters per assessment/exam are described in 
Section 8. 
Starting Cycle 1 Day 1 and during the whole treatment period, (during the Main study and the Study extension periods) , 
all procedures/assessments should take place  in a + 3 day- window from the 
corresponding visit, unless otherwise specified. 
Except C1D1, the visit can be miss ed. Theoretical cycles dates (7 days ± 3) are kept constant 
irrespectively of whether the visit is done and/or the product is administered or not. If subject 
doesn´t come for CnD1 visit, the CnD1 assessments will still need to be performed (and shall be 
recorded on the unscheduled visit in the e -CRF).  
Study procedures section is divided in 2 main sub- sections:  
-1 for the study visits and procedures during the Main Study period (until 27 D ec 20 20) 
-1 for the study visits and procedures during the Study extenstion period (from 28 D ec 20 20)  
9.1. MAIN STUDY  PERIOD  (FROM FIRST SUBJECT  SCREENED TO 27  
DEC  2020)  
 
9.1.1.  VISIT 1 – Screening visit ( Day -28 to - 1 prior to Cycle 1 Day 1)_ Main 
study  period  
The subject considered eligible for screening by the Investigator will be informed of the 
characteristics and the consequences of the trial both verbally and by reviewing the  subject 's 
information sheet and ICF (see Section  14.3) . If he/she accepts to  participate in the study, he/she 
will sign the informed consent and will keep a copy. 
All screening procedures to determine eligibility must be performed within specific time windows 
prior to the first dose of protocol treatment. 
The subject will be asses sed for the following: 
• Demographic characteristics (gender, age, race, ethnicity ) 
• Medical history  
• Prior medications/therapies/procedures   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  151/234 
  • Physical examination (incl. height, weight) 
• Vital signs  
• ECOG PS  
• Concomitant medications/therapies (authorized, disallowed) 
• Twelve- lead single ECG (after 5 -min rest in supine position) 
• Full ophthalmic examination  
• Dermatologic examination  
• ECHO/MUGA  
• Serum pregnancy test (for females of childbearing potential only) 
• LH, FSH and/or est radiol measurements (for females who are post-menopausal) 
• Hepatitis B surface antigen, hepatitis C antibody 
• HIV (if required)  
• Hematology  
• Clinical chemistry  
• Coagulation 
• Urinalysis  
• Blood sample for CRP 
• Blood sample for tumor markers (CEA, CA19 -9) 
• A tumor sample (a rchival or fresh) should be sent to central laboratory to test for BRAFV600E 
and RASwt status  and for MSI testing  
• Tumor assessments (CT scan, MRI) as defined by RECIST  
• The Investigator will inform the Sponsor of the screening using IRT. 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  152/234 
  9.1.2.  Cycle 1 - Day 1 _ Main study period  
If the subject still fulfills the eligibility criteria during the screening period and/or the result s of 
additional examinations, the Investigator will dispense to the Subject the box number indicated by 
the IRT. Eligibility is determined using results of screening assessments performed before the first 
dose of study treatment and up to and including Cycle 1 Day 1. 
If the following study procedures were not performed within 72 hours before Day 1, they must be 
repeated on Cycle 1 Day 1 (i.e., first day of dosing): 
• Physical examination, including measurement of body weight 
• Dermatologic examination  
• Obtain blood samples for hematology, coagulation, clinical chemistry  
• Obtain blood samples for tumor markers (CEA and CA19- 9)  
• Obtain urine sample for urinalysis and for pregnancy test for females of childbearing 
potential  
• Assess ECOG PS  
 
All of the following study procedures are to be performed on Cycle 1 Day 1: 
• Visual assessment by investigator: general inspection of the eyes, examination of motility 
and alignment, visual disturbance including diminished central vision, blurred vision or loss of vision
  
• QOL questionnaires (EORTC QLQ-C30, EQ-5D-5L , PGIC )  
• Assess vital signs (blood pressure, pulse, temperature and respiratory rate)  
• Calculate BSA predose 
• Obtain 3 serial, resting and supine 12- lead ECGs conducted within approximately 5 to 
10 minutes total time and prior to the first dose, followed by a single ECG 2.0 (+ /- 0.5) 
hours following administration of encorafenib + binimetinib and before the start of the cetuximab infusion.
 ECGs should be performed prior to the 2- hour post -dose PK blood 
collection.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  153/234 
  • Verify inclusion/exclusion criteria  
• Collect blood samples for: 
− MSI germline control 
− ctDNA for BRAF testing  
− PK p lasma level determination of encorafenib, binimetinib and AR00426032: 2h ( ± 10 min) 
and 6 hours ( ± 30 min) after administratio n of encorafenib and binimetinib. 
− PK s erum level determination of cetuximab : 2h (± 10 min) and 6 hours ( ± 30 min) after the 
start of cetuximab  infusion 
 
• Administer dose of encorafenib and binimetinib with water  
• Administer cetuximab premedication according to SPC (antihistaminic and corticosteroïd 
pretreatment are mandatory for the the first infusion) 
• Administer cetuximab as an IV infusion  
• Document prior (pre -dose) and concomitant medications/therapies  
• Assess AEs  
• Dispense th e treatment n umber using IRT 
• Dispense a 4 -week supply of encorafenib and binimetinib along with a monthly dosing 
diary. Review dosing instructions with the subject .  
 
9.1.3.  Cycle 1 - Day 8  _ Main study  period  
The subject will be assessed for the following: 
• Physical examination if clinically indicated  
•  Visual assessment by investigator if clinically indicated (in case of any abnormalities a full 
ophthalmic examination must be performed by an ophthalmologist) 
• Assess vital signs (blood pressure, pulse, temperature and respiratory rate )  
• Administer cetuximab premedication according to institutional standards  
• Administer cetuximab as an IV infusion  
• Review concomitant medications/therapies  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  154/234 
  • Assess AEs since previous visit  
• Obtain information on Healthcare Resource Utilization in case of hospitalization  since 
previous visit (see S ection  8.7) 
9.1.4.  Cycle 1 - Day 15  _ Main study  period  
• Physical examination if clinically indicated   
•  Visual assessment by investigator if clinically indicated (in case of any abnormalities a full ophthalmic examination must be performed by an ophthalmologist) 
• Assess vital signs (blood pressure, pulse temperature and respiratory rate) 
• Obtain blood samples for hematology and clinical chemistry  
• Obtain single ECG (predose)  
• Administer cetuximab premedication according to institutional standards  
• Administer cetuximab as an IV infusion  
• Review concomitant medications/therapies  
• Assess AEs since previous visit  
• Obtain information on Healthcare Resource Utilization in case of hospitalization since 
previous visit (see S ection 8.7) 
9.1.5.  Cycle 1 - Day 22  _ Main study  period  
• Physical examination if clinically indicated  
• Visual assessment by investigator if clinically indicated (i n case of any abnormalities a full 
ophthalmic examination must be performed by an ophthalmologist) 
• Assess vital signs (blood pressure, pulse  tem perature, and respiratory rate )  
• Obtain a blood sample for hematology  
• Administer cetuximab premedication according to institutional standards  
• Administer cetuximab as an IV infusion  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  155/234 
  • Review concomitant medications/therapies  
• Assess AEs since previous visit  
• Obtain information on Healthcare Resource Utilization in case of hospitalization  since 
previous visit (see section 8.7) 
9.1.6.  Subsequent Cycles  _ Main study  period  
Tumor assessments (i.e., appropriate radiological scans to docum ent all suspected sites of disease) 
are to be performed every 6 weeks (±7 days) from the first dose for the first 12 weeks, then every 8 
weeks (±7 days) thereafter until disease progression, subject decision, withdrawal of consent, 
initiation of subsequent  anticancer therapy, subject  is lost to follow -up, or death, regardless of 
whether study treatment is discontinued.  The time -window allowed for the first tumor assessment (i.e. day 42 from first dose) is +7 days. 
Information on Healthcare Resource Utilization will be obtain in case of hospitalization and during 
the whole treatment period until 30 days after the last administration of study treatment. (see S ection 
8.7)  
9.1.7.  Subsequent Cycles Day 1 _ Main study  period  
• QOL questionnaires (EORTC QLQ-C30, EQ-5D-5L , PGIC ) 
• Weight  
• Calculate BSA  
• Physical examination  
• Assess vital signs (blood pressure, pulse temperature, and respiratory rate )  
• Assess ECOG PS  
• Single ECG are to be performed pre- dose at D1 of each subsequent cycle.  At Cycle 2 only:  
obtain a single ECG predose and 2.0 hours (+ /- 0.5 hour) after administration of encorafenib 
+ binimetinib and before the start of the cetuximab infusion. ECGs should be performed prior to the 2-hour post-dose PK blood collection. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  156/234 
  • Visual assessment by investigator ( in case of any abnormalities a full ophthalmic 
examination must be performed by an ophthalmologist)  
• Dermatologic examination every 8 weeks from Cycle 1 Day 1 (i.e., Day 1 of Cycles 3, 5, 7 , 
etc.)  
• ECHO/MUGA scans Cycle 2 Day 1 and Cycle 5 Day 1, then every 12 weeks  
• Collection of blood samples for:  
− PK: Cycle 2 only:  
. Plasma  level determination of encorafenib, binimetinib and AR00426032: predose (just 
prior to encorafenib/binimetinib dose) and 2 hours ( ± 10 min) following administration 
of encorafenib and/or binimetinib 
. Serum level determination of cetuximab: predose (just prior to cetuximab infusion) and 
2 hours ( ± 10 min) after the start of cetuximab infusion 
 
− Hematology, coagulation and clinical chemistry  
− Tumor markers (CEA and CA19 -9) 
 
• Obtain a urine sample for urinalysis and urine pregnancy testing for women of childbearing 
potential 
• Administer dose of encorafenib and binimetinib with water  
• Administer cetuximab premedication according to institutional standards  
• Administer cetuximab as an IV infusion  
• Assess compliance of encorafenib and/or binimetinib dosing and use of dosing diary.  
• Review concomitant medications/therapies  
• Assess AEs since previous visit  
• Dispense a 4 -week supply of encorafenib and binimetinib along with a monthly dosing 
diary. Review dosing instructions with the subject.  
9.1.8.  Subsequent Cycles - Day 8, Day 15 and Day 22 _ Main study  period  
• Physical examination if clinically indicated  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  157/234 
  • Visual assessment by investigator if clinically indicated  (in case of any abnormalities a full 
ophthalmic examination must be performed by an ophthalmologist) 
• Assess vital signs (blood pressure, pulse, temperature, and respiratory rate) . Vitals signs do  
not need to be done at D8 and 22 starting week 29 (when the Q 2W schedule is  in place) 
• Administer cetuximab premedication according to institutional standards  
• Administer cetuximab as an IV infusion  
• Review concomitant medications/therapies  
• Assess AEs since previous visit  
From week 29 the D8 and D22 visit s will not be performed (b iweekly infusion of cetuximab: no 
cetuximab infusion on D8 and D22).  
Since implementation of the Urgent Safety Measure on 26 M ar 2020, if the investigator implements 
this change, each D8 and D22 visit (before C8D1) for subjects having not yet reached C8D1 at the 
time of USM implementation  will be  performed by phone calls and will have to be documented in 
source documents to ensure subject’s safety.   
 
9.1.9.  End-of-Treatment Visit _ Main study  period  
At the time of study treatment discontinuation, the EOT  visit should be completed for all subject s 
as soon as possible after the last dose of study drug, and every effort should be made to perform the 
procedures listed below. This visit should take place a s soon as possible and ≤  14 days after the last 
dose of study treatment. An e -CRF  should be completed, giving the date and reason for stopping 
the study treatment. All subject s will enter the follow -up period  
If a subject withdrawal occurs or if the subje ct fails to return for visits, the Investigator must 
determine the primary reason for a subject’s discontinuation from the study and record this 
information on the relevant page of the e- CRF . 
Subjects  will be assessed for the following: 
• QOL questionnaires (EORTC QLQ -C30, EQ-5D-5L , PGIC )  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  158/234 
  • Physical  examination including weight    
• Full ophthalmic examination  
• Vital signs (blood pressure, pulse, temperature and respiratory rate)  
• ECOG PS  
• Single ECG  
• Dermatologic examination   
• ECHO/MUGA  
• Serum pregnancy t est (for female s of child bearing potential only) 
• Collection of blood samples for: 
− Hematology, coagulation and clinical chemistry 
− Tumor markers (CEA and CA19 -9) 
 
• Obtain a urine sample for urinalysis 
• Optional tumor biopsy sample (only i f discontinuation due to disease progression) 
• Assess compliance of encorafenib and/or binimetinib dosing and use of the dosing diary. 
Collect all remaining bottles of study drugs. 
• Review concomitant medications/therapies  
• Assess AEs since previous visit  
• Obtai n information on Healthcare Resource Utilization in case of hospitalization  since 
previous visit (see S ection 8.7) 
9.1.10.  Safety Follow-up Visit and Surviv al Visits _ Main study  period  
Tumor assessments (i.e., appropriate radiological scans to document all suspected sites of disease) 
should continue  to be performed every 6 weeks (±7 days) for the first 12 weeks, then every 8 weeks 
(±7 days) thereafter until disease progression , initiation of subsequent anticancer therapy, subject is 
lost to follow -up, subject decision, withdrawal of consent or death. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  159/234 
  When clinically appropriate, it is recommended that subjects be monitored with physical 
examinations, dermatological examinations and CT scans for cutaneous and non‑ cutaneous 
secondary malignancies for up to 6 months after the last encorafenib dose or until initiation of 
another antineoplastic therapy.  
9.1.10.1.  Safety 30 Day -Follow -up Visit _ Main study  period 
All subject s will return for a Safety Follow -up visit approximately 30 days after the last dose of 
study drug, or prior to the initiation of subsequent anticancer therapy, whichever occurs first.  
Information related to AEs (including concomitant medication taken for ongoing AEs) and ongoing 
antineoplastic treatments will be collected for 30 days after the last dose of study drug.  
The following study procedures will be performed, completed or reported:  
• QOL questionnaires (EORTC QLQ-C30, EQ-5D-5L , PGIC )  
• Physical examination including weight  
• Vital signs (blood pressure, pulse, temperature and respiratory rate)  
• ECOG PS  
• Single ECG  
• Visual assessment by investigator (full ophthalmic examination by an ophthalmologist only 
in case of ocular clinical event at the EOT visit)  
• Urine pregnancy test  
• Hematology, coagulation and clinical chemistry 
• Urinalysis  
• Survival Status 
• Documentation of subsequent anticancer therapy 
• Obtain information on Healthcare Resource Utilization in case of hospitali zation  since 
previous visit (see S ection 8.7) 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  160/234 
  9.1.10.2.  Survival Visit (every 3 months)  _ Main study  period 
The Survival f ollow- up period will start after the completed 30 days safety follow up, until the End 
of Study.  
If a subject discontinues the treatment for a reason other than progressive disease, tumor assessment 
must be performed (as per local and central review) until the start of a new anti -cancer therapy, 
disease progression, death, lost to follow -up, subject decision or withdrawal of consent. Subjects 
who discontinue the treatment will be contacted by phone every 3 months (or more frequently as 
needed) for collection of information during the survival follow-up period: 
• Survival s tatus  
• Documentation of subsequent anticancer therapy  
• Documentation of the date of progressive disease following the initiation of subsequent 
anticancer therapies  
 
9.2. STUDY EXTENSION PERIO D (FROM 28  DEC  2020)  
 
9.2.1.  Subsequent Cycles_Study extension period  
Written information and consent form addendum related to Study extension period must be 
submitted to the subject with an oral explanation. It must be agreed and signed by the subject before 
any Study extension- related procedure starts.  
Tumor assessments (i.e., appropriate radiological scans t o document all suspected sites of disease) 
are to be performed every 12 weeks (±7 days) until disease progression, subject decision, 
withdrawal of consent, initiation of  subsequent anticancer therapy, subject is lost to follow -up, or 
death, regardless of w hether study treatment is discontinued.  
 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  161/234 
  9.2.2.  Subsequent Cycles Day 1 _ Study extension period  
 
• Weight  
• Calculate BSA  
• Physical examination  
• Assess vital signs (blood pressure, pulse, temperature, and respiratory rate)  
• Assess ECOG PS  
• ECGs scans must be performed every 3 cycles at D1  D1 or more frequently if clinically 
indicated  
• Visual assessment by investigator (in case of any abnormalities a full ophthalmic examination 
must be performed by an ophthalmologist)  
• Dermatologic examination every 8 weeks   
• ECHO/MUGA scans every 12 weeks or more frequently if clinically indicated  
• Collection of blood samples for:  
o Hematology and clinical chemistry  
o Tumor markers (CEA and CA19-9) – only if as per  routine clinical practice  
• Obtain a urine sample for urinalysis and urine pregnancy testing for women of childbearing 
potential 
• Administer dose of encorafenib and binimetinib with water  
• Administer cetuximab premedication according to institutional standards  
• Administer cetuximab as an IV infusion  
• Assess co mpliance of encorafenib and/or binimetinib dosing and use of dosing diary.  
• Review concomitant medications/therapies  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  162/234 
  • Assess AEs since previous visit  
• Dispense a 4 -week supply of encorafenib and binimetinib along with a monthly dosing diary. 
Review dosing instructions with the subject.  
9.2.3.   Subsequent Cycles - Day 15 _ Study extension period  
• Physical examination if clinically indicated  
• Visual assessment by investigator if clinically indicated  (in case of any abnormalities a full 
ophthalmic examination must be performed by an ophthalmologist) 
• Assess vital signs (blood pressure, pulse, temperature, and respiratory rate ). 
• Administer cetuximab premedication acco rding to institutional standards  
• Administer cetuximab as an IV infusion  
• Review concomitant medications/therapies  
• Assess AEs since previous visit  
9.2.4.   End-of-Treatment Visit _ Study extension period  
At the time of study treatment discontinuation, the EOT visit should be completed for all subjects 
as soon as possible after the last dose of study drug, and every effort should be made to perform the 
procedures listed below. This visit should take place a s soon as possible and ≤  14 days after the last 
dose of study treatment. The e-CRF should be completed, giving the date and reason for stopping 
the study treatment. The  e-CRF should be completed, giving the date and reason for stopping the 
study treatment.  All subjects will then enter the follow -up period until the End of Study. 
If a subject withdrawal occurs or if the subject fails to return for visits, the Investigator must 
determine the primary reason for a subject’s discontinuation from the study and record this 
information on the relevant page of the e- CRF.  
Subjects  will be assessed for the following: 
• Physical examination including weight    
• Full ophthalmic examination  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  163/234 
  • Vital signs (blood pressure, pulse, temperature and respiratory rate)  
• ECOG PS  
• Single ECG  
• Dermatologic examination  
• ECHO/MUGA  
• Serum pregnancy test (for females of childbearing potential only) 
• Collection of blood samples for: 
o Hematology and clinical chemistry  
o Tumor markers (CEA and CA19- 9) if as per ro utine clinical practice  
• Obtain a urine sample for urinalysis 
• Optional tumor biopsy sample (only if discontinuation due to disease progression) 
• Assess compliance of encorafenib and/or binimetinib dosing and use of the dosing diary. Collect 
all remaining bo ttles of study drugs. 
• Review concomitant medications/therapies  
• Assess AEs since previous visit  
9.2.5.    Safety Follow-up Visit and Survival Visits _ Study extension period  
Tumor assessments (i.e., appropriate radiological scans to document all suspected sites of disease) 
should continue to be performed every 12 weeks (±7 days) thereafter until disease progression, 
initiation of subsequent anticancer therapy, subject is lost to follow -up, subject decision, withdrawal 
of consent or death. 
When clinically appropriate, it is recommended that subjects be monitored for physical 
examinations, dermatological examinations and CT scans for cutaneous and non‑ cutaneous 
secondary malignancies for up to 6 months after the last encorafenib dose or until initiation of 
another antineoplastic therapy.  
9.2.5.1.  Safety 30 Day -Follow -up Visit _ Study extension period 
 
All subjects will return for a Safety Follow -up visit approximately 30 days after the last dose of 
study drug, or prior to the initiation of subsequent anticancer therapy, whichever occurs first.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  164/234 
  Information related to AEs (including concomitant medicatio n taken for ongoing AEs) and ongoing 
antineoplastic treatments will be collected for 30 days after the last dose of study drug.  
 
The following study procedures will be performed, completed or reported:  
• Physical examination including weight  
• Vital signs (b lood pressure, pulse, temperature and respiratory rate)  
• ECOG PS  
• Single ECG  
• Visual assessment by investigator (full ophthalmic examination by an ophthalmologist only in 
case of ocular clinical event at the EOT visit)  
• Urine pregnancy test  
• Hematology and clinical chemistry  
• Urinalysis  
• Survival Status 
• Documentation of subsequent anticancer therapy 
9.2.5.2.  Survival Visit (every 3 months)  _ Study extension period  
 
The Survival follow -up period will start after completion of the  30 days safety follow up visit, and 
all subjects will be followed until the End of the study, i.e. until the last subject  will have either 
progressed or discontinued study treatments (including 30- day Safety Follow -Up visit) for any other 
reason  (unacceptable toxicity, subject’s decision, withdrawal of consent, initiation of subsequent 
anticancer therapy or death).  
If a subject discontinues the treatment for a reason other than progressive disease, tumor assessment 
must be performed (as per local  review ) until the start of a new anti- cancer therapy, disease 
progression, death, lost to follow -up, subject decision or withdrawal of consent. Subjects who 
discontinue the treatment will be contacted by phone every 3 months (or more frequently as needed) 
for collection of information during the survival follow -up period: 
• Survival status  
• Documentation of subsequent anticancer therapy 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  165/234 
  • Documentation of the date of progressive disease following the initiation of subsequent 
anticancer therapies  
     
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  166/234 
   
10. ADVERSE EVENTS: DEFI NITION, NOTIFICATION AND 
REPORTING  
10.1. ADVERSE EVENTS  
10.1.1.  Definition  
An AE  is any untoward medical occurrence, including the exacerbation of a pre -existing condition, 
in a patien t or clinical investigation subject administered a pharmaceutical product and which does 
not necessarily have a causal relationship with this treatment.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not related to the medicinal (investigational) product (ICH -Guideline for GCP).  
Any new or worsening adverse event that is assessed by the investigator as related to the disease progression must be reported as an AE. 
The relationship to disease progression must be captured as specified in e- CRF . 
If the AE meets the seriousness definition and thus becomes SAE, it should be notified to the 
Sponsor Pharmacovigilance Department by the investigator as soon as he/she is informed of the 
event and no later than 24 hours after knowledge. 
Note:   Disease progression documented solely by medical imaging techniques with no new or 
worsening symptoms will not require to be reported as an AE nor notified as SAE to the Sponsor 
Pharmacovigilance Department but documented as progression of disease in the tumor assessments 
(RECIST) e -CRF forms.  
All laboratory tests, vital signs, ECGs  collected after study treatment initiation  for which abnormal 
results  meet the criteria for AE  are collected after study treatment initiation should  be repeated until 
the values return to normal or to a stable status and recorded into the e- CRF .  
The frequency with which such checks should be made will be defined by the investigator according 
to the degree of abnormality.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  167/234 
  For any of the following reasons, an abnormal result should be considered as clinically significant 
and reported as an AE. : 
- A symptomatic value.  
- A value or a change that requires active management (e.g., study treatment dose modification, 
discontinuation of study treatment, more frequent follow -up assessments, corrective 
treatment  …). 
- Any value judged by the investigator as clini cally significant.  
Laboratory abnormalities that meet the criteria for AEs should be followed until they have returned 
to normal or baseline, or per Investigator discretion. 
10.1.2.  Severity of Adverse Events  
The severity rating of an AE refers to its intensity. The severity of each AE will be determined by the Investigator using the NCI -CTCAE, v4.03. For any term that is not specifically listed in the 
CTCAE scale, intensity should be assigned a Grade of 1 through 5 using the following CTCAE guidelines: 
Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated 
Grade 2:  Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living  
Grade 3:  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -
care activities of daily living  
Grade 4:  Life-threatening consequences; urgent intervention indicated 
Grade 5:  Fatal  
To avoid confusion or misunderstanding of the difference between the terms “serious” and “severe”, 
the following note of clarification is provided:  
- - “Severe” is used to describe the inte nsity of a specific AE, which may be of relatively minor 
medical significance.  
- - “Seriousness” is based on the regulatory definition supplied below (see S ection  10.2.1) 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  168/234 
   
10.2. SERIOUS ADVERSE EVENTS 
10.2.1.  Definition  
A serious adverse event (SAE) includes but is not necessarily restricted to any event which: 
- results in death (whatever may be the cause)  
Death is an outcome of an SAE and not an SAE in itself. Death should only be reported as an SAE 
term when no additional information is known about a fatal event. When death is an outcome, the 
event(s) resulting in death should be reported (e.g., “pulmonary embolism” with a fatal outcome) 
and assigned severity Grade 5. 
- is life -threatening   
- results in persistent or significant disability/incapacity  
- requires the subject’s in- patient hospitalisation or prolongation of current hospitalisation* 
- is a congenital anomaly or birth defect  
- is serious for other reason: medical and scientific judgment should be exercised in other 
situations, such as important medical even ts that may not be immediately life -threatening or 
result in death or hospitalisation but may jeopardize the patient  or may require intervention to 
prevent one of the outcomes described in the definition above. These should also usually be 
considered serious.  
In addition, for all subjects with COVID -19 (with critical symptoms and/or hospitalization) , a 
Serious Adverse Event should be declared.  
*Note that  any hospitalisation, or prolongation of hospitalisation due to the circumstances listed 
below will not be notified as an  SAE to the Sponsor by the Investigator: 
- a visit to the emergency room, or outpatient observation that does not result in admission,  
-  preparation for routine health assessment/procedure (e.g. routine colonoscopy), 
- planned medical/surgical admission (planned prior to entry into study trial, appropriate 
documentation required), 
- administrative or social reasons (e.g. lack of housing, economic inadequacy, care- giver respite, 
family circumstances) . 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  169/234 
   
10.2.2.  Reporting of Serious and non -serious AEs  
All AEs, serious and non- serious and regardless of causality to study drug (including the 
exacerbation of a pre -existing condition), will be fully recorded on the appropriate e -CRF. For each 
AE, the Investigator must provide its duration (start and end dates or ongoing), severity (intensity), 
assessment of causality and seriousness and whether co rrective action or therapy was required and 
whether action was taken with regard to study drug treatment. 
Any AE that occurs after the signing of the ICF should be recorded on the AE e -CRF page regardless 
the relationship with the study procedure. All AEs occurring from the first dose of study drug 
including the 30 days after the last dose of study (30- day follow -up period) drug must be recorded 
on the AE e- CRF  regardless of the relationship with the study drug. 
If an AE occurs more than once in the same subject during the study, each occurrence must be 
recorded as a separate AE.  
Any SAE occuring from the signing of the ICF should be reported as an SAE regardless of the 
relationship with the protocol procedure or with study drug.  
The investigator must notify the sponsor of this event by sending within 24 hours the "SAE F orm” , 
with all the available information about the event , to the sponsor's Corporate Vigilances e -mail 
dedicated box : 
HQ.pharmacovigilance@pierre- fabre.com  
In case it is not possible to send the report by e-mail it can be sent by fax to:  
+ 33 1 49 10 80 90 
In addition, all  SAEs must be recorded into the e- CRF . 
Study disease progression (including malignant disease progression with fatal outcome), if 
document ed by the use of appropriate method (as per protocol) will be reported as progression of 
study disease in the e -CRF (study end- point) and should NOT be reported as a n SAE unless a causal 
relationship to study treatment is suspected. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  170/234 
   
10.2.3.  Follow-up of SAEs  
The Investigator will provide follow -up information regarding a reported SAE using the SAE form 
providing t he results of relevant examinations , laboratory and diagnosic tests, and hospitalisation 
records as needed.  
Investigators must follow subject s with AEs/SAEs until the event has resolved, the condition has 
stabilized, withdrawal of consent, subject  is lost to follow -up or death OR until 30 days after the 
last dose of study drug, whichever occurs first. Ongoing tr eatment -related AEs/SAEs may be 
followed beyond the 30-day follow-up period if clinically indicated. 
10.2.4.  SAEs occurring after the 30-day safety follow -up period  
After the 30  day follow -up period, any  SAEs that are considered related  to any study drug or 
protoc ol procedures will be captured i n the e -CRF  and reported to the Sponsor using the SAE form. 
10.3. REPORTING OF STUDY T REATMENT OVERDOSE TO  THE 
SPONSOR  
An overdose of study drug (whether symptomatic or asymptomatic) is to be reported as an AE  in 
the e- CRF . 
For the purpose of this trial , an overdose will be defined as any study drug dose administration 
exceeding the subject’s assigned dose of study drug (s ) as per protocol recommendations. 
In the absence of associated AE  seriousness criteria, the overdose and associated non- serious AE , 
are reported only on the AE page of the e-CRF . If the definition  of seriousness criteria is met  for 
any associated AE , the SAE form must be also completed and transmitted to the Sponsor. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  171/234 
   
10.4. REPORTING OF PREGNANCY TO THE SPONSOR  
Pregnancy occurring during the period between signing of the ICF but before any study treatment 
exposure is not to be reported to the Sponsor unless a ssociated to an AE.  
If pregnancy is suspected while the female subject is receiving study treatment, the study treatment(s) should be discontinued immediately until the result of the pregnancy testing is known. 
If pregnancy is confirmed, administration of  study drug is to be discontinued immediately and the 
subject must be withdrawn from the study.  
The Investigators must report to the Sponsor any on- treatment pregnancy of a female subject or a 
female partner of a male subject which occurs during study treatment and within the 30 days after 
the last dose administration of binimetinib or encorafenib and within the 6 months after the last dose 
administration of cetuximab.   
On-treatment pregnancy (of female subject and female partner of male subject)  must be reported to 
the Sponsor within 24 hours of the Investigator’s knowledge using the investigational product 
pregnancy form.  
Any pregnancy will be followed through to outcome, and the outcome must be reported to the 
Sponsor, including the infant’s health status, using the pregnancy outcome report form. 
10.5. SPONSOR'S RESPONSIBI LITIES FOR SAFETY RE GULATORY 
REPORTING PURPOSES  
The Sponsor and/or designee  will submit expedited and periodic reports to both Competent 
Authorities and Ethics Committees as regards to the Directive 2001/20/EC EU regulations or as per 
local specific regulatory requirements  in participating countries. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  172/234 
   
11. DATA COLLECTION AND STUDY MONITORING  
11.1. DATA COLLECTION  
11.1.1.  Case Report Form s   
An e -CRF  will be provided by the CRO.  It will contain field s for all the data required to be obtained 
based on  the protocol, except any computeriz ed data which will be directly transferred to the 
database.  
The Investigator is responsible for ensuring that all required data are properly recorded in each 
subject’s e -CRF  and related documents. Prior to the start of the study, the Investigator will complete 
a delegation  form. The signature and initials of all persons in charge of e -CRF  completion should 
be recorded on this form. 
The e- CRF s are to be completed in a timely manner and preferably within 3 days of the study visit, 
allowing extraction of appropriate e -CRF  data available for S ponsor review. All the information 
will be recorded from source documents into the e- CRF  by an authoriz ed person.  
All answer fields in the e- CRF  pages must be filled in for all visits, otherwise an explanation should 
be given.  
The completed e- CRF , including any paper SAE/pregnancy/pregnancy  outcome forms, must be 
promptly reviewed, signed and dated by a qualified person, who is an Investigator.  
Each subject who will have received the study treatment must be entered into the e- CRF .  
For all other subjects  having signed an ICF, the subject's summary page of the e -CRF , along with 
all applicable information documenting the screen failure/discontinuation reason must be 
completed.  
The Investigator is responsible for the management, completeness and accuracy of the information in the e- CRF . The CRAs will be trained about the e- CRF  and have access to the e- CRF  module for 
monitoring purposes. 
A copy of the e- CRF  with all related documentation will be stored by the Sponsor at the end of the 
study. Another copy of the e -CRF  data will be stored by the Investigator for at least 25 years or 
according to the local requirements. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  173/234 
   
11.1.2.  Source D ocuments  
A source document is an original record or certified copy of an original record of clinical findings, 
observations or any other medical or paramedical activities performed during the clinical trial, 
necessary for the transcription and the verifica tion of the collected data.  
Source documents along with all other trial -related documents (copies of all ICFs , e-CRF s, 
treatment inventories and any correspondence related to the study) must be kept in the Investigator's 
file throughout the study, and then must be stored in the study cent er's archives for a period of at 
least 25 years or as per local legal requirements.  
For further details see S ection  15.2  
11.2. STUDY MONITORING  
11.2.1.  Monitoring visits  
On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) 
prior to study initiation and at regular intervals to closely monitor the study throughout its duration. Additional visits and communication by telephone, mail, email, fax or meeting may be performed 
if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the 
Investigator's s ite file.  
11.2.1.1.  Site Preselection Visit  
Before selecting a cent er for the study, a visit will be carried out by the CRA and/or the Study 
Manager to ensure that the Investigator has the necessary capacities (availability  subject , 
recruitment, environment), technical means and staff to carry out the study. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  174/234 
   
11.2.1.2.  Initiation Visit  
Before the start of the study at all investigational  sites, an initiation visit will be carried out by the 
CRA to check at a minimum that: 
• The Investigator:  
− has received the technical protocol, administrative and financial agreement signed by all 
parties  
− has received the written statement of the IEC/IRB  approval and the list of its members and 
their functions 
− has received the written statement of Competent Authority approval 
• The original dated and signed curriculum vitae of the Investigator (s) has been collected  
• Laboratory normal ranges have been collected  
• All study materials are available on the study site  
• All participants agree with the monitoring procedures and know the study procedures 
• All participants are aware of a possible audit or inspection  
The CRA also has to provide training on the study protocol requirements and study specific 
procedures. 
11.2.1.3.  Follow -up Visits 
Throughout the study, regular follow -up visits will be carrie d out by the CRA to check compliance 
with GCP, strict application of the protocol , subject’s informed consents, proper retention, storage 
and management of the study treatment, as well as the source and other trial -related documents. It 
is the CRA’s responsibility to inspect e -CRF s at regular intervals throughout the study to verify the  
completeness, accuracy and consistency of the data, to verify the conformity of the data entered into 
the e- CRF  with the source documents and to ensure its correct completion, and AE  reporting . 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  175/234 
   
11.2.1.4.  Closing Visit  
At the end of the study, a final visit will be carried out by the CRA to: 
• Verify that the copies  of e-CRF s are correctly stored  
• Control the accountability of intact and used treatment units before destruction 
• Obtain the last data clarifications and/or solutions if any  
• Make an on -site review of all study documentation and complete it if necessary 
• Remind the Investigator of his /her regulatory obligations, study document archiving process 
and duration. 
 
11.2.2.  Direct Access to Source Documents  
In accordance to the requirements of GCP, all Sponsor representatives (Study Manager, CRA and 
Auditors) must be given direct access to all source and study data to perform quality 
monitoring/audit, thus ensuring accuracy and completeness of data.  
Investig ators are reminded that all Sponsor representatives maintain professional confidentiality 
with regards to the subject data. 
11.3. PERIODIC SAFETY DATA  REVIEW  
All safety data collected from the study (SAE s, AE s, clinical laboratory data, vital signs, physical 
examination s, ophthalmic examinations , dermatologic examination s, tumor assessment s, ECG, 
ECHO/MUGA scans , etc. ) are periodically reviewed by the medical monitor or designee  to detect 
any potential safety signal s during the study and to review safety critical  data. The modalities of 
this safety signal detection review is described in a separate document.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  176/234 
   
11.4. STEERING COMMITTEE  
A steering committee (SC) will be established comprising Investigator s participating in the trial and 
Sponsor s’ representatives from the Clinical Study Team.  
The SC will ensure transparent management of the study according to the protocol through 
recommending and approving modifications as circumstances require. The SC  will be responsible 
for reviewing the safety da ta of the subjects treated in the study as well as reviewing efficacy results 
for ORR  from the interim and final analyses. 
The SC will review protocol amendments as appropriate. The details of the role of the Steering Committee will be defined in a SC  charter.   
 
11.5. IDSMC  
An Independent Data Safety Monitoring Committee (iDSMC) will be established to perform additional review of available safety data at regular intervals to ensure that the overall safety of the 
trial remains acceptable. The iDSMC will also have  the opportunity to review toxicities observed 
over time, in cycles of treatment beyond the first cycle. Following each meeting, the iDSMC will provide in writing, recommendations to the Sponsor whether to continue, modify, or stop the study 
in compliance with the iDSMC Charter . 
The iDSMC membership, data to be reviewed, timing of the planned reviews as well as the operating procedures will be described in the iDSMC charter.  
12. DATA MANAGEMENT  
Data management will be subcontracted to a CRO braf under the supervision of the Sponsor’s Data 
Manager of the IRPF Biometry Department.  
All clinical data related to the study will be collected and saved in a computeriz ed database 
according to the following procedures.   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  177/234 
   
12.1. DATA COLLECTION  
12.1.1.  Electronic Case Report Form (e -CRF)  
An e -CRF  will be developed for this study. The electronic Case Report Form ( e-CRF ) will be used 
to record all subject data required by the protocol. 
The e- CRF  should be compliant with FDA regulations (Guidance for industry: Computerized 
systems used in clinical investigations 2007) , European regulations (GCP guidelines – ICH E6 R2 ), 
compliant with 21CFR part 11 (electronic records and electronic signatures)  and Japanese 
regulations,  fully validated, and should include an access control and a traceability system for data 
corrections (audit trail).  
Prior to the start of the study, the Investigator will complete a  delegation  form. The signature and 
initials of all persons in charge of e- CRF  completion should be recorded on this form. Each person 
involved in e -CRF  completion, review, correction and/or validation will be trained and will then 
have an individual login and access code to the e -CRF . An e -CRF  user guide will be available for 
Investigators/on- site personnel involved in e- CRF  completion and for CRAs.  
All information entered into the e -CRF  will be recorded from source documents by authori zed 
personne l. The Investigator is responsible for the management and accuracy of the information 
entered into the e- CRF . 
Each local assessment or examination  (ECG, Laboratory samples, Questionnaires, …) will be 
entered into the appropriate e- CRF forms by the designated investigational site staff at each site.  
An e -CRF  must be completed for each subject enrolled in the study (i.e. signed ICF ).  
12.1.2.  Pharmacokinetics data  
Actual dates and times of blood collections for study treatment s dosing will be entered in both the 
e-CRF  and the requisition form. Appropriate dates and times of study treatment intake will be 
entered in the e- CRF . The samples will be sent to a designated CRO for analysis. 
Validated results from bioanalysis of treatments concentrations in plasma or serum will be 
transmitted by the bioanalytical center  to the sponsor or designated CRO. The study treatment 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  178/234 
  concentrations will be uploaded in the final database from an electronic data file provided by the 
bioanalytical laboratory. 
12.1.3.  Biomarkers  
Dates and actual times of biomarker samples will be entered in both the e -CRF and the requisition 
form.  
BRAFV600E  mutation status : is assessed by local laboratory  and/or by central laboratory. R esults 
from central laboratory will be sent to each site for validation of local result. The result from local 
laboratory will be entered by the designated investigational site staff at each site  into the e -CRF as 
well as th e confirmation provided by the central laboratory. The result from the central laboratory 
will be provided with an electronic data file.  
Other biomarkers : The samples will be sent to sponsor or a designated CRO for analysis. If any of 
the biomarker analyses are intended to form part of the CSR, they will be transferred to the data 
management CRO for validation and integration into the study database. 
CEA, CA 19 -9: are assessed by local laboratory, and data will be entered in to the appropriate e -
CRF forms by the designated investigational site staff at each site.  
12.1.4.  Imaging  
Local assessment  (Main study and Study e xtension periods) : scans will be assessed by local 
radiologists at the sites and RECIST measurements will be entered into the appropriate e -CRF forms 
by the designated investigational site staff at each site.  
Central assessment  (Main study period only) : scans will then be submitted for a centralized review. 
The central imaging reader will review the scans and results will be provided with an electronic 
data file to the CRO.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  179/234 
   
12.2. DATA CLEANING  
The Data Manager will define descriptions of manual and electronic edit checks  in the study Data 
Validation Plan for reviewing and querying data. Upon approval, the edit checks and lis tings will 
be programmed. 
The Data Manager will follow the cleaning of the data over the course of the study. The Investigator 
will be asked to resolve queries by making changes directly into the e -CRF . The system’s automatic 
audit trail will record the da te, time and author of the changes. 
12.3. DATA CODING  
AEs, concomitant diseases, medical/surgical histories will be coded using MedDRA dictionary 
(latest version in use). 
Prior and concomitant medications will be coded using WHO -DRUG dictionary (latest version i n 
use).  The coding will be validated by a physician. 
12.4. DATABASE LOCK  
The validated database will be locked upon request of the Sponsor’s Data Manager following the 
completion of all required steps, i.e.: entry, reception and check of all data, resolution of all queries, 
validation of the coding, Clinical and Pharmacov igilan ce database reconciliation , and data review / 
validation c ommittee meeting performed.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  180/234 
   
12.5. DATA STORAGE  
Data and any  modifications will be saved and kept available upon request of the Sponsor. The 
Sponsor’s Data Manager will assume storage of the locked clinical database in SAS format on a 
secured server.  
Electronic capture of all e- CRF s will be sent in PDF format to th e Sponsor, and then stored on a 
dedicated secured server by the Sponsor.  
A CD- ROM containing the PDF version of all e -CRF s of the site (including audit -trail) will be 
archived by the investigational site. 
 
13. STATISTICAL ANALYSIS  
13.1. GENERAL CONSIDERATIO NS 
A det ailed statistical analysis plan (SAP) will be prepared by the Sponsor. This plan may modify 
the statistical methods outlined in the protocol; however, any major modifications related to the 
primary outcome measure definition or analysis will also be descri bed in a protocol amendment.   
The statistical analysis will be done under the supervision of the study statistician at the Biometry 
Department, IRPF. Analys es will be programmed in accordance with the SAP.  
The CSR is planned to be written at the time of th e primary outcome measure analysis (after Stage 
1 if the study is stopped for futility, otherwise after Stage 2).  
The cut -off date for futility analysis and S tage 2 analysis  is estimated to occur a pproximately when 
all treated subject s with a centrally confirmed BRAFV600E mutation of the concerned stage have 
either discontinued or have four post -baseline tumor asses sments . And in case the last subject 
required for the concerned stage has an objective response, it should be confirmed in the following 
tumor assessment before the analysis is being performed. However, it will be possible to proceed 
to Stage 2 as soon as 40 subjects with  a centrally confirmed BRAFV600E mutation are treated and 12 
confirmed responses are observed.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  181/234 
  All available data will be included at the time of the cut- off date for secondary time- to-event 
endpoints and safety assessments. Unless the study is stopped at an earlier point in time, any further 
CSR update (or addendum) will be written  at the end of study. 
After the p rimary outcome measure analysis (after Stage 1 if the study is stopped for futility, 
otherwise after Stage 2), an analysis will be performed at the end of the Main study period, and at 
the end of the Study extension period). 
Descriptive methods will be used to present all relevant data:  
- Continuous data will be summarized with: frequency, median, range, mean, standard deviation 
and standard error if relevant. 
- Categorical data will be presented in contingency tables with frequencies and percentages of 
each modality.  
13.2. OUTCOME MEASURES  
13.2.1.  Primary outcome measure  
The best overall confirmed response assessed per RECIST v1.1 will be used to evaluate the tumor 
response in terms of c ORR for the combination of encorafenib, binimetinib and c etuximab. This 
will be based on local radiologist/investigator- assessed tumor evaluations.  
The cORR is defined as the number of subjects achieving an overall best confirmed response of CR 
or PR divided by the total number of subjects . This may also refer to as confirmed ‘objective 
response rate’ in some protocols or publications. 
13.2.2.  Secondary outcome measures  
The following secondary outcome measures will be determined : 
- The cORR assessed by central radiologist review. 
- The ORR (for confirmed + unconf irmed responses) based on local radiologist/investigator-
assessed tumor evaluations, and ORR assessed by central radiologist review. 
- Overall survival defined as the time from first dose  to death due to any cause. If a subject is not 
known to have died, survival will be censored at the date of last known date the subject was 
alive  or at the cutoff date, whatever is earlier . OS will be calculated for FAS ( see Section  13.5). 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  182/234 
  - Progression-f ree survival, defined as the time from first dose  to the earliest documented date of 
disease progression or death due to any cause , per RECIST v1.1 and as determined by local 
radiologist/investigator assessments. Tumor assessment assessed by central review will be also 
used in a supportive analysis of PFS. 
- Duration of response is defined as the time from first radiographic evidence of response to the 
earliest documented PD or death due to underlying disease and is calculated for responders only. Responders who do not have a PD or death date by the data cutof f date will be censored for 
DOR at their last adequate tumor assessment of CR, PR or SD prior to the cutoff date. It will be 
assessed based on local radiologist/investigator review and central radiologist review. 
- Time to r esponse (CR or PR) is defined as t he time from first dose  until first documented 
radiographic evidence of  response of CR or PR. Subjects  who do not have a CR or PR by the 
cutoff date will be censored for TTR at their last adequate tumor assessment  date.  It will be 
assessed based on local radiologist/investigator review and central radiologist review. 
Endpoints for Study extension period will be based on local radiologist/investigator review only  
13.3. SAMPLE SIZE  
The sample size is based on a two -stage design  with nominal alpha=2.5% and beta=20%. The null 
hypothesis that the true response rate is 30% will be tested against a one -sided alternative. In the 
first stage, 40 subjects will be treated . In case of discordance in the results between the local assay 
and the central laboratory (potential false -positive local result), or lack of BRAFV600E confirmation, 
subject will be replaced.  If there are 11 or fewer confirmed responses in the 40 treated subjects  with 
a centrally confirmed BRAF BRAFV600E mutation , inactivity will be declared and the study will be 
stopped for futility. 
If the study continues to the second stage, 50 additional subjects  will be treated to achieve a total of 
90 subjects . In case of discordance in the results between the local  assay and the central laboratory 
(potential false -positive local result), or lack of BRAFV600E confirmation, subject will be replaced. 
The null hypothesis will be rejected if 37 or more confirmed responses are observed in 90 treated  
subjects  with a centrally confirmed BRAFV600E mutation . This design yields a 1- sided type I error 
rate equal to 1.6% and power of 80% when the true response rate is 45%.  
The sample size calculation  was based on binomial probabilities calculated in R (version 3.2.3). 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  183/234 
  This binomial design matches the O’Brien -Fleming design ( O'Brien, 1979) for one sample 
obtained using East software (version 6.4) with a 1- sided type I error  rate equal to 2.5% and a power 
of 81%.  
If 37 confirmed responders are observed in 90 subjects , the Clopper -Pearson (exact) binomial 95% 
confidence interval would be [30.8%, 52.0%] with the lower limit exceeding the clinically relevant 
response rate of 30% . 
 
13.4.  PROTOCOL DEVIATIONS  
A protocol deviation will be considered major when it is likely to significantly bias the estimate of the primary outcome measure.  
Major protocol deviations will be identified using the list of pre -defined reasons for exclusion from 
analysis sets for the study described in a specific document separately from the statistical analysis 
plan. 
All deviations will be reviewed and classif ied as major or minor before analysis.  
 
All protocol deviations linked to COVID -19 pandemic will be identified in the list of protocol 
deviations with a dedicated code and will be reviewed on a regular basis by the Study Sponsor, and 
by iDSMC. 
 
Subject s with major deviation s will be excluded from the Per Protocol set (see S ection  13.5
) 
13.5.  ANALYSIS SETS  
For inclusion in any analysis set, it is required that a subject has signed his /her informed consent.  
The analysis sets are defined as follows:  
• The Full Analysis Set  (FAS) is composed of all included subjects having received at least 
one dose of study treatment  (partial or full). Unless otherwise specified , the FAS will be the 
default analysis set used for all analyses.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  184/234 
  • The Efficacy Set (ES) is composed of all FAS subjects with  a centrally confirmed 
BRAFV600E mutation. The ES will be the analysis set used for the primary analysis of the 
main criterion and a ll other efficacy analyses.  
• The Per Protocol Set  (PPS) will consist of all subjects  from the FAS without any major 
protocol deviations. The PPS will be the analysis set used for the supportive analysis of the 
main criterion.  
• The PK Set will consi st of all subject s who receive at least 1 dose of encorafenib, 
binimetinib or cetuximab and who have at least 1 post -dose PK blood collection with 
associated bioanalytical results.  
 
 
13.6.  HANDLING OF DROPOUTS  AND MISSING DATA  
As of the date of data-cutoff for the primary CSR for the purposes of reporting:  
Subjects  continuing to receive study drugs at the time of analysis will have time -to-event data (e.g., 
PFS, DOR ) censored at the time of last tumor assessment prior to the da ta cut -off point used. 
Ongoing events (e.g., AEs , concomitant medication, etc.) will be summarized using the data cut -
off date as the date of completion, with an indication that the event is ongoing. For subjects who drop out from the study with ongoing events, the discontinuation date will be used 
as the completion date of the event with the appropriate censoring. The reason for discontinuation from study will be summarized, along with the dates of first and last 
study drugs, duration of exposure to study drugs and date of discontinuation for each subject.  
Specific details regarding the handing of missing data will be included in the statistical analysis 
plan. 
13.7.  DEMOGRAPHIC AND OTHE R BASELINE CHARACTERISTICS  
Baseline subject characteristics including demographics and other baseline data, ECOG PS, 
histology, primary site of disease and medical history will be summariz ed using the ES and  FAS.  
Demographic and disease characteristics will be also summarized for the subgroup of Japanese subjects.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  185/234 
   
 
13.8.  ANALYSIS OF O UTCOME MEASURES  
Efficacy analyses will be conducted using the ES and FAS. A supportive analysis of the primary 
outcome will be conducted using the PPS. 
13.8.1.  Analysis of Primary Outcome Measure  
13.8.1.1.  Primary Analysis  
The cORR will be provided with a corresponding Clopper- Pearson (exact) binomial  95% CI 
(Clopper CJ et al, 1934 ) for the ES . As detailed (in Section  13.3), the two -stage method will be 
used to test the null hypothesis with the possibility  of stopping accrual earlier for futility.  If the 
observed cORR at the end of the first stage is less than 28% (i.e., ≤ 11 confirmed CRs and/or PRs 
among 40 treated subjects  with a centrally confirmed BRAFV600E mutation ), then insufficient 
efficacy will be concluded. Otherwise, at the end of stage 2, if the observed ORR is ≥41% (i.e., ≥37 confirmed responses among 90 treated subjects  with a centrally confirmed BRAF
V600E mutation ), 
the null hypothesis will be rejected . 
 
13.8.1.2.  Supportive Analys is 
The cORR will be provided with a corresponding Clopper- Pearson (exact) binomial  95% CI for  the 
PPS and FAS (see S ection 13.5).  
13.8.1.3.  Exploratory Analysis 
Exploratory analyses may be performed on various subgroups such as by age (< 65 vs. ≥ 65 years 
old), gender, CRP levels (>ULN and <ULN), MSI status (high and low), location of primary disease  
and possibly others. The primary endpoint and the corresponding 95% CI will be displayed using a 
forest plot by subgroups. Further details including the precise subgroups used will be detailed in the 
SAP.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  186/234 
  cORR based on investigator -assessed tumor evaluation for the subgroup of Japanese subjects will 
also be examined separately.  
 
13.8.2.  Analysis of Secondary Outcome M easures  
The cORR based on central review, and ORR ( for confirmed + unconfirmed responses) based on 
local radiologist/investigator- assessed tum or evaluations and central radiologist review will be 
provided with a corresponding Clopper- Pearson (exact) binomial  95% CI for the ES and FAS.  
The Kaplan -Meier (KM) method used to describe OS  will present median time with 95% CI and 
estimates at several t ime points (including 2, 4, 6, 8, 10 and 12 months ). Subjects  without a death 
date by the data cut -off date will be censored for OS at their last contact date.  
PFS will be calculated for the FAS  and summari zed using the KM method. The corresponding 
median PFS as well as PFS rates at selected time points (e.g. 3 and 6 months) will be provided with 
a 95% CI.  
Progressive disease and death from any cause will be considered as event s. If death or PD is not 
observed, the PFS will be censored at the date of last adequate tumor assessment prior to the cutoff 
date. However, if a PFS event is observed after more than 1 missing or inadequate tumor 
assessment, it will be censored at the last adequate tumor assessment. If a PFS event is observed 
after a single missing or non- adequate tumor assessment, the actual date of event will be used.  
Subject s who received a new anti -tumoral treatment (chemotherapy, hormonotherapy, radiotherapy, 
surgery or other anti tumoral treatment), whatever the type of treatment before their disease progression will be censored at the last adequate assessment prior to the start date of the new 
antitumoral treatment. 
Additional sensitivity analyses examining alternative censoring rules could be applied and will be 
described in  the SAP.  
Analysis of DOR and TTR will be summarized using KM method in a similar way. 
Secondary outcomes measures in the subgroup of Japanse subjects will be examined separately. 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  187/234 
   
13.9. SAFETY ANALYSIS   
The FAS will be used to perform all analyses of the safety criteria.  
13.9.1.  Treatment exposure  
Duration of study drug exposure, actual and relative dose intensity will be summarized. The number 
of subjects with dose changes/interruptions will be presented, along with reasons for the dose 
change. The actual daily doses and reasons for dose change will be listed. These analyses will be 
applied for each study drug individually on the FAS . 
Separate summaries will be generated for the subgroup of Japanese subjects.  
13.9.2.  Adverse Events  
Any AE reported during the study for a given subject  will be classified by preferred term and 
corresponding system organ class using the MedDRA terminology. 
The occurrence of an AE  will be defined by the appearance of a new single event, the reappearance 
of a pr eviously recovered event or the worsening of a continuous event (relative to its previous 
status).  
A treatment emergent adverse event (TEAE) is defined as any event that first occurred during the 
treatment period (i.e. from first treatment administration date up to last administration date + 30 
days) or that worsened during that study period.  
Summary tables will display the number and percentage of subjects with TEAEs overall and by 
maximum grade, system organ class (SOC) and preferred term (PT). A subjec t with multiple 
occurrences of an AE will only be counted under the maximum NCI-CTCAE grade for this AE.  
Similar analyses will also be performed for  TEAEs assessed as related to study treatment by the 
investigator. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  188/234 
   
SAEs  will also be described on an individual basis: subject’s code, sex and age, Investigator's 
reported term, preferred term, date  of the first study treatment administration, duration of each study 
drug, action taken regarding the study treatments administration, use of a corrective treatm ent, 
outcome and relationship to the study treatments in the Investigator’s opinion. 
Categories of adverse event s of special interest (AESI s) will be considered. Such categories consist 
of one or more well -defined safety events which are similar in nature and for which there is a 
specific clinical interest in connection with the study drugs. These analyses will be specified in the 
SAP.   
The number and percentage of subjects  with at least one AE occurr ing before the first administration 
will be tabulated by MedDRA SOC  and PT.  
As per the EudraCT requirement:  The number and percentage of subjects with at least one TEAE, 
and the number of occurrences of TEAEs, will be tabulated by MedDRA SOC, PT and seriousness  
(by descending order of frequency). 
The same analy sis will be performed for TEAEs  assessed as related to study treatment by the 
investigator. AE analyses will be generated for the subgroup of Japanese subjects. 
All Adverse Events related to COVID -19 pandemic will be flagged in listings to assess any potential 
impact of the pandemic on the study integrity and subjects’ safety. These Adverse Events will be 
reviewed by iDSMC. 
 
13.9.3.  Clinical Safety Laboratory Evaluation  
For each hematology and chemistry laboratory parameter, data will be tabulated over time an d plots 
of measurements over time will be generated for selected parameters.  
The absolute changes in post- trial treatment administration versus baseline (the baseline value being 
the value measured on the last blood sample collected before the first study treatments administration) will be calculated and tabulated by parameter and post -trial treatment administration 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  189/234 
  assessment time. Results of retests performed post -trial treatment administration will not be 
analy zed and tabulated  and will only be displayed in individual data listings.  
For laboratory tests covered by the NCI -CTCAE v4.03, laboratory data will be graded accordingly. 
For laboratory tests covered by the NCI -CTCAE, Grade 0 will be assigned for all non- missing 
values not graded as 1 or higher. Grade 5 will not be used. Shift tables of baseline grade vs. 
maximum grade on study will be presented. 
For laboratory parameters that are not gradable by NCI -CTCAE, shift tables of normal -abnormal 
will be provided. Analyses of laboratory data will be generated for the subgroup of Japanese subjects. 
13.9.4.  Other Safety D ata 
Vital signs, body weight, ECOG PS, ECG, dermatologic and ophthalmic examination data will be 
summarized descriptively over time for values and changes from baseline and/or with shift tables  
if applicable. Summaries of clinically notable measurements will also be provided. Definitions will 
be detailed in the SAP.  
13.10.  QUALITY OF LIFE ANAL YSIS  
Quality of Life will be evaluated through the EORTC QLQ -C30, EQ-5D- 5L QoL and PGIC 
questionnaires. 
Descri ptive statistics will be used to summarize the scores over time  on the FAS. Additionally, 
changes from baseline for EORTC QLQ -C30 and EQ -5D- 5L scores  will be describ ed over time.  
Further analysis will be detailed in the SAP.  
13.11.  EXPLORATORY ANALYSIS  
The relationship between protein levels, mutations and/or gene expression and clinical outcomes 
may be explored. Details of all exploratory analyses will be provided in the SAP.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  190/234 
   
13.12.  CONCOMITANT THERAPIES AND THERAPEUTIC/ DIAGNOSTIC 
PROCEDURE  
Concomitant therapies prior to and after the start of the study treatments will be tabulated from  a 
descriptive perspective. They will be classified by therapeutic area according to the WHO -DRUG 
dictionary using the "anatomical therapeutic chemical (ATC) classification for the FAS .  
These summaries will include medications starting on or after the start of study drugs or medications 
starting prior to the start of study drugs and continuing after the start of study drugs. 
Any other medications starting and ending prior to the start of study drugs will be listed. 
Numbers and percentages of subjects with at least one concomitant therapeutic / diagnostic 
procedure will be tabulated by treatment group, SOC  and PT  using the MedDRA terminology. 
13.13.  HEALTHCARE RESOURCE UTILIZATION  
Type of hospital facility, reason and length of hospitalization and hospital discharge will be 
summarized descriptively on the FAS.  
13.14.  PHARMACOKINETICS ANA LYSIS  
Plasma concentrations of encorafenib, binimetinib and the active metabolite of binimetinib (AR00426032) and related descriptive statistics will be summarized . Serum concentrations of 
cetuximab and related descriptive statistics will be reported in tables . 
Given the sparse PK sample collection, PK parameters for encorafenib, binimetinib and the active 
metabolite of binimetinib (AR00426032) and cetuximab may be generated by a compartmental approach such as a population approach, as appropriate . Details of these analyses and of the 
incorporation of prior information to support the model building will be provided in a specific standalone modeling plan. Analyses will be provided in a separate report. 
Relationships between PK and biomarkers, clinical response and/or safety will be explored if 
appropriate and if data quality is adequate. Details of analyses wi ll be included in a specific 
standalone modeling plan and results will be reported separately. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  191/234 
   
13.15.  INTERIM ANALYSIS  
The two -stage design involves an  interim analysis to allow for the possibility of stopping the study 
early for futility.  
The interim analysis of the c ORR is planned and based on the 40 treated subjects  from stage 1 of 
the study. 
The time point for the futility analysis will be after all 40 treated subjects  of stage1 with centrally 
confirmed BRAFV600E mutation had the opportunity to complete  four post baseline tumor 
assessment. And in case last subject required for the futility analysis has an objective response, it 
should be confirmed in the following tumor assessment before the futility analysis is performed.  
However, it will be possible to proceed to Stage 2 as soon as 40 subjects with  a centrally confirmed 
BRAFV600E mutation are treated and 12 confirmed responses are observed. 
Subjects data that will be analyzed during the futility analysis will be reviewed on an ongoing basis  
in order to determine as soon as possible (even before the inclusion of the 40th subject ) whether the 
criteria for continuing to stage 2 (12 confirmed responses) have been met . 
As it may take several treatment cycles for sub jects to achieve a confirmed response, if 12 confirmed 
responses are not observed at the time the 40th subject is treated  in Stage 1, a limited number of 
subjects (maximum 12) subjects from stage 2 may be treat ed while waiting for all subjects in the 
initial cohort of 40 subjects in Stage 1 to be evaluable for a confirmed response  providing no safety 
concern was raised by the iDSMC . They will not count towards responses in Stage 1 but will be 
included as part of the Stage 2 cohort, should the study move forward into Stage 2. 
If at any time it becomes evident that the threshold of 12 responses is unlikely to be met, then 
additional subjects  may not be recruited (eg: 6 or fewer responses among 35 subjects  with sufficient 
follow up [potential for at lea st 2 ass essments]).  
If 11 or fewer confirmed responses are observed in subjects  with centrally confirmed BRAFV600E 
mutation  in stage 1, the treatment will be deemed not efficacious. Inactivity will be declared and 
the study will be stopped for futility. 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  192/234 
   
If 12 or more confirmed responses are observed in stage 1,  50 additional subjects with a centrally 
confirmed BRAFV600E mutation have to be treated. The cut -off for stage 2 analysis will be after all 
90 treated subjects  of stage 1 and 2 with centrally confirmed B RAFV600E mutation had the 
opportunity to complete  four post -baseline tumor assessments, and after subjects with an initial 
objective response have had an opportunity to have a confirmation scan. 
An S C will review the primary outcome an d safety d ata for the  interim a nd final analys es (see 
Section 11.4).  
An iDSMC will review the available safety information at regular interval (see S ection 11.5). 
Analyses for iDSMC will be based on safety, thus this will not affect the statistical operating  
characteristics of the Stage 1 and Stage 2 analyses. 
14. GENERAL ETHICAL CONS IDERATIONS  
14.1. ETHICAL CONDITIONS  
This study is performed in accordance with the principles stated in the Declaration of Helsinki and 
subsequent amendments and in accordance with the Good Clinical Practice Guideline 
(EMA/CHMP/ICH/135/1995).  
14.2. INDEPENDENT ETHICS C OMMITTEE AND LEGAL 
REQUIREMENTS  
All documents required by National Regulations and any other informative documents that may be 
requested are submitted for review to the appropriate IEC/IRB whose procedures and operations 
meet national l egal r equirements.  
Depending on national regulations, the application is submitted to the IEC/IRB by the S ponsor or 
by the Investigator.  
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  193/234 
   
A copy of the formal written approval from the IEC/IRB is provided to the S ponsor (directly by the 
IEC/IRB or via the Investigator) with a list of names and qualifications of its members.  The request 
for authori zation by the Competent Authority or notification (depending on national regulations) is 
carried out by the Sponsor. 
Screening of subjects will not start before the approval of the IEC/IRB  has been obtained and the 
study was authoriz ed by the Competent Authority (or notified to the Competent Authorit y, 
depending on the national regulations). 
14.3. SUBJECT’S INFORMATION LEAFLET AND INFORM ED 
CONSENT FORM  
Information must be given to each subject  before his/her decision to participate or abstain from 
participation.  This information is based on the elements set  out in the Declaration of Helsinki and 
the ICH GCP guideline. It must also describe the measures taken to safeguard subject’s privacy and 
protection of personal data, according to EU General Data Protection Regulation (2016/679). 
Restraints and risks must be explained, as well as the right to discontinue participation in the study 
at any stage, without affecting their further relationship with the Investigator and/or their future 
care.  
The written information and consent form must be submitted to the subject with an oral explanation. 
It must be agreed and signed by the subject before any study- related procedure starts.  
This information and consent procedure is under the Investigator’s responsibility. 
The information and consent document s are prepared i n duplicate: the original copy is kept by the 
Investigator, and the other copy is given to the subject. 
If any information becomes available during the trial that may be relevant to the subject’s 
willingness to continue participating in the trial, an updated written informed consent must be 
submitted to the subject to confirm his /her agreement to continue participating. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  194/234 
   
14.4. PERSONAL DATA PROTEC TION 
All information from this study (excluding data from the informed consent ) are captured in an 
electronic database into a computer under the S ponsor’s responsibility in accordance with the 
French law, "Loi Informatique et Libertés" (January 6, 1978 and subsequent amendments) and with 
the EU General Data Protection Regulation (20 16/679). 
14.5. INSURANCE POLICY  
In accordance with the provisions of the law and GCP, the Sponsor Pierre  Fabre Medicament  has 
an insurance policy intended to guarantee against possible damage resulting from the research. 
The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Medicament are 
specifically and expressly guaranteed. It is advisable to underline that non- compliance with the Research Legal Conditions is a cause for 
guarantee exclusion.  
Unintentional infringements and vicarious liability are covered by our insurance .  
14.6.  FINANCIAL CONSIDERAT IONS  
The funding of research is provided by the S ponsor ( Investigator fees, study costs, subject 
compensation for travel expenses , etc. ). 
By signing the protocol, the Investigator declares no con flicts of interest.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  195/234 
   
15. ADMINISTRATIVE PROCE DURES  
15.1. PROTOCOL AMENDMENT S 
Neither the Investigator nor the S ponsor may alter the protocol without the authori zation of the 
other party. All changes to the protocol will be subject to an amendment which must be dated and 
signed by both parties and must appear as an amendment to the protocol.  
Substantial amendments are submitted for approval/authorization to the IEC/IRB and Competent 
Authorities . Urgent amendments are submitted for approval/authori zation to the IEC/IRB and 
Competent Authorities but may be implemented immediately under specific conditions defined with 
the Sponsor. 
15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE ST ORAGE 
The Investigator: 
- keeps all trial -related documents in appropriate file folders. Records of subjects , original ICFs , 
source documents, e- CRFs , treatment inventory, IEC/IRB  and S ponsor correspondence pertaining 
to the study must be kept on file, 
- retains all documents relat ing to the screening (consent and investigation results) of all subjects  
screened in the trial or not ,  
- retains a list of the subjects ’ names, addresses (and/or number of medical file), code numbers, 
dates of entry into and completion of the trial period, to allow checking of data reported on e- CRF s 
with those from source documents,  
- authorizes direct access to source documents for monitoring, audits and inspections. 
The trial -related documents must be retained as strictly confidential at the Investigator's site for a 
duration of 25 years or according to local requirement s, after the completion or discontinuation of 
the trial.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  196/234 
   
 
15.3. END OF STUDY  
15.3.1.  Definition of the end of study  
The end of the study is defined as the time point when all treated subjects will have either progressed 
or discontinued study treatment s (including 30- day Safety Follow -Up visit)  for any other reason 
(unacceptable toxicity, subject’s decision, withdrawal of consent, initiation of subsequent anticancer therapy or death). 
15.3.2.  Supply of product after Main s tudy period  
After  the Main  study period (from first subject screened to 1 year after the start of study treatment 
of the last subject enrolled  – 27 D ec 20 20),  access to study treatment will be provided through a 
Study extension period (from 28  Dec 2020) to all subjects whom the investigator considers are 
continuing to benefit from study treatment.  
These subjects  will receive treatment with encorafenib/binimetinib/cetuximab as long as they 
continue to demonstrate benefit and do not experience unacceptable toxicities and as long as none of the treatment discontinuation criteria are met or until binimetinib/encorafenib are commercially 
available in the first line setting of BRAF 
V600E mutated mCRC  or until the binimetinib/encorafenib 
development program is stopped (whichever comes first) . 
15.4. AUDIT  
The purpose of a sponsor’s audit, independent of and separate from monitoring or quality control 
activities, is to evaluate trial conduct and compliance with the protocol, sponsor’s standard 
operating procedures, Good Clinical Practice, and the applicable regulatory requirements. 
Audits may be conducted by the sponsor’s Clinic al Quality Assurance Department or delegate at 
each relevant location where activities dedicated to clinical trial are performed: for example at 
sponsor’s site(s), at the investigational site(s), at CRO(s) site(s) and laboratory(ies) if applicable. 
All stu dy related documentation must be directly accessible to auditors. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  197/234 
  The practical conditions for the audit are discussed between the auditees and the sponsor’s Clinical 
Quality Assurance Department or their delegate.  
 
15.5. INSPECTION  
The relevant Health Authorities may inspect any investigational  site or the S ponsor during the 
course of the study or after its completion, to verify the conduct of the study and quality of the data. 
The Investigator must provide direct access to the respective source documents.  
15.6. CONFIDENTIALITY  
The study materials (protocol, e- CRF , Investigator 's brochure s) contain confidential information. 
Except if agreed to in writing with the S ponsor, the Investigators must hold such information 
confidential, and must not disclose it to others (except where required by applicable law). 
15.7. CLINICAL STUDY REPORT 
Data analysis and CSR writing are the S ponsor’s responsibility. Upon completion of the data 
analysis, a final report including a review of the objectives and methods, a presentation and 
discussion of the results are drawn up according to ICH Guidelines (Structure and Content of 
Clinical Study Reports, ICH-E3, CPMP/ICH/137/95. 
The report is a clinical, (and) statistical, and pharmacokinetic integrated report. It must be signed 
by the sponsor's representative(s) and the coordinating Investigators. 
15.8. STUDY RESULTS COMMUNICATION  
Within a maximum period of 12 months after study completion global results of the r esearch will 
be communicated to the Investigator.  
According to the l ocal regulations, subjects can ask the I nvestigator for the results.   
If this study is part of a marketing authorisation application, its results will be published on the 
European Medicines Agency ( EMA ) website  and on Pharmaceuticals and Medical Devices Ag ency 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  198/234 
  (PMDA) website (Japan) . In that case, the documents will be anonymised to ensure data protection 
of individuals. 
 
15.9. STUDY RESULTS PUBLIC ATION  
The results of this study including data, reports, discoveries and inventions are the property of the 
Sponsor a nd are considered as confidential. Subject to any applicable laws in force, the Sponsor 
retains the right to be the first to publish or communicate the results of the study. In any case, no publication or communication relating to results of the study, in written or oral form, shall be made 
without Sponsor’s prior written consent and shall comply with the following provisions: 
- any communication or publication project must be provided to the S ponsor for review at least 
60 days prior to the expected date of submission to the intended publisher or of planned 
presentation. 
If requested by the S ponsor, the communication or publication project shall be withhe ld for an 
additional 60 days, to allow the filing of a patent application, or to allow the S ponsor to take any 
measures deemed  appropriate to establish and preserve proprietary rights. 
In case of a multi centric study, the Sponsor , in consultation with the SC, shall determine the author’s 
list and order within the publication project according to their participation in the design of the protocol as well as their recruitment of eligible and analy zable subjects . 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  199/234 
   
16. REFERENCES 
 
Baselga J, Trigo JM, Bourhis J, et al.  
Phase 2 multicenter study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum -based chemotherapy in patients with platinum-
refractory metastatic and/or recurrent squamous cell carcinoma of the head and ne ck. 
J Clin Oncol. 2005;23:5568 -77. 
Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, et al: Colon Cancer, Version 1, 2017, NCCN  Clinical Practice Guidelines in Oncology.  J Natl Compr Canc Netw. 3: 370-398, 2017. 
 
Binimetinib I nvestigator’s Brochure  _Current version  
Bokemeyer C, Bondarenko I, Hartmann JT, et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX -4 as first -line treatment for 
metastatic colorectal cancer: the OPUS study.  
Ann Oncol . 2011;22(7):1535 –46.  
Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of c etuximab to chemotherapy as first -line treatment for KRAS wild -type metastatic 
colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials.  
Eur J Cancer . 2012;48:1466 -75. 
Bonner JA, Harari PM, Giralt J, et al .  
Radiotherapy plus cetuximab for squamous -cell carcinoma of the head and neck.  
N Engl J Med. 2006;354:567 -78. 
Bouchahda M, Macarulla T, Liedo G, et al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis .
 
Med Oncol. 2011;28(suppl 1):S253 –S258.  
Cetuximab Summary Of Product Characteristics  
Clinical Trials Facilitation Group (CTFG)  
Recommendations related to contraception and pregnancy testing in clinical trials.  Final Version 2014-09-15. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01About_HMA/Working_Groups/CT
FG/2014_09_HMA_CTFG_Contraception.pdf  
Carneiro BA, Ramanathan RK, Fakih MG, et al.  
Phase II study of irinotecan and cetuximab given every 2 weeks as s econd-line therapy for 
advanced colorectal cancer .  
Clin Colorectal. 2012;11:53–59. 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  200/234 
  Clopper CJ, Pearson ES.  
The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial.  
Biometrika; 1934, 26(4): 404 -413. 
Corcoran RB, Ebi H, Turke AB, et al.  EGFR- mediated reactivation of MAPK signaling contributes to insensitivity of  BRAF-mutant 
colorectal cancers to RA F inhibition with vemurafenib.  
Cancer Discov. 2012;2(3):227 -35. 
Corcoran RB, Dias-Santagata D, Bergethon K, et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. 
Sci Signal.2010;3:ra84  
Corcoran RB, André T, Yoshino, JC.  Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti -EGFR antibody panitumumab (P) in patients (pts) with 
BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC). 
Ann Oncol. 2016;27:abstr 455 º 
Cremolini  C, Loupakis F, Antoniotti C, et al.  
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first -line treatment of 
patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open- label, phase 3 TRIBE study.  
Lancet Oncol. 2015;16:1306 -1315.  
Cunningham D, Humblet Y, Siena S, et al.  
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic 
colorectal cancer.  
N Engl J Med. 2004;351:337 -45. 
De Roock  W, Claes B, Bernasconi D, et al.  
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective 
consortium analysis.  
Lancet Oncol. 2010;11:753 -62.  
Di Nicolantonio F, Martini M, Molinari F.  Wild -type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal 
cancer.  
J Clin Oncol. 2008;26:5705 -12. 
Douillard JY, Oliner KS, Siena S, et al.   
Panitumumab- FOLFOX4 treatment and RAS mutations in colorectal cancer.  
N Engl J Med 2013;369:1023 –1034 .  
Dummer R, Robert C, Nyakas M, et al.  Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.  J Clin Oncol. 2013;31: suppl;abstr 9028. 
 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  201/234 
  Dummer R, Ascierto PA, Gogas H, et al 
Results of COLUMBUS part 1: A phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF -Mutant Melanoma.  
Presentated at: The society for melanoma Research 2016 Congress; November 6-9, 2016; 
Boston Massachusetts  
Dummer R, Ascierto  PA, Gogas  H, et al. 
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma.  Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx377.002 
Dummer R, Schadendorf D, Ascierto PA, et al.  
Binimetinib versus dacarbazine in patients with advanced NRAS- mutant melanoma (NEMO): a 
multicentre, open-label, randomised, phase 3 trial. 
Lancet Oncol 2017; 18:435 –445. 
Encorafenib Investigator’s Brochure _ Current version  
Erbitux® USPI  
Copyright © 2004, 2019, ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company. 
All rights reserved.  
ERB -0005- USPI -20190423  
Gomez-Roca CA, Delord J, Robert C, et al.  Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC): Results of dose expansion in an open-label, phase 1 study.  Ann Oncol. 2014;25(suppl 4):iv167-iv209. 
Ince WL, Jubb AM,  Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, 
Kabbinavar F, Novotny WF, Hillan KJ, et al.  
Association of k-ras, b- raf, and p53 status with the treatment effect of bevacizumab. 
J Natl Cancer Inst. 2005 ;97(13):981 –989. 
Kopetz S, McDonough S,Lenz HJ.  
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF -mutant 
metastatic colorectal cancer (SWOG S1406). 
J Clin Oncol. 2017;35:abst 3505  
Lacouture ME, Anadkat MJ, Bensadoun RJ et al.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.  
Support Care Cancer 2011;19:1079 –95  
Loupakis F, Cremolini C, Salvat ore L et al.  
FOLFOXIRI plus bevacizumab as first -line treatment in BRAF mutant metastatic colorectal 
cancer  
Eur J Cancer 2014; 50: 57 –63. 
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk 
S, Harris R, Fish er D, Kenny SL, Kay E, Mitchell JK, Madi A, et al.,   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  202/234 
  and MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatinbased first -line 
combination chemotherapy for treatment of advanced colorectal cancer: results of the 
randomised phase 3 MRC COIN trial.   
Lancet. 2011; 377:2103–14. 
 
Martin -Martorell P, Rosello S, Rodriguez-Braun E, et al. 
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy:results of a phase II single institution trial
. 
Br J Cancer. 2008;99:455 –458  
Mesa AM, Gotlib J, Gupta V, et. al.  Effect of ruxolitinib therapy on myelofibrosis -related symptoms and other patient-reported 
outcomes in COMFORT -1: A randomized, double -blind, placebo- controlled trial.  
J Clin Oncol. 2013;31:1285 -92. 
Morris V, Overman MJ, Jiang ZQ, et al. Progression -free survival remains poor over sequential lines of systemic therapy in patients 
with BRAF-mutated colorectal cancer. 
Clin Col Cancer Res. 2014;13:164 -71 
Mrabti H, De la Fouchardiere C, Desseigne F, et al.  
Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer
.  
J Cancer Res Ther. 2009;5:272 –276.  
Nardone B, Hensley JR, Kulik L, et al.  
The effet of hand-foot skin reaction associated with the multikinase inhibitors Sorafenib and Sunitinib on health- related quality of life  
JDD, 2012,Volume 11, Issue 11, article 61 
 
(O’Brien)  
A Multiple Testing Procedure for Clinical Trials  
Biometrics . (1979). 35:549 –556 
Pfeiffer P, Bjerregaard JK, Qvortrup C.  Every second week cetuximab (cet) and irinotecan (iri) as third line therapy in patients with advanced colorectal cancer (ACRC) .  
Presented at the 2007 American Society of Clinical  Oncology Gastrointestinal Cancers 
Symposium,  
Pfeiffer P, Nielsen D, Bjerregaard J, et al : 
Biweekly cetuximab and irinotecan as thirdline therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin  
and 5-fluorouracil.
  
Ann Oncol. 2008;19:1141 –1145.  
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.  
Nature 2012;100:100 -4. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  203/234 
  Roca JM, Alonso V, Pericay C, et al :  
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously 
treated patients with metastatic colorectal cancer.  
Chemotherapy. 2010; 56:142 –1460  
Rozek LS,  Herron CM, Greenson JK, Moreno V, Capella G, Rennert G, et al.  
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(3):838–43. 
 
Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M.  Is BRAF mutation associated with interval colorectal cancers? 
Dig Dis Sci. 2010;55(8):2352 –6. 
Shitara K, Yuki S, Yoshida M, et al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. 
Invest New Drugs. 2012; 30:787 –793.  
Smith CG, Fisher D, Claes B et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy þ/- cetuximab.  
Clin Cancer Res 2013; 19: 4104 –4113.  
Sobrero AF, Maurel J, Fehrenbacher L, et al.  
EPIC: Phase 3 trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. 
J Clin Oncol. 2008;26:2311 -9. 
Sorbye H, Dragomir A, Sundström M, Pfeiffer P, Thunberg U, Bergfors M et al.  High BRFA mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort.  
PLoS One 2015;10(6)e0131046 . 
Stintzing S, Jung A, Rossius L et al. Mutations within the EGFR signaling pathway: influence on efficacy in FIRE -3–A randomized 
phase III study of FOLFIRI plus cetuximab or bevacizumab as first -line treatment for wild -type 
(WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. 
J Clin Oncol 2014; 32: 445.  
Tabernero J, Cervantes A, Martinelli E et al.  
Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC).   
J Clin Oncol 2006;24(18 suppl):142s.  
Tabernero J, Pfeiffer P, Cervantes A.  
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an 
effective, more convenient alternative to weekly administration .  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  204/234 
  Oncologist.2008;13:113 –119. 
Tabernero J, Ciardiello F, Rivera F, et al . 
Cetuximab administered once every second week to patients with metastatic colorectal cancer: 
a two-part pharmacokinetic/pharmacodynamics phase I dose-escalation study . 
Ann Oncol. 2010;21:1537–1545. 
 
Tabernero  J, Van Geel  R, Kyrre Guren  T, Rona D. Yaeger, Anna Spreafico, Jason 
Edward Faris, Takayuki Yoshino, Yasuhide Yamada, Tae Won Kim, Johanna C. Bendell, Martin H. Schuler, Heinz-Josef Lenz, Ferry Eskens, Jayesh Desai, Howard S. Hochster, 
Emin Avsar, Tim Demuth, Victor Sandor, Elena Elez, and Jan H.M. Schellens 
Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) 
in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). 
Journal of Clinical Oncology 2016, 34:15_suppl, 3544 - 
Thakur MD and Stuart DD  
Molecular pathways: Response and resistance to BRAF and MEK inhibitors in BRAFV600E tumors. 
Clin Cancer Res. 2014;20:1074 -80. 
Tol J and Punt CJ.  Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review .  
Clin Ther 2010;32(3):437 -53. 
Tveit KM, Guren T, Glimelius B et al.  
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first -line treatment of metastatic colorectal 
cancer: the NORDIC -VII study .  
J Clin Oncol 2012; 30: 1755 –1762.  
Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J 
Med 2009; 360:1408 -17. 
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first -line treatment for metastatic 
colorectal cancer: updated analysis of overall survival according to tumor KRAS and B RAF 
mutation status.  
J Clin Oncol. 2011;29(15):2011 –9.  
Van Cutsem E, Cervantes A, Nordlinger B, et al.  Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow -up.  
Ann Oncol. 2014;25 (suppl 3):iii1 -iii9. 
Van Cutsem E, Atreya C, André T . 
Updated results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti -
EGFR antibody panitumumab (P) in patient (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)  
Ann Oncol. 2015;26(suppl 4):iv117 -iv121.  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  205/234 
  Van Cutsem E, Cerv antes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al.  
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.  
Ann Oncol. 2016;27(8):1386 -1422.  
 
Van Cutsem E., Cuyle PJ., Yaeger R., et al.  
BEACON CRC Study Safety Lead- in (SLI) in Patients With BRAFV600E Metastatic Colorectal 
Cancer (mCRC): Efficacy and Tumor Markers.  
Poster session presented at: The Annual ASCO Gastrointestinal Cancers Symposium; January 
16, 2018; San Francisco, California ; 
Von Moos R, Thuerlimann B, Aapro M, et al.  
Pegylated liposomal doxorubicin-associated hand foot syndrome: recommendations of an international panel of experts  
Eur J Cancer 2008, 44(6):781 -90 
Vermorken JB, Mesia R, Rivera F, et al.  Platinum- based chemotherapy plus cetuximab in head and neck cancer.  
N Engl J Med. 2008;359:1116 -27. 
Yang H, Higgins B, Kolinsky K et al.  Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.  
Cancer Res 2012; 72: 779 –789. 
Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P et al. Mechanisms of resistance to anti -EGFR therapy in colorectal cancer. 
Oncotarget 2017;8 : 14012 . 
Zheng Z, Hanna N, Onukwugha E, Reese ES, Seal B, Mullins CD.  Does the type of first- line regimens influence the receipt of second -line chemotherapy 
treatment? An analysis of 3211 metastatic colon cancer patients.
  
Cancer Med.2014;3(1):124 –133. 
   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  206/234 
   
17. APPENDICES  
 
17.1. RECOMMENDED GUIDELINES FOR THE MANAGEMEN T OF 
CETUXIMAB -INDUCED, E NCORAFENIB -INDUCED AND/OR 
BINIMETINIB -INDUCED SKIN TOXICITY  
Clinical judgment and experience of the treating physician should guide the management plan of 
each subject . In general, the following interventions are in addition to the cetuximab -induced rash 
and the encorafenib- induced and/or binimetinib- induced rash dosing guidelines provided ( in 
Section 1.2) . 
The Initial Rash Treatment Regimen may be initiated as prophylactic treatment 24  hours prior to 
the first treatment, or later as needed to treat mild rash ( NCI-CTCAE Grade 1).  
Initial Rash Treatment Regimen : 
• Application of topical agents to the most commonly affected skin areas such as face, scalp, 
neck, upper chest and upper back. Topical agents include the following: 
− Non-oily sunscreen (PABA- free, SPF ≥ 30, UVA/UVB protection);  
− Topical steroids, preferably mometasone cream (e.g., Elocon®); 
− Topical erythromycin (e.g., Eryaknen®); 
− Topical pimocrolimus.  
Note: Topical agents should be applied on a daily basis starting on Day 1 of study treatment or 
24 hours prior to first treatment, and more often as needed. 
• Possibly oral doxycycline (100 mg daily) for the first 2 to 3 weeks of study drug 
administration.  
Other effective medications are antihistamines, other topical corticosteroids, other topical 
antibiotics and low-dose systemic corticosteroids. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  207/234 
   
The treatment algorithm based on NCI -CTCAE grade is as follows: 
Mild Rash (CTCAE Grade 1) Treatment Regimen:  
• Initiate Initial Rash Treatment Regimen, if not already started.  
• Use of topical corticosteroid (e.g., mometasone cream) and/or topical antibiotic (e.g., 
erythromycin 2%) is recommended. 
• The subject  should be reassessed within a maximum of 2 weeks, or as per Investigator 
opinion. 
Moderate Rash (CTCAE Grade 2) Treatment Regimen:  
• Use of topical erythromycin or clindamycin (1%) plus topical mometasone or topical pimecrolimus (1% cream) plus oral antibio tics, such as lymecycline (408 mg QD), 
doxycycline (100 mg BID) or minocycline (50 to 100 mg BID).  
• Although there has been no evidence of phototoxicity or photosensitivity in subject s treated 
with binimetinib, doxycycline (or minocycline as second- line) sh ould be used with thorough 
UV protection (i.e., avoidance of direct exposure to sunlight, use of sunscreen and sunglasses, etc.). 
• Use of acitretin is not recommended. 
Severe Rash (CTCAE Grade 3 -4) Treatment Regimen:  
CTCAE Grade 3:  
• In addition to the interv entions recommended for moderate rash, consider oral prednisolone 
at a dose of 0.5 mg/kg. Upon improvement, taper the dose in a stepwise manner (25 mg for 
7 days, subsequently decreasing the dose by 5 mg/day every day). 
• Alternatively, in addition to the in terventions recommended for moderate rash, consider oral 
isotretinoin (low dose, i.e., 0.3 to 0.5 mg/ kg) ( Kopetz S el al, 2017; Lacouture ME et al, 
2011) 
• Use of acitretin is not recommended. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  208/234 
   
CTCAE Grade 4 Treatment Regimen:  
• Immediately discontinue the subject  from study drug and treat the subject  with oral or 
topical medications (see recommendation CTCAE Grade 3).  
Symptomatic Treatment Regimen:  
It is strongly recommended that subject s who develop rash/skin toxicities receive symptomatic 
treatment: 
• For pruritic lesions: use cool compresses and oral antihistamine agents. 
• For fissuring: use Monsel’s solution, silver nitrate or zinc oxide cream. If not sufficient, use 
mild corticosteroid ointments or o intments containing a combination of corticosteroid and 
antibiotic such as Fucicort®. 
• For desquamation: use emollients that are mild pH 5/neutral (recommended to contain 10% urea).  
• For paronychia: use antiseptic bath and local potent corticosteroids, use oral antibiotics, and, if no improvement is seen, refer to a dermatologist or surgeon. 
• For infected lesions: obtain bacterial and fungal cultures and treat with topical or systemic antibiotics, if indicated, based on sensitivity of culture. 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  209/234 
   
17.2. RECOMMENDED GUIDELINES FOR THE MANAGEMEN T OF 
ENCORAFENIB -INDUCED HAND -FOOT SKIN REACT IONS (HFSR)  
Clinical judgment and experience of the treating physician should guide the management plan of 
each subject . In addition to the HFSR dosing guidelines in  the p rotocol, the following algorithm is 
recommended for the management of HFSR based on the severity (CTCAE grading,) of HFSR (adapted from  Nardone B  et al, 2012). HFSR (adapted from  Nardone B  et al, 2012).  
Algorithm for the Management of HFSR Based on the Severity of HFSR 
HFSR severity  Intervention  
No HFSR  Maintain Frequent Contact with physician to ensure early diagnosis of HFSR  
Therapy initiation  Full body-skin examination, pedicure, evaluation by podiatrist or orthotist; wear thick cotton 
gloves and/or socks; avoid hot water, constrictive footwear and excessive friction  
If symptoms develop, proceed to next step  
 
Grade 1  Maintain current dose of BRAF inhibitor; monitor subject  for change in severity  
Minimal skin changes or dermatitis without pain e.g.:  
• Numbness  
• Tingling  
• Dysesthesia  
• Paresthesia 
• Erythema 
• Edema 
• Hyperkeratosis  
No interference with ADL  Avoid hot water; use moisturizing cream for relief; wear thick cotton gloves and/or socks; use a 20 -40% urea , salicylic acid 3 -6%; ammonium lactate 12 % or lactic acid 12 % based 
creams to aid exfoliation.  
If symptoms worsen, proceed to next steps  
 
  
 
 
Grade 2  Maintain current dose of BRAF inhibitor; monitor subject  for change in severity  
Skin changes with pain e.g.  
Peeling  
• Blisters  
• Bleeding  
• Edema 
• Hyperkeratosis  
Limited instrumental ADL  
  
 Treat as with Grade 1 toxicity, with the following additions: clobetasol 0.05% ointment, 2-
4% lidocaine, opiates, NSAIDS, or GABA agonists for pain; f ollow dose modifications 
listed in Table 14  
If no improvement within 15 days, proceed to next steps.  
 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  210/234 
  The following supportive care measures for the prevention, and/or management of HFSR 
summarized in the table below should be instituted along with proper subject education. 
Supportive Care for the Prevention and Management of HFSR  
 
Stage  Recommendations  
Prior to initiation of study treatment  Educate the subject  about the early signs and symptoms of HFSR and 
discuss the importance of early reporting. HFSR could start as early as 2- 5 
days after study drug initiation, and mostly expected to occur during the 
first 2 months of treatment.  
Prevention of HFSR for the first 2 months of treatment with encorafenib  Monitor the subject  for signs and symptoms of HFSR. Instruct the subject  
to: 
- Apply emollient cream regularly to hands and feet: use 20 -40% urea , 
salicylic acid 3 -6%; ammonium lactate 12% or lactic acid 12 % based 
creams  
- Wear cotton socks or gloves to bed to enhance the absorption of creams  
- Avoid tight, irritating or ill-fitting clothing and shoes  
- Avoid repetitive activity or staying in one position for long periods of 
time 
- Pat (do not rub) skin dry with towels  
- Avoid extremes of temperature, pressure and friction  
- Avoid performing mechanically stressful manual work  
- Cushioning of callused areas  
- Use of moisturizing and keratolytic creams  to control existing palmar 
and plantar hyperkeratosis  
Treatment of HFSR  1) Ensure that subject  follows treatment interruption or dosage reduction 
guidelines  
2) Monitor the subject  for worsening/resolution of HFSR (Normal 
frequency monthly, except if subj ect has Grade 2 or 3 HFSR, where bi 
weekly - visits are recommended)  
3) Prescribe analgesics if necessary  
4) Instruct the subject  to: 
- Continue the use of prevention strategies  
- Cushion sore skin  
- For control or relief of pain symptoms, subject  may submerge hands and 
feet in cool water baths or apply cold compresses for relief  
a Wear loose-fitting clothing made of soft, natural fabrics and shoes that are wide and comfortable. Avoid tight belts, panties 
and bras.  
This table is adapted from ( VonMoos et al, 2008 ). 
   
Grade 3  Interrupt dose until improvement to Grade 0-1 
Severe skin changes with pain e.g. 
Peeling  
• Blisters  
• Bleeding  
• Edema 
• Hyperkeratosis  
Limiting self -care ADL  Treat as for Grades 1 and 2  
 Follow dose modifications listed in Table 14 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  211/234 
   
17.3. RECOMMENDED GUIDELINES FOR THE MANAGEMEN T OF 
BINIMETINIB -INDUCED DIARRHEA 
 
Proactively Investigate for Occurrence of Diarrhea and Educate Subject : 
1. Remind subject s at each visit to contact the Investigator immediately upon the first sign of 
loose stool or symptoms of abdominal pain. Additionally, at each study visit, each subject  
should be asked regarding occurrence of diarrhea or diarrhea -related symptoms. If the 
subject  has had symptoms, the subject  should be asked regarding the actions taken for these 
symptoms and re- instruct if indicated.  
2. Subject s should be instructed on dietary modification and early warning signs of diarrhea 
and potentially life -threatening illnesses (e.g., severe cramping might be a sign of severe 
diarrhea; fever with diarrhea might be a sign of infection; fever and dizziness on standing 
might be a sign of shock).  
3. Subject s should be educated about what to report to the Investigator (i.e., number of stools, 
stool composition, stool volume). 
Anti -Diarrhea Therapy:  
In order to effectively manage diarrhea and mitigate the escalation in severity or duration of diarrhea, subject  education as outlined above, as well as proper management of diarrhea is 
important.  
Management  of diarrhea should be instituted at the first sign of abdominal cramping, loose stools 
or overt diarrhea. All concomitant therapies /used for treatment of diarrhea must be recorded on the 
e-CRF . It is recommended that subject s be provided loperamide tablets and be instructed on the use 
of loperamide on the first day of binimetinib dosing. In addition to the binimetinib- induced diarrhea 
dosing guidelines provided in Table 14 of the protocol, these instructions should be provided at 
each visit and the site should ensure that the subject understood the instructions.  
See Section 7 in the protocol to explain the frequency of diarrhea and its relationship to NCI -
CTCAE, v.4.03 grading and to determine if diarrhea is complicated or uncomplicated. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  212/234 
   
Rule out Other or Con comitant Causes : 
These may include:  
• Infection with Candida, Salmonella, Clostridium difficile, Campylobacter. Giardia, 
Entamoeba or Cryptosporidium species, which can lead to severe infections in 
immunosuppressed subject s. 
• Medication -induced diarrhea. 
• Malabsorption/lactose intolerance. 
• Fecal impaction, partial bowel obstruction.  
For Uncomplicated Grade 1/2 Diarrhea:  
• Stop all lactose- containing products and alcohol, and eat frequent small meals that include 
bananas, rice, applesauce or toast. 
• Stop laxatives, bulk fiber (e.g., Metamucil®), and stool softeners (e.g., docusate sodium, 
Colace®). 
• Stop high-osmolar food supplements (e.g., Ensure® Plus, Jevity® Plus [with fiber]).  
• Drink 8 to 10 large glasses of clear liquids per day (e.g., water, Pedialyte®, Gatorade®, 
broth). 
• Consider administration of a standard dose of loperamide: initial administration 4  mg, then 
2 mg every 4 hours (maximum of 16 mg/day) or after each unformed stool. 
• Discontinue loperamide after 12-hours diarrhea- free (Grade 0) interval.  
• Consider temporary interruption of binimetinib until resolved to Grade ≤ 1. Re -treatment 
may then be resumed at current dose level . 
• If uncomplicated Grade 1 to Grade 2 diarrhea persists for more than 24 hours, escalate to high- dose loperamide: 2 mg every 2 hours (maximum of 16 mg/day) or after each unformed 
stool. 
Note:  Oral antibiotics may be started as prophylaxis for infections under the discretion of the 
physician. 
• If uncomplicated Grade 1 to Grade 2 diarrhea persists after 48 hours of treatment with loperamide, discontinue loperamide and begin a second- line agent which can be an opiate 
(opium tincture or paregoric), octreotide acetate or steroid (budesonide). 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  213/234 
   
For Complicated Grade 1/2 Diarrhea or Any Grade 3/4 Diarrhea: 
• The subject  must call the Investigator immediately.  
• Temporarily interrupt binimetinib treatment until resolved to Grade ≤ 1. Restart binimetinib 
at a reduced dose level.  
• If loperamide has not been initiated, initiate loperamide immediately. Initial administration 4 mg, then 2 mg every 4 hours (maximum of 16 mg/day) or after each unformed stool. 
• Administer IV fluids and electrolytes as needed. In case of severe hydration, replace loperamide with octreotide acetate.  
• Monitor/continue IV fluids and antibiotics as needed. Intervention should be continued until the subject  is diarrhea -free for at least 24 hours. 
• Hospitalization may need to be considered. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  214/234 
   
17.4. SNELLEN EQUIV ALENCE (VISUAL ACUITY CONVERSION 
CHART)  
 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  215/234 
   
17.5. LIST OF CONCOMITANT MEDICATIONS  
The following lists are not necessarily exhaustive lists of every possible 
substrate/inhibitor/inducer. 
Table A:  List of CYP450 Substrates to be Used With Caution* 
CYP2C8  CYP2C9  CYP2C19  CYP3A**  
Amodiaquine  Acenocoumarol  Clopidogrel  Alfentanil 1,2 Ergotamine 2 
Cerivastatin  Celecoxib  Diazepam  Alpha -
dihydroergocryptine 1 Everolimus 1 
Repaglinide  Diclofenac  Esoprazole  Alprazolam  Felodipine 1 
Rosiglitazone  Glipizide  Lansoprazole  Amlodipine  Fentanyl 2 
Torasemide  Irbesartan  Moclobemide  Aplaviroc  Fluticasone 1 
 Losartan  Omeprazole  Aprepitant 1 Indinavir 1 
Phenytoin 2 Pantoprazole  Aripiprazole  Lopinavir 1 
Piroxicam  Phenobarbitone  Atorvastatin  Lovastatin 1 
S-ibuprofen  Phenytoin 2 Boceprevir  Maraviroc 1 
Sulfamethoxazole  Proguanil  Brecanavir  Midazolam 1 
Tolbutamide  Rabeprazole  Brotizolam 1 Nifedipine  
Torasemide  S-mephenytoin  Budesonide 1 Nisoldipine  
  Buspirone 1 Nitrendipine  
capravirine  Perospirone 1 
casopitant  Quinine  
Conivaptan 1 Saquinavir 1 
Cyclosporine 2 Sildenafil 1 
Darifenacin 1 Simvastatin 1 
Darunavir 1 Sirolimus 1,2 
Diazepam  Telaprevir  
Diergotamine 2 Tipranavir 1 
Diltiazem  Tolvaptan  
Ebastine 1 Triazolam 1 
Eletriptan 1 Verapamil  
Eplerenone 1  
*Table was compiled from the Indiana University School of Medicine’s “Clinically Relevant” table, a list by the United States  Food and Drug 
Administration (FDA) fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm, and 
the University of Washington’s Drug Interaction Database. 
1 Sensitive substrates: Drugs whose plasma area under concentration- time curve (AUC) values have been shown to increase 5 -fold or higher 
when co -administered with a potent inhibitor of the respective enzyme.  
2 Substrates with narrow therapeutic index (NTI): Drugs whose exposure -response indicates that increases in their exposure levels by the 
concomitant use of potent inhibitors may lead to serious safety concerns (e.g., TdP).  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  216/234 
   
 
Table  B : List of CYP450 Substrates to be u sed w ith Caution – CYP2B6  
CYP2B6*  
bupropion 1 
Cyclophosphamide  
Efavirenz 1 
Ifosfamide  
Methadone  
Thiotepa  
*Table was compiled from the Indiana University School of Medicine’s “Clinically Relevant” table, a list by the FDA 
(http://.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm) and the Univer sity of 
Washington’s Drug Interaction Database. 
1 Sensitive substrates: The area under the concentration -time curves (AUCs) of these substrates were not increased by 5- fold or more with a 
CYP2B6 inhibitor, but they represent the most sensitive substrates studied with available inhibitors evaluated to date.  
 
 
Table  C:  Strong/moderate CYP3A4 Inhibitors and CYP3A4 Inducers to be Prohibited or 
Administered w ith Caution when Co -administered with Encorafenib  
Strong Inhibitors (prohibited)  
boceprevir  nefazodone  
Clarithromycin  Nelfinavir  
Conivaptan  Posaconazole  
Indinavir  Ritonavir  
Itraconazole  Saquinavir  
Ketoconazole  Telithromycin  
Lopinavir  Troleandomycin  
Telaprevir  Grapefruit juice (citrus paradisi fruit juice)  
Mibefradil  Voriconazole  
Moderate inhibitors (use with caution)  
Ciprofloxacin  Erythromycin  
Fluconazole  Amprenavir  
Verapamil  Imatinib  
Atazanavir  Schisandra sphenanthera  
Aprepitant  Casopitant  
Cyclosporine  Cimetidine  
Tofisopam  Dronedarone  
Fosamprenavir  Darunavir  
Diltiazem   
Strong Inducers (prohibited)  
Avasimibe  Rifampin  
Carbamazepine  St. John’s wort  
Phenytoin   
Moderate Inducers (prohibited)   
Bosentan  Efavirenz  
Etravirine  Modafinil  
Reproduced from fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  217/234 
   
Table  D:  Substrates  of BCRP, OCTs , OATs  and OATPs to be administered with Caution  
 Substrates  
BCRP  Imatinib, irrinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan  
P-gp Aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, 
imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, 
sitagliptin, talinolol, tolvaptan, topotecan  
OCT2 Amantadine, amiloride, cimetidine, dopamine, famotidine, memantine, metformin, pindolol, 
procainamide, ranitidine, varenicline, oxaliplatin  
OAT1  Adefovir, captopril, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, zalcitabine, 
zidovudine  
OAT3 Acyclovir, bumetanide, ciprofloxacin, famotidine, furosemide, methotrexate, zidovudine, 
oseltamivir acid, (the active metabolite of oseltamivir), penicillin G, pravastatin, rosuvastatin, 
sitagliptin  
OATP1B1  Atrasentan, atorvastatin, bosentan, ezetimibe , fluvastatin, glyburide, SN -38 (active metabolite of 
irinotecan), rosuvastatin, simvastatin acid, pitavastatin, pravastatin, repaglinide, rifampin, 
valsartan, olmesartan  
OATP1B3  Atorvastatin, rosuvastatin, pitavastatin, telmisartan, valsartan, olmesartan  
Reproduced from fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm  
 
 
Table  E:  Pg-P and BCRP Inhibitors/Inducers to be u sed with Caution 
Transporter  Gene  Inhibitor 1 Inducer 2 
P-gp ABCB1  Amiodarone, azithromycin,captopril, 
carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, dronedarone, 
erythromycin, felodipine, itraconazole, 
ketoconazole, lopinavir and ritonavir, quercetin, 
quinidine, ranolazine, verapamil  Avasimibe,carbamaze pine,phenytoin, 
rifampin, St John’s wort, tipranavir/ritonavir  
BCRP  ABCG2  Cyclosporine, elacridar (GF120918), 
eltrombopag, gefitinib  Not known  
Reproduced from fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm  
 
1. Inhibitors listed for P -gp are those that showed >  25% increase in digoxin area under the concentration- time curve (AUC) or otherwise 
indicated if subs trate is other than digoxin.  
2. Inducers listed for P -gp are those that showed >  20% decrease in digoxin AUC or otherwise indicated if substrate is other than digoxin.  
 
 
Table F:  List of Inhibitors of UGT1A1 to be u sed w ith Caution  
Inhibitors of UGT1A1  atazanavir, erlotinib, flunitrazepam, gemfibrozil, indinavir, ketoconazole, nilotinib, 
pazopanib, propofol, regorafenib, sorafenib  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  218/234 
   
Table G: List of Potential QT Prolonging Drugs of Potential QT Prolonging Drugs1 
Drug  QT risk2 Comment  
Alfuzosin  possible risk    
Amantadine  possible risk    
Amiodarone  known risk  Females  > Males, TdP risk regarded as low  
Amitriptyline  conditional risk  Risk of TdP with overdosage. Substrate of CYP2C19  
Arsenic trioxide  known risk    
Astemizole  known risk  No Longer available in U.S. Substrate for 3A4  
Atazanavir  possible risk    
Azithromycin  possible risk  Rare reports  
Bepridil  known risk  Females  > Males  
Chloral hydrate  possible risk    
Chloroquine  known risk    
Chlorpromazine  known risk    
Ciprofloxacin  conditional risk  Drug metabolism inhibitor - Risk for drug interactions  
Cisapride  known risk  No longer available in the U.S.; available in Mexico. Substrate for 3A4  
Citalopram  known risk    
Clarithromycin  known risk  Substrate for 3A4  
Clomipramine  conditional risk    
Clozapine  possible risk    
Desipramine  conditional risk  Risk of TdP with overdosage  
Diphenhydramine  conditional risk  Risk of QT increase/TdP in overdosages  
Disopyramide  known risk  Females  > Males  
Dofetilide  known risk    
Dolasetron  possible risk    
Domperidone  known risk  Not available in the U.S.  
Doxepin  conditional risk    
Dronedarone  possible risk  Substrate for 3A4  
Droperidol  known risk    
Eribulin  possible risk    
Erythromycin  known risk  Females>Males. Substrate for 3A4  
Escitalopram  possible risk    
Famotidine  possible risk    
Felbamate  possible risk    
Fingolimod  possible risk    
Flecainide  known risk    
Fluconazole  conditional risk  Drug metabolism inhibitor - Risk for drug interactions  
Fluoxetine  conditional risk    
Foscarnet  possible risk    
Fosphenytoin  possible risk    
Galantamine  conditional risk    
Gatifloxacin  possible risk    
Gemifloxacin  possible risk    
Granisetron  possible risk    
Halofantrine  known risk  Females>Males  
Haloperidol  known risk  When given intravenously or at higher -than- recommended doses, risk 
of sudden death, QT prolongation and torsades increases. Substrate for 
3A4 
Ibutilide  known risk  Females>Males  
Imipramine  conditional risk  Risk of TdP in overdosage  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  219/234 
  Drug  QT risk2 Comment  
Indapamide  possible risk    
Isradipine  possible risk    
Itraconazole  conditional risk  Drug metabolism inhibitor - Risk for drug interactions  
Ketoconazole  conditional risk  Drug metabolism inhibitor  
Levofloxacin  possible risk    
Levomethadyl  known risk  Not available in the U.S.  
Lithium  possible risk    
Mesoridazine  known risk    
Methadone  known risk  Females>Males. Substrate for 3A4  
Moexipril/HCTZ  possible risk    
Moxifloxacin  known risk    
Nicardipine  possible risk    
Nortriptyline  conditional risk    
Octreotide  possible risk    
Ofloxacin  possible risk    
Ondansetron  possible risk    
Oxytocin  possible risk    
Paliperidone  possible risk    
Paroxetine  conditional risk    
Pentamidine  known risk  Females  > Males  
Perflutren lipid microspheres  possible risk    
Pimozide  known risk  Females  > Males. Substrate for 3A4  
Probucol  known risk  No longer available in U.S. 
Procainamide  known risk    
Protriptyline  conditional risk    
Quetiapine  possible risk  Substrate for 3A4  
Quinidine  known risk  Females  > Males. Substrate for 3A4  
Ranolazine  possible risk    
Risperidone  possible risk    
Ritonavir  conditional risk  Substrate for 3A4  
Roxithromycin*  possible risk  *not available in the United States  
Sertindole  possible risk    
Sertraline  conditional risk    
Solifenacin  conditional risk    
Sotalol  known risk  Females  > Males  
Sparfloxacin  known risk    
Tacrolimus  possible risk  Substrate for 3A4  
Telithromycin  possible risk  Substrate for 3A4  
Terfenadine  known risk  No longer available in U.S.Substrate for 3A4  
Thioridazine  known risk    
Tizanidine  possible risk    
Trazodone  conditional risk  Substrate for 3A4  
Trimethoprim -Sulfa  conditional risk    
Trimipramine  conditional risk    
Vandetanib  known risk    
Vardenafil  possible risk  Substrate for 3A4  
Venlafaxine  possible risk    
Voriconazole  possible risk    
Ziprasidone  possible risk    
1 Additional agents can be found at https://www.crediblemeds.org   
2 Classification according to the Qtdrugs.org Advisory Board of the Arizona CERT  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  220/234 
   
17.6. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS RECIST 
VERSION 1.1  
 
17.6.1.  Measurability of Tumor at baseline  
• Definitions  
At baseline, tumor lesions/lymph nodes will be categorized measurable or non- measurable as 
follows: 
• Measurable  
Tumor  lesions : Must be accurately measured in at least one dimension ( longest  diameter in the plane 
of measurement is to be recorded) with a minimum  size of:  
− 10 mm by CT scan (CT scan slice thickness no greater than 5 mm); 
− 10 mm caliper measurement by clinical examination  (lesions which cannot be accurately 
measured with calipers should be recorded as non- measurable);  
− 20 mm by chest X- ray. 
Malignant lymph nodes : To be considered pathologically enlarged and measurable, a lymph node 
must be ≥ 15 mm in short  axis when assessed by CT scan (CT scan slice thickness recommended 
to be no greater than 5 mm). At ba seline and in follow -up, only the short  axis will be measured and 
followed. 
• Non-measurable 
All other lesions, including small lesions (longest diameter < 10 mm or pathological lymph nodes 
with ≥  10 to < 15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly 
non-measurable include: leptomeningeal disease, ascites, pleural or pericardial effusion, and 
inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses /abdominal organomegaly identified by physical examination  that is not measurable by reproducible 
imaging techniques. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  221/234 
   
• Special cons iderations regarding lesion measurability 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular 
comment: 
Bone lesions : 
− Bone scan, PET scan or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
− Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue components , 
that can be evaluated by cross sectional imaging techniques such as CT or MRI can be 
considered measurable lesions if the soft tissue component  meets the definition of 
measurability described above. 
− Blastic bone lesions are non -measurable.  
 
Cystic lesions : 
− Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non- measurable) since they are, by 
definition, simple cysts.  
− ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable  
lesions, if they meet the definition of measurability described above. However, if non- cystic 
lesions are present in the same subject, these are preferred for selection as target lesions.  
 
Lesions with prior local treatment : 
− Tumor lesions situated in a pr eviously irradiated area, or in an area subjected to other loco-
regional therapy, are usually not considered measurable unless there has been demonstrated 
progression in the lesion. Study protocols should detail the conditions under which such lesions would be considered measurable. 
 
17.6.2.  Specifications by methods of measurements  
• Measurement of lesions  
All measurements should be recorded in metric notation, using calipers if clinically assessed. All 
baseline evaluations should be performed as close as possible t o the treatment start and never more 
than 4 weeks before the beginning of the treatment.   
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  222/234 
   
• Method of assessment  
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow- up. Imaging based evaluation should 
always be done rather than clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.  
Clinical lesions : Clinical lesions will only be considered measurable when they are superficial and 
≥ 10 mm diameter as assessed using calipers (e.g., skin nodules). For the case of skin lesions, 
documentation by colour photography including a ruler to estimate the size of the lesion is 
suggested. As noted above, when lesions can be evaluated by both clinical examination  and 
imaging, imaging evaluation should be undertaken since it is more objective and may also be reviewed at the end of the study. 
Chest X -ray: Chest CT is preferred over chest X -ray, particularly when progression is an important 
endpoint, since CT is more sensitive than X -ray, particularly in identifying new lesions. However, 
lesions on chest X -ray may be considered measurable if they are clearly defined and surrounded by 
aerated lung.  
CT, MRI: CT is the best curre ntly available and reproducible method to measure lesions selected 
for response assessment. This guideline has defined measurability of lesions on CT scan based on the assumption that CT slice thickness is 5 mm or less. When CT scans have slice thickness g reater 
than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (e.g., for body scans).  
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used a s a method 
of measurement. Ultrasound examinations cannot be reproduced in their entirety for independent 
review at a later date and, because they are operator dependent, it cannot be guaranteed that the 
same technique and measurements will be taken from o ne assessment to the next. If new lesions are 
identified by ultrasound in the course of the study, confirmation by CT or MRI is advised. If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances. 
Endoscopy, laparoscopy : The utilization of these techniques for objective tumor evaluation is not 
advised. However, they can be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials were recurrence following complete response or surgical 
resection is an endpoint. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  223/234 
   
Tumor  markers : Tumor markers alone  cannot be used to assess objective tumor response. If markers 
are initially above the upper normal limit, however, they must normalize for a subject  to be 
considered in complete response. Because tumor markers are disease specific, instructions for their 
measurement should be incorporated into protocols on a disease specific basis. Cytology, histology : These techniques can be used to differentiate between PR and CR in rare cases 
if required by protocol (for example, residual lesions in tumor types such as germ cell tumor s, where 
known residual be nign tumor s can remain).When effusions are known to be a potential adverse 
effect of treatment (e.g., with certain taxane compounds of angiogenesis inhibitors), the cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment can 
be considered if the measurable tumor has met criteria for response or stable disease in order to 
differentiate between response (or stable disease) and progressive disease.  
17.6.3.  Tumor Response Evaluation  
• Assessment of overall tumor  burden a nd measurable disease  
To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline  and use this as a comparator for subsequent measurements. Measurable disease 
is defined by the presence of at least one measurable lesion (as detailed above).  
• Baseline documentation of ‘target’ and ‘non- target’ lesions  
When more than one measurable lesio n is present at baseline all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all involved organs should 
be identified as target  lesions  and will be recorded and measured at baseline (this means in in stances 
where subject s have only one or two organ sites involved, a maximum  of two and four lesions 
respectively will be recorded).  
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements . It may be the case that, on occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstance the next largest le sion which can 
be measured reproducibly should be selected.   
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  224/234 
   
Lymph nodes  merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor . As previously noted, pathological nodes which 
are defined as measurable and may be identified as target lesions must meet the criterion of a short 
axis of ≥ 15 mm by CT scan. Only the short  axis of these nodes will contribute to the baseline sum. 
The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image 
is obtained (for CT scan this is almost always the axial plane; for MRI the plane of acquisition may 
be axial, saggital, or coronal). The smaller of these measures is the short axis.  
For e xample, an abdominal node which is reported as being 20 mm X 30 mm has a short axis of 20 
mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≥  10 mm but <  15 mm) 
should be considered non -target lesions. Nodes that have a short axis <  10 mm are considered non-
pathological and should not be recorded or followed. 
A sum of the diameters  (longest for non- nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters . If lymph nodes are to be 
included in the sum, then as previously noted, only the short  axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.  
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions  and should also be recorded at baseline. Measurements are not required and these 
lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ (more details to follow). In addition, it is possible to record multiple non- target lesions involving the same 
organ as  a single item on the case record form (e.g., ‘multiple enlarged pelvic lymph nodes’ or 
‘multiple liver metastases’).  
• Response criteria  
This section provides the definitions of the criteria used to determine objective tumor response for 
target lesions.  
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  225/234 
   
• Evaluation of target lesions 
Complete Response (CR) : Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 mm. 
Partial Response (PR) : At least a 30% decrease in the sum o f diameters of target lesions, taking 
as reference the baseline sum diameters.  
Progressive Disease (PD) : At least a 20% increase in the sum of diameters of target lesions, taking 
as reference the smallest sum on study  (this includes the baseline sum if that is the smallest on 
study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.  
Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study. 
• Special notes on the assessment of target lesions  
 
Lymph nodes . Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline examination), even 
if the nodes regress to below 10 mm on study. This means that when lymph nodes are included as 
target lesions, the ‘sum’ of lesions may not be zero even if complete response criteria are met, since 
a normal lymph node is defined as having a short axis of <  10 mm. Case report forms ( e-CRF s) or 
other data collection methods may therefore be designed to have target nodal lesions recorded in a  
separate section where, in order to qualify for CR, each node must achieve a short axis <  10 mm. 
For PR, SD, and PD, the actual short axis measurement of the nodes is to be included in the sum of target lesion.  
Target lesions that become ‘too small to measure’ . While on study, all lesions (nodal and non-
nodal) recorded at baseline should have their actual measurements recorded at each subsequent 
evaluation, even when very small (e.g., 2 mm). However, sometimes lesions or lymph nodes which 
are recorded as t arget lesions at baseline become so faint on CT scan that the radiologist may not 
feel comfortable assigning an exact measure and may report them as being ‘too small to measure’. When this occurs , it is important that a value be recorded on the e- CRF . If it is the opinion of the 
radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm. If 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  226/234 
  the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 
mm should be assigned ( Note : It is less likely that this rule will be used for lymph nodes since they 
usually have a definable size when normal and are frequently surrounded by fat such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but too small 
to measure, a default value of 5 mm should be assigned in this circumstance as well). This default 
value is derived from the 5 mm CT slice thickness (but should not be changed with varying CT slice 
thickness). The measurement of these lesions is potentially non- reproducible, therefore providing 
this default value will prevent false responses or progressions based upon measurement error. If the radiologist is able to provide an actual measurement, that should be recorded, even if below 5 m m. 
Lesions that split or coalesce on treatment . When non- nodal lesions ‘fragment’, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion sum. 
Similarly, as lesions coalesce, a plane between them may be mai ntained that would aid in obtaining 
maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the 
maximal longest diame ter for the ‘coalesced lesion’.  
 
17.6.4.  Evaluation of non -target lesion  
This section provides the definitions of the criteria used to determine the tumor response for the 
group of non- target lesions. While some non- target lesions may actually be measurable, they need 
not be measured and instead should be assessed only qualitatively  at the time points specified in the 
protocol. 
Complete Response (CR): Disap pearance of all non -target lesions and normalization of tumor 
marker level. All lymph nodes must be non- pathological in size (<  10 mm short axis). 
Non-CR/Non -PD: Persistence of one or more non -target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.  
Progressive Disease (PD) : Unequivocal progression of existing non- target lesions. The appearance 
of one or more new lesions is also considered progression. 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  227/234 
   
• Special notes on assessment of progression of non- target disease  
The concept of progression of non- target disease requires additional explanations as follows:  
When the subject  also has measurable disease . In this setting, to achieve ‘unequivocal progression’ 
on the basis of the non- target disease, there must be an overall level of substantial worsening in 
non-target disease such that, even in presence of SD or PR in target disease, the overall tumor 
burden has increased sufficiently to merit discontinuation of therapy. A modest ‘increase’ in the 
size of one or more non- target lesion s is usually not sufficient to qualify for unequivocal progression 
status. The designation of overall progression solely  on the basis of change in non- target disease in 
the face of SD or PR of target disease will therefore be extremely rare.  
When the subj ect has only non- measurable disease . This circumstance arises in some phase III trials 
when it is not a criterion of study entry to have measurable disease. The same general concepts 
apply here as previously noted, however, in this instance there is no mea surable disease assessment 
to factor into the interpretation of an increase in non- measurable disease burden. Because worsening 
in non- target disease cannot be easily quantified, a useful test that can be applied when assessing 
subject s for unequivocal progression is to consider if the increase in overall disease burden based 
on the change in non- measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: i.e., an increase in tumor burden repres enting an 
additional 73% increase in ‘volume’ (which is equivalent to a 20% increase in diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, an 
increase in lymphangitic disease from localized to wide spread, or may be described in protocols as 
‘sufficient to require a change in therapy’. If ‘unequivocal progression’ is seen, the subject should be considered to have had overall PD at that point. While it would be ideal to have objective criteria 
to apply to non- measurable disease, the very nature of that disease makes it impossible to do so, 
therefore the increase must be substantial.  
• New lesions  
The appearance of new malignant lesions denotes disease progression. There are no specific criteria 
for the i dentification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal: i.e., not attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumor . This  is particularly important when 
the subject ’s baseline lesions show partial or complete response. 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  228/234 
   
A lesion identified on a follow-up study in an anatomical location that was not scanned at baseline 
is considered a new lesion and will indicate disease progression. An example of this is the subject  
who has visceral disease at baseline and while on study has a CT or MRI brain scan ordered which 
reveals metastases. The subject ’s brai n metastases are considered to be evidence of PD even if 
he/she did not have brain imaging at baseline.  If a new lesion is equivocal, for example because of its small size, continued therapy and follow -up 
evaluation will clarify if it represents truly new  disease. If repeat scans confirm there is definitely a 
new lesion, then progression should be declared using the date of the initial scan.  
While FDG -PET response assessments need additional study, it is sometimes reasonable to 
incorporate the use of FDG -PET scanning to complement CT scanning in assessment of progression 
(particularly possible ‘new’ disease). New lesions on the basis of FDG -PET imagine can be 
identified according to the following algorithm: 
a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD based 
on a new lesion. A ‘positive’ FDG-PET scan lesion is one which is FDG avid with an uptake 
greater than twice that of the surrounding tissue on the attenuation corrected image. 
b. No FDG -PET at baseline and a positive FDG- PET at follow -up: 
If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by CT, this is 
PD. 
If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, additional 
follow- up CT scans are needed to det ermine if there is truly progression occurring at that time (if 
so, the date of PD will be the date of the initial abnormal FDG -PET scan).  
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT that is not 
progressing on the basis of the anatomic images, this is not PD. 
• Evaluation of best overall response 
The best overall response is the best response recorded from the start of the study treatment until 
the end of treatment taking into account any requirement for confirmation. On occasion a response 
may not be documented until after the end of therapy so protocols should be clear if post -treatment 
assessments are to be considered in determination of best overall response. Protocols must specify how any new therapy introduced before progression will affect best response designation. The 
subject ’s best overall  response assignment will depend on the findings of both target and non- target 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  230/234 
   
• Best overall response: all time points  
The best overall response  is determined once all the data for the subject  is known.  
Best response is defined as the best response across all time points (for example, a subject who has 
SD at first assessment, PR at second assessment, and PD on last assessment has a best overall 
response of PR). When SD is believed to be the best response, it must also meet the protocol 
specified minimum time from baseline. If the minimum time is not met when SD is otherwise the 
best time point response, the subject ’s best response depends on the subsequent assessments. For 
example, a subject  who has SD at first assessment, PD at second and does not meet minimum 
duration for SD, will have a best response of PD. The same subject  lost to follow -up after the first 
SD assessment would be considered not evaluable.  
• Special notes on response assessment  
When nodal disease is included in the sum of target lesions and the nodes decrease to ‘normal’ size (< 10 mm), they may still have a measurement reported on scans. This measurement should be 
recorded even though the nodes are normal in order not to overstate progression should it be based 
on the increase in size of the nodes. As noted earlier, this means that subject s with CR may not have 
total sum of ‘zero’ on the e- CRF . 
Subject s with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as ‘symptomatic deterioration’. Every effort should be made to document objective progression even after 
discontinuation of treatment. Symptomatic deterioration is not  a descriptor of an objective response: 
it is a reason for stopping study therapy. The objective response status of such subject s is to be 
determined by evaluation of target and non- target disease.  
Conditions that define ‘early progression, early death and inevaluability’ are study specific and should be clearly described in each protocol (depending on treatment duration, treatment 
periodicity). 
In some circumstances it may be di fficult to distinguish residual disease from normal tissue. When 
the evaluation of complete response depends upon this determination, it is recommended that the 
residual lesion be investigated (fine needle aspirate/biopsy) before assigning a status of complete 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  231/234 
  response. FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or scarring. The use 
of FDG -PET in this circumstance should be prospectively described in the protocol and supported 
by disease specific medical literature for the indication. However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG -PET and biopsy 
resolution/sensitivity.  
For eq uivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes or 
necrosis in existing lesion), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date  of progression should be the earlier 
date when progression was suspected. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumor s: 
revised RECIST guideline (version 1.1). Eur J Cancer 2009;45 (2):2 
 
               
 
    
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  232/234 
  17.7. RECOMMENDED GUIDELINES FOR THE MANAGEMEN T OF 
BINIMETINIB  AND CETUXIMAB -ASSOCIATED INTERSTITIAL 
LUNG DISEASE /PNEUMONITIS  
Clinical judgment and experience of the treating physician should guide the management plan of 
each subject . In general, the following interventions are in addition to the binimetinib- associated 
interstitial lung disease (ILD) dosing guidelines provided in Table 14 of the protocol  and, moreover 
if ILD is diagnosed, cetuximab must be discontinued.  
Drug -associated ILD or pneumonitis is a clinical diagnosis based on clinical signs and symptoms, 
radiological changes, pulmonary function tests (PFT) and exclusion of other possible etiologies of 
parenchymal lung disease. The most common symptoms of ILD are nonspecific and include 
dyspnea, dry cough, fever, fatigue, hypoxia, and occasional hemoptysis. The CTCAE v.4.03 criteria 
for ILD (pneumonitis) are provided below. 
 
 
CTCAE v. 4.03 Criteria for P neumonitis  
 Grade  
Adverse 
Event  1 2 3 4 5 
Pneumonitis  Asymptomatic; 
clinical or diagnostic observations only; intervention not indicated  Symptomatic; medical intervention indicated; limiting instrumental ADL  Severe symptoms; limiting self care ADL; oxygen indicated  Life-threatening 
respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation)  Death  
Definition: A disorder characterized by inflammation or diffusely affecting the lung parenchyma.  
 
All subject s should be instructed to immediately report new or worsening respiratory symptoms. 
Diagnostic procedures include PFT and high- resolution CT scans. In case of ILD the subject should 
be treated according to the best available local practices and procedures.  
The principal management of ILD consists of drug interruption and/or dose reduction and treatment 
with steroids (eg. as specified below ). Empirical antibiotics directed at likely pathogens should also 
be considered while the results of diagnostic procedures and cultures are pending.  
• Prednisolone 40 mg oral, daily 
− Reduce dose by 10 mg every 2 weeks × 2 (until dose reduced to 20 mg oral, daily) 
− Reduce dose by 5 mg weekly × 4 weeks 
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  233/234 
   
• Combine with empirical antimicrobial therapy while awaiting results of diagn ostic 
procedures 
Willemsen A, Gutters J, Gerritsen W, et al. mTOR inhibitor -induced interstitial lung disease in 
cancer patients: Comprehensive review and practical management algorithm. In J Cancer 
(2016):138:2312-2321. 
 
  
PII
exclusive property of Pierre Fabre  W00090 GE 2 01   
 
Clinical Study Protocol_W00090 GE 2 01_Version 9.0_ 17JUL20  234/234 
   
17.8. PATIENT GLOBAL I MPRESSION OF C HANGE (PGIC)  
Subject s will be asked the following:  
Since starting treatment, my colorectal cancer symptoms are: 
(1) Very much improved 
(2) Much improved 
(3) Minimally improved  
(4) No change 
(5) Minimally worse  
(6) Much worse 
(7) Very much worse 
(Mesa AM et al, 2013). 
 
PII